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List of abbreviations 
 
aq aqueous 
Ac Acetyl 
BOC t-Butyloxycarbonyl 
Bz Benzoyl 
Bn Benzyl 
c concentration 
Cbz Carbobenzyloxy 
CSA Camphorsulfonic acid 
Δ reflux 
DBU 1,8-Diazabicyclo[5.4.0]undec-7-ene 
DCM Dichloromethane 
de diastereomeric excess 
DMF Dimethylformamide 
DMSO Dimethyl Sulfoxide 
dr diastereomeric ratio 
E Entgegen (opposite, trans) 
eq equivalent 
Et Ethyl 
g gram 
h hours 
iPr isopropyl 
LiHMDSA Lithium Hexamethyldisilazide 
M M molar mol/L 
MCPBA meta-Chloroperbenzoic Acid 
Me Methyl 
min minutes 
mg milligram 
mL millilitre 
mp melting point 
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Nu nucleophile 
Ph Phenyl 
PMB para-Methoxybenzyl 
ppm parts per million 
PPTS Pyridinium p-toulensulfonate 
Py Pyridine 
rt room temperature 
TBAF tetra-n-butylammonium fluoride 
TEA Triethylamine 
Tf Triflate 
TFA Trifluoroacetic acid 
THF Tetrahydrofuran 
TMS Trimethylsilyl 
TS tosyl group 
Z Zusammen (together, cis) 
  
bs broad singlet (NMR) 
δ Chemical shift (NMR) 
13C-NMR Carbon-13 Nuclear Magnetic Resonance 
COSY Correlation Spectroscopy (NMR) 
d doublet (NMR) 
dd doublet of a doublet (NMR) 
DEPT Distorsionless Enhancement by Polarisation Transfer (NMR) 
EI Electronic Impact (MS) 
ESI Electron Spray Ionisation 
FID Free Induction Decay (NMR) 
FT Fourier Tranform 
Hz Hertz 
HETCOR Heteronuclear Correlation (NMR) 
HMQC Heteronuclear Multiple Quantum Coherence (NMR) 
HPLC High Performance Liquid Chromatography 
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IR Infrared 
J Coupling constant (NMR) 
LC Liquid Chromatography 
m multiplet (NMR) 
MS Mass Spectrum 
NMR Nuclear Magnetic Resonance 
NOESY Nuclear Overhauser Effect (Spectroscopy) 
ORTEP Oak Ridge Thermal Ellipse Program 
q quartet (NMR) 
Rf Retention Factor (chromatography) 
s singlet (NMR) 
t triplet (NMR) 
TLC Thin Layer Chromatography 
tr retention time (HPLC) 
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Thesis outline  
 
The aim of this thesis was to investigate the synthesis of enantiomerically enriched 
heterocycles and dehydro-β-amino acid derivatives which can be used as scaffolds or 
intermediates of biologically active compounds, in particular as novel αvβ3 and α5β1 
integrin ligands. The starting materials of all the compounds here synthesized are 
alkylideneacetoacetates. Alkylidene derivates are very usefull compounds, they are 
usually used as unsaturated electrophiles and they have the advantage of introducing 
different kind of functionality that may be further elaborated. 
In chapter 1, regio- and stereoselective allylic amination of pure carbonates is presented. 
The reaction proceeds via uncatalyzed or palladium-catalyzed conditions and affords 
enantiopure dehydro-β-amino esters that are useful precursor of biologically active 
compounds. 
R
CO2Et
OCOOMe
R
CO2Et
NHR'
R
CO2Et
NHR'
Path.A: 
NH2R'
Path. B:
Pd2(dba)3
NH2R'
+
 
Chapter 2 illustrates the synthesis of substituted isoxazolidines and isoxazolines via 
Michael addition followed by intramolecular hemiketalisation. The investigation on the 
effect of the Lewis acid catalysis on the regioselectivity of the addition it also reported. 
Isoxazolidines and isoxazolines are interesting heterocyclic compounds that may be 
regarded as unusual constrained β-amino acids or as furanose mimetics. 
R
O
O
OEt
NHTMSO
R
OTMS
O
OEt
NHTMSO R
O
O
OEt
HN
OH
 
 
 
 8 
The synthesis of unusual cyclic amino acids precursors, that may be envisaged as 
proline analogues, as scaffolds for the design of bioactive peptidomimetics is presented 
in chapter 3. The synthesis of 2-substituted-3,4-dehydropyrrole derivatives starting from 
allylic carbonates via a two step allylic amination/ring closing metathesis (RCM) 
protocol is carried out. The reaction was optimized by testing different Grubbs’ 
catalysts and carbamate nitrogen protecting groups. Moreover, in view of a future 
application of these dehydro-β-amino acids as central core of peptidomimetics , the 
malonate chain was also used to protect nitrogen prior to RCM.  
R-N
CO2tBu
CO2tBu
R-N Grubbs catalyst
          A-D
MTBE, Δ
 R =BOC
 R =Cbz
 R =malonyl
* *
 
Finally, chapter 4 presents the synthesis of two novel different classes of integrin 
antagonists, one derived from dehydro-β-amino acid prepared as described in chapter 1 
and the other one has isoxazolidines synthesized in chapter 2 as rigid constrained core. 
Since that these compounds are promising RGD mimetics for αvβ3 and α5β1 integrins, 
they have been submitted to biological assay and. Furthermore to interpret on a 
molecular basis their different affinities for the αvβ3 receptor, docking studies were 
performed using Glide program. 
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I 
 
Regio - and stereoselective allylic carbonate amination. 
Synthesis of Dehydro-β-amino esters and Dehydro-β-amino 
acids as valuable precursors of biologically active compounds 
   
1.1 Introduction  
Allylic compounds are privileged substrates in organic synthesis allowing the 
substitution reaction to be performed with a variety of nucleophiles.1 The C-N bond 
formation2 is one of the most important linkages in organic chemistry and allows the 
preparation of unusual amino acids. In this contest the substitution of allylic acetates or 
carbonates is a powerful method for the preparation of allylic amines and represents one 
of the most attractive  procedures for  their  asymmetric synthesis. While primary allylic 
carbonates have been widely studied, the substrates bearing substituents in Cα, Cβ and 
Cγ have received less attention. One of the most interesting aspects of this chemistry is 
the control of the regio- and the stereoselectivity on the allylic moiety. The reaction may 
be carried out in the absence of catalyst, depending on the nature of the nucleophile the 
substitution can occur via SN2 or through an SN2’ process.1b-d Under Pd-catalyzed 
conditions for symmetrically substituted compounds, the step of formation of the metal 
complex is irrelevant for the regioselectivity of the overall reaction. On the contrary, for 
substrates bearing different substituents at the two allylic termini, interest increases 
when the regioselectivity can be controlled.3 
In this work of thesis, the allylic amination of enantiomerically pure carbonates with 
proper amines, afforded dehydro-β-amino esters that are interesting precursors of 
unsaturated or saturated β-amino acids and also β-lactams.4 They could be inserted as a 
rigid core in small constrained  non-peptidic molecules mimicking the RGD (Arg-Gly-
Asp) motif, present in a wide number of extracellular matrix (ECM) proteins.5 These 
ligands  bind to αvβ3 and α5β1 integrins, a large family of heterodimeric transmembrane 
glycoproteins, involved in the pathogenesis of several diseases, such as atheroschlerosis, 
osteoporosis, cancer and a variety of inflammatory disorders.6 The recognition sequence 
binds to the receptor mainly through electrostatic interactions with regions in the protein 
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having opposite charges: Arg interacts with two Asp situated in the α unit of the protein 
and Asp with a metal cation.7 Dehydro-β-amino acids can be used as a rigid core that 
may be easily linked to appendages corresponding to arginine and aspartic acid side 
chains. 
 
1.2 Synthesis of optically active allylic acetates and carbonates 
Optically active ethyl 3-hydroxy-2(1'substituted-methylidene)-butyrates, as well as their 
acetates,  were obtained from enzymatic resolution of a series of racemic ethyl 3-
Hydroxy-2(1'substituted-methylidene)-butyrates using Pseudomonas Cepacia lipase 
(EC 3.1.1.3) as a catalyst8, with a good yield and an excellent enantiomeric excess. 
(Scheme 1. 1) 
R
OH
CO2Et
R
OAc
CO2Et
R
OH
CO2Et
Pseudomonas Cepacia
Lipase
OAc
1a-c (3S)-1a-d(3R)-2a-d
OMe
a: R =
b: R =
d: R =
+
 
Scheme 1. 1 
 
The racemic alcohols were prepared in a two steps extremely simple way by treating 10 
equiv. of proper aldehyde and 1 equiv. of ethyl acetoacetate in the presence of 0.15 
equiv. of piperidine under microwave assisted conditions for 7.5 min (Scheme 1. 2). 
Microwave assisted organic synthesis9 is in fact a rapidly expanding area of research 
that offers the opportunity to strongly reduce reaction times from hours to minutes. 
After the usual work up, 30/ 70 mixtures of E and Z ketones were obtained in good 
yields. 
The mixture of ketones was submitted to reduction in the presence of 1 equiv. of CeCl3 
and 1.1 equiv. of NaBH4 in THF/MeOH 9:1 (Scheme 1. 2).10 The corresponding Z/E 
alcohols 1a-d were obtained in excellent yields and were  separated by flash 
chromatography. 
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R
OH
CO2Et
1a-d
R
O
CO2Et
R H
O
O
EtO2C
+
Piperidine NaBH4
CeCl3.7H2O
THF/MeOH
3a-d
 Z/E  70/30 Z/E 70/30
67-77%
70-85%
MW
 
Scheme 1. 2 
 
In order to select the most useful enzyme for the kinetic resolution of these compounds, 
a series of screening experiments was carried out with various lipases. Therefore, the 
lipases from Candida cylindracea, Mucor miehei, Aspergillus niger and Rhizopus 
nivens were tested via irreversible acylation by treating the substrates with 4 equiv. of 
vinylacetate and 0,5 mass equiv. of enzime in diethylether at r.t. for several days.11 
Finally, the use of Pseudomonas cepacia proved to be very successful for the resolution 
of Z-1a-d alcohols, affording the acetylated compounds in good yields and high ee, 
although in lengthy reaction times. However, any effort to resolve the allylic alcohols E-
1a-d under these conditions failed. Lipase from Pseudomonas cepacia (EC 3.1.1.3) is a 
well known catalyst in organic synthesis, used both for kinetic resolution of racemic 
mixture of secondary alcohols, as well as in hydrolysis and transesterification.12 The 
racemic alcohols 1a-d were submitted to catalyzed enzymatic acetylation employing 
vinyl acetate in diethyl ether at 30 °C (Table 1).  
 
Table 1 
Entry Substrate Products Time (days) 
Conversion 
(%)b 
Isolated 
yield 
(%)c 
[α]D eed Ee 
1 1a 
(3S)-1a 
(3R)-2a 
5 50 
45 
34 
-11.0 
+36.5 
>99 
>99 
>1000 
 
2 1b 
(3S)-1b 
(3R)-2b 
5 47 
45 
42 
-8.7 
+27.2 
88 
>99 
37 
 
3 1d 
(3S)-1d 
(3R)-2d 
5 50 
36 
40 
-4.0 
+44.3 
>99 
>99 
>1000 
 
a The substrate at 0.2 M concentration in diethyl ether was stirred with 0.5 mass equiv. of enzyme, 5 equiv. of vinyl 
acetate for five days at room temperature. b As monitored by GC-MS an d by 1H NMR integrals c Determined on 
isolated and purified products. d Determined by HPLC with chiral column (see experimental) e Values determined 
using Sih's method, from the extent of conversion and enantiomeric excess of the recovered substrate as described 
and checked via values determined from the enantiomeric excess of the product.  
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 Monitoring of the reaction  progress by GC-MS allowed for determination of the 
conversion. Samples of racemic acetates 2a-d were prepared as reference compounds, 
via acetylation of racemic alcohols 1a-d.  
Although several different basic conditions were tested for the reaction with acetyl 
chloride (TEA, NaH, K2CO3), good results could be obtained only when the reaction 
was performed in the presence of  1.5 equiv. of  LiHMDS (Scheme 1. 3). 
R
OH
CO2Et
1a-d
R
OAc
CO2Et
2a-d
LiHMDS
Acetyl chloride
THF
O°C to  r.t.
85-90%  
Scheme 1. 3 
 
After the required conversion in the lipase catalyzed reaction was achieved, the enzyme 
was filtered off and the mixture was submitted to the usual work up. The 1H NMR  of 
crude material showed a 1:1 ratio of alcohol/acetate, based on the peak area of the 
hydrogen adjacent to the secondary alcohol and its corresponding acetate (a quartet at 
4.50-4.60 ppm for alcohols 1a-d and  a quartet at 5.60-5.70 ppm for acetate 2a-d). The 
resulting acetates and the remaining alcohols were separated by flash chromatography. 
The racemic alcohols were analytically resolved into their enantiomers by chiral HPLC 
and were compared with the alcohols that derived from enzymatic resolution. 
Since the analytical resolution of acetates could not be easily achieved, the acetates (+)-
2a-d were hydrolyzed to the corresponding alcohols. To this purpose, samples of the 
optically active acetates 2a-d were treated with K2CO3 in methanol (Scheme 1. 4).  The 
enatiomeric excesses of (+)-1a-d were determined via HPLC by comparison with the 
corresponding racemates. 
R
OH
CO2Et
(+)-1a-d
R
OAc
CO2Et
(+)-2a-d
K2CO3, MeOH
30 min, rt
90%
ee>99% 
Scheme 1. 4 
 
The stereoselectivity of Lipase prepared from Pseudomonas cepacia have been widely 
studied via models based on a classification of the relative size of the substituens (small 
and large) at the stereocenter of the secondary alcohol.9 The Kazlauskas' rule to predict 
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which enantiomer of the secondary alcohol reacts faster, has received reliable 
application. On the basis of the data reported in the literature,  we have attributed the S 
configuration to the allylic alcohols and the R to their corresponding acetates. In fact in 
our case the methyl group is unequivocally identified as the  smaller substituent  in 
comparison to the large one  (Figure 1. 1).  
R
OAc
CO2Et
R
OH
CO2Et
(3S)-1a-d
(3R)-2a-d
R
HO
CO2Et
H
LARGE
SMALL
Fast reacting enantiomer
R
HO
CO2Et
H
(3S)-1a-d
(3R)-1a-d
PCL
 
Figure 1. 1 
 
The carbonates 4a-c have been obtained from the corresponding (S) and (R)-alcohols by 
treatment with LiHMDS and methyl chloroformate in dry THF. (Scheme 1. 5) 
R
CO2Et
OCO2Me
R
CO2Et
OH
*
LiHMDS
THF
O
O Cl
+
1a-c 4a-c  
Scheme 1. 5 
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1.3 Solvent-dependent regio- and stereoselective amination 
The reaction carried out in the absence of catalyst or under palladium-catalyzed 
conditions led to dehydro-β-amino esters 5 and 613 interesting precursors of unsaturated 
β-amino acids14 and α-alkylidene-β-lactams.15 (Scheme 1. 6) 
R
CO2Et
OR'
R
CO2Et
NHBn
R
CO2Et
NHBn
Path.A: 
NH2Bn
Path. B:
Pd2(dba)3
NH2Bn
2a: R' = COCH3
4a-c: R' = COOCH3
5a-c
6a-c
+
 
Scheme 1. 6 
 
The optically active amino acetate 2a and carbonate 4a-c were synthetized as described 
in the previous paragraph. The amination reactions were carried out with benzylamine 
as nucleophile in different solvents, following pathway A or pathway B16 (Scheme 1. 6). 
The regioselective nucleophilic displacement may afford respectively the dehydro-β-
amino esters 5a-c and 6a-c. 
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1.3.1 Uncatalyzed amination 
In the initial experiments, (±)-2a and benzylamine were refluxed in CH2Cl2, affording 
(±)-5a in 65% yield although in a very long reaction time (Table 2, entry 1). On 
changing the solvent to THF, faster quantitative conversion to (±)-5a was observed 
(entry 2).  
CO2Et
OAc
R
CO2Et
NHBn
 
NH2Bn
2a 5a
R S
SN2'
R
CO2Et
OCO2Me
R
CO2Et
NHBn
 
NH2Bn
4a-c 5a-c
RS
SN2'
 
Scheme 1. 7 
 
Table 2 
Entry Substrate Solventa Time (h) 5b,c/6 
1 (±)-2a CH2Cl2 96 >99/1 
2 (±)-2a THF 42 >99/1 
3 (R)-2a THF 42 >99/1 
4 (R)-2a CH3CN 50 90/10 
5 (±)-4a THF 24 >99/1 
6 (±)-4a CH3CN 40 >99/1 
7 (S)-4a THF 24 >99/1 
8 (S)-4a CH3CN 40 >99/1 
9 (±)-4b THF 24 >99/1 
10 (±)-4b CH3CN 40 95/5 
11 (S)-4b THF 24 >99/1 
12 (±)-4c THF 24 >99/1 
13 (±)-4c CH3CN 40 88/12 
14 (S)-4c THF 24 >99/1 
a The reactions were carried out in refluxing solvent. b The regioisomeric ratio was determined by 1H NMR. 
Configuration of the double bond in 3 4/1 Z/E. c Yield of compounds purified by flash chromatography on silica gel 
>90% (65% only for entry 1) d A 12% of racemization of the benzylic position was observed by HPLC on chiral 
column.  
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Following the same protocol on enantiomerically enriched (R)-2a, optically active 5a 
was obtained as exclusive regioisomer in THF, while a 90/10 regioisomeric mixture of 
5a/6a was observed carrying out the reaction in acetonitrile (entries 3-4). Complete 
conversion of the starting material to 5a in reduced reaction time was observed in both 
solvents starting from the carbonate 4a (entries 5-6).  
On repeating the reaction on (S)-4a, the chirality of the starting carbonate was 
completely transferred to the dehydroamino ester 5a (99% ee determined by chiral 
HPLC on the pure isolated Z-5a, entries 7,8). Similar results have been obtained for 
compounds 4b and 4c (entries 9-13) although (S)-4c afforded enriched 5c with a partial 
racemization of the benzylic position (entry 14).  
The regiochemistry of the products accounts for a nucleophilic displacement occuring 
via SN2' mechanism. Since a syn attack is to be predicted for neutral nucleophiles,17 
starting from (R)-acetate 2a, the (S) configuration was attributed to the dehydro-β-
amino ester 5a, while from (S)-carbonates 4a-c the (R) configuration was assigned to 
products 5a-c (Scheme 1. 7).  
 
1.3.2 Pd-Catalyzed amination 
Treating racemic or (S)-4a allylic carbonate18 with benzylamine in the presence of 
Pd2(dba)3CHCl3 catalyst, either in THF or CH3CN, the reaction show a strong solvent-
dependent regiocontrol.(Table 3) 
CO2Et
OCO2Me
CO2Et
NHBn
CO2Et
NHBn
2%Pd2(dba)3CHCl3
4a 5a 6a
+
NH2Bn
 
Scheme 1. 8 
Table 3 
Entry Substrate Solventa 5a/6ab,c (%) 
1 (±)-4a THF 93/7 
2 (±)-4a CH3CN 20/80 
3 (S)-4a THF 90/10d 
4 (S)-4a CH3CN 20/80d 
5 (S)-4a CH3CN+ PPh3 >99/1d 
a The reactions were carried out in refluxing solvent (solution  0.1 M of 2). b The regioisomeric ratio was determined 
by 1H NMR. Configuration of the double bond in 3a 4/1 Z/E. c Yield of compounds purified by flash chromatography 
on silica gel >90% d 90% ee from HPLC on chiral column, starting from (S)-2a having 90% ee. 
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The reaction carried out in THF at reflux gave compound 5a in 93/7 regioisomeric ratio 
(entry 1). When (S)-4a was used as starting material, the chirality was completely 
retained affording 5a with the same enantiomeric excess of the starting carbonate (entry 
3). Complete inversion of the regiochemistry occurred in CH3CN at reflux, 6a /5a being 
obtained in 80/20 regioisomeric ratio (entries 2 and 4). Similarly to what observed in 
THF, the reaction performed in CH3CN on (S)-4a gave 6a in 90% ee (entry 4). In order 
to enhance the regioselectivity of the reaction, the amination was performed in the 
presence of PPh3.19 A significative increase of regioselectivity was observed  for the 
reaction carried out in CH3CN, being 6a formed as the exclusive regioisomer (entry 5).  
Since both the oxidative addition leading to palladium complex and the nucleophilic 
attack normally occur stereoselectively with inversion of configuration at the reacting 
allylic carbon atom, the overall process proceeds with retention of configuration.20 
Therefore, starting from (S)-4a, the (R) configuration was assigned to 5a, also 
confirmed by the observed optical rotation, and the (S) configuration was assigned to 
6a. Thus, starting from (S)-4a carbonate, selected conditions gave access to the two 
different optically active dehydroamino esters (R)-5a or (S)-6a through a solvent 
depending regioselective control.  
On the basis of these results, 4b and 4c were reacted in CH3CN (Table 4, entries 1 and 
2) giving 6b and 6c in satisfactory regioselectivity (>85/15), that was strongly improved 
when PPh3 was added to the reaction mixture, in agreement with the above reported 
results on the  isopropyl derivative (entries 3 and 4).  
 
Table 4 
Entry Substrate Solventa 5/6bc (%) 
1 (S)-4b CH3CN 15/85  
2 (S)-4c CH3CN 11/89  
3 (±)-4b CH3CN+ PPh3 5/95 
4 (±)-4c CH3CN+ PPh3 5/95 
a The reactions were carried out in refluxing solvent (solution  0.1 M of 2). b The regioisomeric ratio was determined 
by 1H NMR. Configuration of the double bond in 3  4/1 Z/E. c Yield of compounds purified by flash chromatography 
on silica gel >90% d 90% ee from HPLC on chiral column, starting from (S)-2 having 90% ee. 
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1.3.3 Conversion dehydro-β-amino esters to α-alkylidene-β-lactams 
The dehydro-β-amino esters were then converted to α-alkylidene-β-lactams, in order to 
obtain compounds of interest in our research group 21. 
To this purpose, (S)-6a-b were easily quantitatively transformed into the corresponding 
Z-β-lactam (S)-7a-b by treatment with LiHMDS in anhydrous THF at –20 °C (Scheme 
1. 9). The Z configuration of the double bond was attributed on the basis of vinyl proton 
1H NMR chemical shift (5.33-5.36 ppm)22 and confirmed by NOE experiments. 
CO2Et
NHBn
(S)-6a
N
O Bn
(S)-7a
LiHMDS
THF
CO2Et
NHBn
(S)-6b
N
O Bn
(S)-7b
LiHMDS
THF
[α]D = -61.2 ;
[α]D = -39.0 ;
87% ee
84% ee 
Scheme 1. 9 
 
 
1.3.4 Enantioselective allylic amination of racemic carbonates  
Finally, a preliminary study on the enantioselective variant of this methodology by 
reaction of (±)-4a with benzylamine was performed using (R,R)-DACH-Phenyl Trost 
chiral ligand in CH2Cl2 and THF (Scheme 1. 10). In the presence of 5% amount of Pd 
and 8% amount of enantiopure chiral ligand, a strong effect on the regioselectivity 
could be observed. Compound 6a was obtained as exclusive product in CH2Cl2, while it 
was isolated in 80/20 regioisomeric ratio when the reaction was performed in THF. In 
both cases only a moderate 40% enantiomeric excess could be observed. Otherwise, 
decreasing the amount of Pd/ligand (2%/6%) in THF, 6a was isolated in 30/70 
regioisomeric ratio and 61%ee, being the major isomer 5a obtained in racemic form 
through uncatalyzed SN2' reaction.  
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CO2Et
OCO2Me
CO2Et
NHBn
Pd2(dba)3CHCl3
4a
(R)-5a
NH2Bn
L*
L* =
NH HN
OO
PPh2 Ph2P
e.e. 5a: up to 61%
N
O Bn
(R)-7a
LiHMDS THF
 
Scheme 1. 10 
 
The (R) absolute configuration of the predominant enantiomer of 6a was determined by 
comparison of the HPLC retention times on chiral column and optical rotation values 
[(R)-6a [α]D = +4, 61% ee] with (S)-6a ([α]D = -7, 87% ee). The attribution was further 
confirmed by the comparison of HPLC of the corresponding β-lactams (S)-7a and      
(R)-7a. 
 
1.4 Regio- and stereoselective palladium-catalyzed allylic carbonate 
amination 
The reaction was carried out in CH3CN. Initially, a series of experiments was performed 
using racemic carbonates 8-11 with bifunctionalized amines in the presence of 2.5 mol 
% Pd2(dba)3-CHCl323. We decided to use  terbutyl-ester since its hydrolysis is simpler 
than ethyl-ester one. The usual work-up and purification  by column chromatography 
provided the products. (Table 5) 
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Table 5 
Entry Reagent Amine Product  Yield a(%) Z/E 
1 
 
 
12a 
40 
35b 
50/50 
2 
  
12b 35b 20/80 
3 
 
 
8 
  
12f 60 30/70 
4 
 
 
13a 47 95/5 
5 
  
13b 45 95/5 
6 
  
13c 40 95/5 
7 
 
 
13d 60 95/5 
8 
 
 
13e 60 92/8 
9 
 
 
9 
  
13f 65 95/5 
10 
 
10 
  
14f 70 90/10 
11  
11 
  
15f 87 20/80 
a All experiments were  performed using racemic carbonates 8-11 with bifunctionalized amines in the presence of 
2.5% Pd2(dba)3-CHCl3 and refluxing in CH3CN for 12 h.  Yields were calculated after purification of the products by 
flash chromatography on silica gel. bThe reaction was conducted with 5 mol % PPh3 as additive. 
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Carbonate 8 reacted with N-methylpiperazine in the presence, or in the absence, of 
PPh324 giving the expected regioisomer 12a in low yield and in both cases with 
complete isomerization of the double bond  (E:Z ratio 1:1, entry 1).25 Similar results 
have been obtained  in the reaction of  8 with p-methoxybenzylaniline and 12b was 
isolated in moderate yield as a mixture 80:20 of  E:Z isomers (entry 2). The 
configuration of the double bond was attributed on the basis of the vinyl proton 1H 
NMR chemical shift and confirmed by NOE experiments.26 On reaction of 8 with 4-
aminomethylaniline as a nucleophile, 12f was obtained in higher yield, in a 70:30 E:Z 
ratio of geometrical isomers (entry 3). 
 The carbonate 9 also provided the corresponding products in good yield, but in this 
case with preferential formation of the Z isomer (Z/E ratio from 92/8 to 95/5). No trace 
of the regioisomer deriving from the SN2I mechanism was detected  in the 1H NMR of 
the crude, while traces of about 10-20% of the unreacted starting material were 
observed (entries from 4, 5, 6, 8 and 9). The benzyl L-proline (entry 7) underwent 
substitution giving almost exclusively the corresponding dehydro-β-amino esters with 
the Z geometry of the double bond (Z/E ratio 95:5) but as a 1:1 mixture of 
diastereoisomers,  with respect to the newly formed C-N bond.  Finally the reaction of 
carbonates 10 and 11 with 4-aminomethylaniline acting as the nucleophile gave the 
corresponding compounds 14f and 15f, isolated in good yield by flash chromatography 
on silica gel. The 4-aminomethylaniline exclusively reacted at the benzylamine function 
to give complete regioselectivity (Table 1 Entries 10-11). A good Z/E ratio could be 
observed for 14f (90/10), while for 15f the preferential formation of the E isomer was 
obtained (Z/E ratio 20:80), as already observed for 12b and 12f.  
 
1.4.1 Reactions of  enantiomerically pure carbonates 
The substitution reactions were performed with 4-aminomethyaniline since that the 
corresponded products are interesting intermediates for the synthesis of potential RGD 
mimetics. The results obtained  on treating optically active carbonates 8-11 with 4-
aminomethylaniline are reported in Table 6. 
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Table 6 
Entry Substrate Producta eeb(%) Yield (%) 
1 
 (S)-8 (S)-12f 
>99 72 
2 
 (R)-8 (R)-12f 
>99 58 
3 
  (S)-9   (S)-13f 
>99 61 
4 
  (R)-9   (R)-13f 
>99 59 
5 
  (S)-10 (S)-
14f 
>99 68 
6 
(R)-10 (R)-
14f 
>99 60 
7 
 (S)-11 
  (S)-15f 
>99 85 
8 
 (R)-11 
  (R)-15f 
>99 78 
aReaction carried out in the presence of 2.5 mol % Pd2(dba)3-CHCl3 in refluxing CH3CN. b Determined by HPLC on 
chiral column on isolated pure compounds (Chiralcel AD column  for 12f and 14f,  Chiralcel IA column  for 13f,  
Chiralcel OJ column for 15f). 
 
The enantiomeric excess of isolated products were determined by HPLC on chiral 
column, after separation of the Z isomer from the E isomer. The configuration of the 
newly created stereocentre was unequivocally attributed on the basis of previously 
reported research and on the basis of mechanistic considerations. In fact, the mechanism 
for the palladium-catalyzed allylic amination is generally accepted to proceed via a 
palladium-allyl complex that in the second step is attacked directly by the amine 
nucleophile, in analogy with the reaction mechanism for soft carbon nucleophiles. Since 
both the oxidative addition leading to palladium complex and the nucleophilic attack 
occur with inversion of configuration at the reacting allylic carbon atom, the overall 
process proceeds with retention of configuration.27 
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1.4.2 Pd-nanoparticles catalyzed reaction 
In order to verify the usefulness of our procedure and to optimize our methodologies on 
the basis of modern techniques, we tested palladium nanoparticles as catalysts. In a 
recent paper Ranu and coworkers28 explored the efficient allylic amination of allyl 
alcohol derivatives catalyzed by palladium nanoparticles in the presence of a base. This 
research group described a new protocol that gave good yields of allylated amines.  On 
the basis of the considerable interest in the metal nanoparticles,29 we applied the Ranu’s 
protocol to our substrate. The reaction was first performed on the racemic 9, then on the 
(S)-9 carbonate. After the period of time required for completion, the reaction was 
worked-up as usual.  
 
Scheme 1. 11 
 
The regioisomers (S)-13f and (R)-16 were obtained in 60:40 ratio and were separated by 
flash chromatography. The 1H NMR spectrum of (S)-13f showed the exclusive presence 
of the Z  isomer and the chiral HPLC analysis showed only the (S) enantiomer. On the 
contrary, (R)-16 was isolated as a 1:1 mixture of Z:E isomers. This protocol lacked in 
regioselectivity, affording both 13f and 16, but a high stereoselectivity could be 
observed in the double bond and the stereocentre formation of 13f.  
 
1.5 Synthesis of dehydro-β-amino acids under SN2’ conditions 
In initial experiments to displace the carbonate from racemic starting material, we used 
methyl 4-aminobenzoate in CH3CN at reflux. The substitution reaction did not occur 
due to the low reactivity of the selected aromatic amine (Table 7, entry 1). On changing 
the nucleophile with methyl 4-aminomethyl-benzoate in refluxing CH3CN (Scheme 1. 
12), the corresponding dehydro-β-amino esters 17a-d were obtained in good yield and 
(S)-9 
(S)-13 
(R)-16 
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complete regioselectivity30 (entries 2-5). The reaction was followed by TLC and 
stopped at disappearance of the starting material and the products were isolated and 
purified by flash chromatography on silica gel. 
R
CO2tBu
OCO2Me
1a-d
R'
H2N
+ R
CO2tBu
2a-d  R' = CO2Me
3a-d  R' = NH2
NH
R'
 
Scheme 1. 12 
 
The regiochemistry of the products was easily attributed on the basis of their 1H NMR 
spectra and accounts for a nucleophilic displacement occurring via SN2’ mechanism. 
The good reactivity of the benzylamine function, prompted us to use 4-
aminomethylaniline as nucleophile in refluxing CH3CN. Under these conditions, 
compounds 12f-15f were isolated in 62-65% yield by flash chromatography on silica 
gel (entries 6-9). 
Table 7 
Entry Substrate Nucleophile Product Time
a  
(d) 
Yieldb 
(%) 
1 8 H2N CO2Me  
/ 4 / 
2 8 CO2Me
H2N
 
17a 4 45 
3 9 “ 17b 4 70 
4 10 “ 17c 4 65 
5 11 “ 17d 4 35 
6 8 NH2
H2N
 
12f 3 62 
7 9 “ 13f 3 65 
8 10 “ 14f 3 62 
9 11 “ 15f 3 63 
aReaction carried out in refluxing CH3CN. b Configuration Z/E  of the double bond 3/1. Yield of product  purified by 
flash chromatography on silica gel.  
 
Although long reaction time was required to convert the starting material into the 
products, the regioisomers 12f-15f were exclusively obtained, confirming the low 
reactivity of the aromatic amine compared to the aliphatic one. Following the same 
8-11 
12f 15f
17a-d
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protocol on chiral non racemic (R)- or (S)- 8-10, compounds (R)- or (S)- 12f-14f were 
obtained with complete regio- and stereoselectivity (Scheme 1. 13, Table 8).  
R
CO2tBu
OCO2Me
(S)-1a-c
NH2
H2N
+ R
CO2tBu
(R)-3a-c
NH
R
CO2tBu
OCO2Me
(R)-1a-c
NH2
H2N
+
R
CO2tBu
(S)-3a-c
NH
H2N
H2N
 
Scheme 1. 13 
 
Table 8 
Entrya Substrate Product Yieldb(%) eec(%) 
1 (S)-8 (R)-12 65 >99 
2 (R)-8 (S)-12 63 >99 
3 (S)-9 (R)-13 60 >99 
4 (R)-9 (S)-13 65 >99 
5 (S)-10 (R)-14 63 >99 
6 (R)-10 (S)-14 60 >99 
aReaction carried out in refluxing CH3CN. b Configuration Z/E  of the double bond 3/1. Yield of product  purified by 
flash chromatography on silica gel. c Determined by HPLC on chiral column 
 
The enantiomeric excesses of isolated products (Table 8) were determined by HPLC on 
chiral column and confirmed complete transfer of  chirality of the starting carbonates to 
the dehydroamino esters. The stereochemistry of the products was unequivocally 
attributed on the basis of  previously reported research. 
 
Finally, we tried to perform the substitution reaction directly on the amide 19, in order 
to obtain a peptidic sequence mimicking the RGD integrin ligand. The amide was 
prepared in two steps as reported in Scheme 1. 14.  By treatment of 9 with 
trifluoroacetic acid, the corresponding acid 18 was obtained in 95% yield.  The presence 
of the methyl carbonate and t-butyl ester allowed the orthogonal deprotection of one of 
the two moieties, by selecting basic or acid conditions.  
8-10 
8-10 12f-14f
12f-14f
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OCO2Me
O N
H
CO2tBu
H2N
NH2
+ CH3CN
Δ
no 
reaction
OCO2Me
O N
Boc
CO2tBu
H2N+
NH
H2N
O N
Boc
CO2tBu
NHH2N
O N
H
CO2H
H3PO4
CH2Cl2
CH3CN
Δ
CO2tBu
OCO2Me
CO2H
OCO2Me
H2N CO2tBu
EDCI
HOBT
(± )-9b (± )-18
(± )-19
(± )-20
(± )-21
(± )22
TFA
95%
65%
70%
95%
NH2
(± )-19
 
Scheme 1. 14 
 
Compound 18 was coupled with glycine tert-butyl ester to afford amide 19. The SN2’ 
displacement of carbonate function with 4-aminomethylaniline in refluxing CH3CN 
failed and the unreacted starting material was recovered almost quantitatively. To 
enhance the reactivity of the amide, by reducing the nitrogen back-donation, an electron 
withdrawing t-butyl carbamate group was introduced on the amide nitrogen, giving 20 
in quantitative yield. This substrate showed to be much more reactive and could be 
converted into the corresponding amino derivative 21 by nucleophilic substitution with 
4-aminomethylaniline under the above reported conditions. Finally, the simultaneous 
acidolysis of the t-butyl ester and of the Boc protection with H3PO4 in 
dichloromethane,31 followed by treatment with Dowex 50WX2-200 ion exchange resin, 
eluting with NH4OH 0.5 M, and removal of the aqueous solvent under vacuum, 
afforded 22 in almost quantitative yield. The ability of this new ligand to inhibit integrin 
  27
mediated cell adhesion gave promising results, having IC50 in the micromolar range. On 
this basis,  a library of derivatives will be prepared and SAR studies will be  performed 
and reported  in due course. 
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1.6 Experimental Section 
 
All chemicals were purchased from commercial suppliers and used without further 
purification. Flash chromatography was performed on silica gel (230-400 mesh). NMR 
Spectra were recorded with 200 or 300 MHz spectrometers. Chemical shifts were 
reported as δ values (ppm) relative to the solvent peak of CDCl3 set at δ = 7.27 (1H 
NMR) or δ = 77.0 (13C NMR). GC-MS analysis were performed on HP-5 (crosslinked 
5% Ph Me silicone , 30m X 0.32 mm X 0.25 μm thikness) using an injection program 
(initial temperature 50°C for 2 ', then 10°C/min up to 280 °C) in scan mode acquisition. 
Microwave assisted reactions were performed with a Milestone Mycrosynth multimode 
apparatus, keeping irradiation power fixed and monitoring internal reaction temperature 
with a Built-in ATC-FO advanced fiber optic automatic temperature control. The 
reactions were performed in an open vessel, equipped with a refrigerator connected to 
fume hood. HPLC analyses were performed an HP1100 instrument with UV-vis 
detector and equipped with Chiralcel OD column (25 X 0.46 cm), Chiralcel OF column 
(25 X 0.46 cm), Chiralcel-OJ Daicel column (Cellulose tris-4-methylbenzoatephase 
coated on 10μm silica gel, 100%) and Chiralcel-AD Daicel column (Amylose tris-3,5-
dimethylphenylcarbamate phase coated on 10μm silica gel) eluted with n-hexane/2-
propanol. Optical rotations were measured in a Perkin Elmer 343 polarimeter using a 1 
dm cuvette and are referenced to the Na-D line value. 
 
Synthesis of ketones 3a-d. Ethyl acetoacetate (10 mmol, 1.3 g, 1.26 mL) was diluted in 
the proper aldehyde (10 equiv., 100 mmol) and piperidine (0.15 equiv., 1.5 mmol, 0.15 
mL) was added in one portion. The mixture was submitted to microwave irradiation 
(Power 500W) for 7.5 minutes and then was diluted with ethyl acetate (20 mL) and 
washed twice with 0.1 M HCl (20 mL). The two phases were separated, the organic 
layer was dried over Na2SO4 and solvent was removed under reduced pressure. 
Compounds Z-3a-c and E-3a-c  were separated by flash chromatography on silica gel 
(cyclohexane/ethyl acetate 90/10 as eluant).  
 
Z-3a: Yellow oil; isolated yield 61%; IR (film) ν/cm-1 2967, 2936, 2872, 1731, 1698, 
1670, 1467, 1321, 1258, 1212, 1036. 1H NMR (200 MHz, CDCl3) δ 1.07 (d, 6H, J = 6.6 
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Hz), 1.31 (t, 3H, J = 7.4 Hz), 2.30 (s, 3H), 2.65 (m, 1H), 4.29 (q, 2H, J =7.4 Hz), 6.60 
(d, 1H, J = 10.6 Hz); 13C NMR (200 MHz, CDCl3) δ 14.1, 21.9 (2), 26.8, 29.6, 61.2, 
134.9, 154.0, 166.6, 195.4; GC-MS rt 11.74 min, m/z: 184(2), 138(100), 123(60), 
110(15), 96(57), 81(24), 67(32), 55(26). 
 
E-3a: Yellow oil; isolated yield 26%; IR (film) ν/cm-1 2965, 2933, 2872, 1705, 1638, 
1467, 1367, 1239, 1200, 1051. 1H NMR (200 MHz, CDCl3) δ 1.02 (d, 6H, J = 6.6 Hz), 
1.30 (t, 3H, J = 7.4 Hz), 2.37 (s, 3H), 2.62 (m, 1H), 4.24 (q, 2H, J =7.4 Hz), 6.69 (d, 1H, 
J = 10.6 Hz); 13C NMR (200 MHz, CDCl3) δ 13.9, 21.6, 21.8, 26.5, 29.4, 61.1, 134.8, 
154.0, 166.5, 197.9; GC-MS rt 11.45 min, m/z: 184(2), 138(100), 123(55), 110(15), 
96(64), 81(26), 67(31), 55(19). 
 
Z-3b: Yellow oil; isolated yield 55%; IR (film) ν/cm-12981, 2928, 2852, 1731, 1698, 
1673, 1635, 1448, 1380, 1305, 1210, 1150, 1035. 1H NMR (200 MHz, CDCl3) δ 1.21-
1.43 (m, 5H), 1.34 (t, 3H, J = 7.0 Hz), 1.60-1.77 (m, 5H), 2.31 (s, 3H), 2.37 (m, 1H), 
4.30 (q, 2H, J =7.0 Hz), 6.63 (d, 1H, J = 9.8 Hz); 13C NMR (200 MHz, CDCl3) δ 14.1, 
25.1(2), 25.3, 26.7, 31.7, 31.8, 39.1, 61.0, 135.2, 152.5, 166.6, 197.9. GC-MS rt 16.60 
min, m/z: 224(2), 178(100), 163(60), 149(20), 135(90), 121(29), 107(33), 95(27), 
79(30), 67(21), 55(25). 
 
E-3b: Yellow oil; isolated yield 23%; IR (film) ν/cm-1 2927, 2853, 2360, 2342, 1701, 
1654, 1637, 1448, 1274, 1253. 1H NMR (200 MHz, CDCl3) δ 1.14-1.26 (m, 5H), 1.27 
(t, 3H, J = 7.0 Hz), 1.66-1.77 (m, 5H), 2.38 (s, 3H), 2.42 (m, 1H), 4.26 (q, 2H, J =7.0 
Hz), 6.72 (d, 1H, J = 10.6 Hz); 13C NMR (200 MHz, CDCl3) δ 14.1, 25.0 (2), 25.6, 
31.3, 31.9 (2), 38.3, 61.0, 133.9, 152.8, 164.7, 201.3. GC-MS rt 16.40 min, m/z: 224(5), 
182(100), 163(9), 135(27), 107(42), 79(27), 67(20), 55(12). 
 
Z-3d: Yellow oil; isolated yield 50%; IR (film) ν/cm-12980, 2936, 2841, 1726, 1655, 
1601, 1513, 1452, 1260, 1222, 1176, 1028. 1H NMR (300 MHz, CDCl3) δ 1.33 (t, 3H, J 
= 7.2 Hz), 2.44 (s, 3H), 3.88 (s, 3H), 4.40 (q, 2H, J =7.2 Hz), 6.93 (d, 2H, J = 7.2 Hz), 
7.46 (d, 2H, J = 7.2 Hz), 7.50 (s, 1H); 13C NMR (200 MHz, CDCl3) δ 14.0, 26.2, 55.2, 
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61.4, 114.2(2), 125.0, 131.6(2), 132.1, 140.9, 161.6, 168.1, 194.6. GC-MS rt 20.30 min, 
m/z: 248(100), 233(80), 217(21), 203(30), 189(8), 174(24), 161(55), 137(18), 117(9), 
89(12). 
 
E-3d: Yellow oil; isolated yield 21%; IR (film) ν/cm-12979, 2935, 2841, 2739, 1700, 
1601, 1577, 1512, 1315, 1258, 1174, 1026. 1H NMR (300 MHz, CDCl3) δ1.31 (t, 3H, J 
= 7.2 Hz), 2.39 (s, 3H), 3.89 (s, 3H), 4.27 (q, 2H, J =7.2 Hz), 7.00 (d, 2H, J = 7.2 Hz), 
7.61 (s, 1H), 7.83 (d, 2H, J = 7.2 Hz); 13C NMR (200 MHz, CDCl3) δ14.1, 26.5, 55.4, 
61.6, 114.4(2), 125.5, 131.7(2), 132.3, 140.3, 161.5, 168.3, 194.6; GC-MS rt 20.20 min, 
m/z: 248(100), 233(88), 217(26), 203(35), 189(12), 174(29), 161(76), 137(31), 117(17), 
103(10), 89(31). 
 
Synthesis of racemic alcohols 1a-d. To a stirred solution of compound  Z-3a-d and E-
3a-d (5 mmol) in THF/MeOH 9:1 (10 mL) at room temperature,  CeCl3.7H2O (1 equiv., 
5 mmol, 1,86 g) and NaBH4 (1.1 equiv., 5.5 mmol, 0.2 g) were added in one portion. 
The solution was monitored by TLC and quenched after disappearence of the starting 
ketone by addition of water (5 mL). After removal of THF and MeOH under reduced 
pressure, the residue was diluted with ethyl acetate (10 ml) and washed twice with water 
(5 ml). The two phases were separated, the organic layer was dried over Na2SO4 and 
solvent was removed under reduced pressure. Racemic alcohols Z-1a-d or E-1a-d were 
isolated by flash chromatography on silica gel (cyclohexane/ethyl acetate 80/20 as 
eluant). 
 
Synthesis of racemic acetates 2a-d. To a solution of compound  Z-1 (1 mmol) in dry 
THF (5 mL), under inert atmosphere at 0°C,  LiHMDS (1.5 equiv., 1.5 mL 1M solution 
in THF) was added dropwise. The solution was stirred for 30 minutes and then acetyl 
chloride (1.5 equiv., 1.5 mmol, 0.1 mL) was added in one portion and ice bath was 
removed. After one hour, the mixture was quenched with water (5 mL) and THF 
removed under reduced pressure. The residue was diluted with ethyl acetate (10 ml) and 
washed twice with water (5 ml). The two phases were separated, the organic layer was 
dried over Na2SO4 and solvent was removed under reduced pressure. Racemic acetates 
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Z-2a-d were isolated by flash chromatography on silica gel (cyclohexane/ethyl acetate 
90/10 as eluant). 
 
Lipase catalyzed resolution of alcohols 1a-d. To a solution of racemic alcohol 1 (5 
mmol) in diethyl ether (25 mL) at 40 °C, vinylacetate (4 equiv., 4 mmol, 0.37 mL) and 
Lipase from Pseudomonas Cepacia (46 U/mg, 0.2 mass equiv.) were added. The 
progress of the reaction was assessed every 12 h by GC-MS. The reaction was stopped 
by filtration of the enzyme and elimination of solvent and byproducts under reduced 
pressure. Enantiomerically pure alcohols (3S)-Z-1a-d and acetates  (3R)-Z-2a-d were 
separated by flash chromatography on silica gel (cyclohexane/ethyl acetate 90/10 then 
80/20 as eluant). 
 
Hydrolysis of enantiomerically pure acetates 2a-d to enantiomerically pure alcohols 
1a-d. Acetate (3R)-Z-2 (0.5 mmol) was stirred in MeOH (5 mL) in the presence of 
K2CO3 (1 equiv., 0.5 mmol, 70 mg) for 30 min. at room temperature. The reaction was 
quenched by addition of 0.1 M HCl (5 mL). After removal of MeOH under reduced 
pressure, the residue was diluted with ethyl acetate (10 mL) and washed twice with 
water. The two phases were separated, the organic layer was dried over Na2SO4 and 
solvent was removed under reduced pressure. Enantiomerically pure alcohols (3R)-Z-
1a-d were purified by flash chromatography on silica gel (cyclohexane/ethyl acetate 
80/20 as eluant). 
 
Z-1a: Yellow oil; IR (film) ν/cm-1 3437, 2964, 2933, 2870, 1717, 1467, 1372, 1228, 
1178, 1159. 1H NMR (200 MHz, CDCl3) δ 1.00 (d, 6H, J = 6.6 Hz), 1.24 (m, 6H), 3.10 
(m, 1H), 4.23 (q, 2H, J =6.6 Hz), 4.42 (q, 1H, J =6.2 Hz)  5.87 (d, 1H, J = 10.0 Hz); 13C 
NMR (200 MHz, CDCl3) δ 14.1, 22.4, 22.5, 28.2, 60.3, 69.2, 133.1, 146.9, 167.7.  GC-
MS rt 11.62 min, m/z: 186(2), 171(36), 144(21), 125(100), 115(20), 97(61), 79(35), 
67(25), 55(24).  
(3S)-Z-1a:  HPLC on Chiralcel OF (97.5/2.5 n-hexane/2-propanol, flow 1.0 mL/min):  
rt 14.5 min., [α]25D = -11.0 (c 1.0 CHCl3) 
(3R)-Z-1a: HPLC on Chiralcel OF (97.5/2.5 n-hexane/2-propanol, flow 1.0 mL/min):  rt 
16.4 min., [α]25D = +12.4 (c 1.0 CHCl3) 
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E-1a: Yellow oil; IR (film) ν/cm-1 3452, 2963, 2871, 1693, 1641, 1466, 1368, 1261, 
1176, 1190. 1H NMR (200 MHz, CDCl3) δ 1.03 (d, 3H, J = 6.6 Hz), 1.06 (d, 3H, J = 6.6 
Hz),  1.24 (t, 3H, J = 7.2 Hz), 1.42 (d, 3H, J = 6.6 Hz),  2.77 (m, 1H), 4.22 (q, 2H, J 
=7.2 Hz), 4.72 (m, 1H), 6.52 (d, 1H, J = 10.2 Hz); 13C NMR (200 MHz, CDCl3) δ 14.1, 
22.2(2), 23.8, 27.1, 60.4, 65.0, 131.7, 149.2, 167.5.  GC-MS rt 11.80 min, m/z: 186(2), 
171(64), 143(27), 125(100), 115(11), 97(46), 79(20), 67(18), 55(15). 
 
Z-1b: Yellow oil; IR (film) ν/cm-1 3438, 2926, 2851, 1714, 1448, 1373, 1303, 1263, 
1208, 1178, 1153. 1H NMR (200 MHz, CDCl3) δ 1.01-1.36 (m, 5H), 1.25 (t, 3H, J = 7.0 
Hz), 1.25 (d, 3H, J = 6.6 Hz), 1.60-1.73 (m, 5H),  2.30 (bs, 1H), 2.75 (m, 1H), 4.24 (q, 
2H, J =7.0 Hz), 4.41 (q, 1H, J =6.6 Hz), 5.88 (d, 1H, J = 10.0 Hz); 13C NMR (200 MHz, 
CDCl3) δ 14.0, 22.5, 25.4, 25.7, 25.9, 32.4, 32.5, 37.9, 60.2, 69.2, 133.4, 145.6, 167.7. 
GC-MS rt 16.40 min, m/z: 226(2), 208(38), 179(33), 162(100), 147(28), 133(51), 
119(37), 107(20), 99(29), 91(36), 81(87), 67(38), 55(34).  
(3S)-Z-1b:  HPLC on Chiralcel OF (97.5/2.5 n-hexane/2-propanol, flow 1.0 mL/min):  
rt 17.7 min., [α]25D = -8.7 (c 1.0 CHCl3) 
(3R)-Z-1b: HPLC on Chiralcel OF (97.5/2.5 n-hexane/2-propanol, flow 1.0 mL/min):  rt 
19.3 min., [α]25D = +9.4 (c 1.0 CHCl3) 
 
E-1b: Yellow oil; IR (film) ν/cm-1 3423, 2926, 2852, 1691, 1448, 1368, 1263. 1H NMR 
(200 MHz, CDCl3) δ 1.11-1.25 (m, 5H), 1.29 (t, 3H, J = 7.4 Hz), 1.39 (d, 3H, J = 6.6 
Hz), 1.44-1.73 (m, 5H),  2.34 (m, 1H), 4.19 (q, 2H, J =7.4 Hz), 4.70 (q, 1H, J =6.6 Hz)  
6.50 (d, 1H, J = 9.8 Hz); 13C NMR (200 MHz, CDCl3) δ 14.1, 23.9, 25.4 (2), 25.7, 
32.1(2), 37.0, 60.6, 65.1, 132.1, 147.8, 167.7. GC-MS rt 16.81 min, m/z: 226(2), 
211(100), 179(18), 165(68), 143(55), 129(38), 119(35), 105(19), 91(32), 81(70), 67(45), 
55(43). 
 
Z-1d: Yellow oil; IR (film) ν/cm-1 3448, 2977, 2934, 1718, 1607, 1511, 1458, 1300, 
1254, 1193, 1031. 1H NMR (200 MHz, CDCl3) δ 1.15 (t, 3H, J = 7.0 Hz), 1.41 (d, 3H, J 
= 6.6 Hz), 3.78 (s, 3H), 4.17 (q, 2H, J =7.0 Hz), 4.58 (q, 1H, J =6.6 Hz), 6.84 (d, 2H, J 
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= 8.8 Hz), 6.88 (s, 1H), 7.26 (d, 2H, J = 8.8 Hz); 13C NMR (200 MHz, CDCl3) δ 13.9, 
22.4, 55.2, 60.8, 70.2, 113.6(2), 127.8, 129.9 (2), 132.2, 135.5, 159.6, 167.6. GC-MS rt 
19.60 min, m/z: 250(21), 232(34), 203(25), 189(75), 159(100), 144(66), 128(21), 
115(57), 89(20), 77(18).  
(3S)-Z-1d:  HPLC on Chiralcel OD (98/2 n-hexane/2-propanol, flow 1.5 mL/min):  rt 
24.8 min., [α]25D = -4.0 (c 1.0 CHCl3) 
(3R)-Z-1d: HPLC on Chiralcel OD (98/2 n-hexane/2-propanol, flow 1.5 mL/min):  rt 
27.1 min., [α]25D = +4.8 (c 1.0 CHCl3) 
 
E-1d: Yellow oil; IR (film) ν/cm-1 3442, 2976, 2929, 1717, 1607, 1512, 1253, 1178. 1H 
NMR (200 MHz, CDCl3) δ 1.21 (t, 3H, J = 7.2 Hz), 1.48 (d, 3H, J = 7.2 Hz), 1.90 (bs, 
1H), 3.81 (s, 3H), 4.09 (q, 1H, J =7.2 Hz), 4.23 (q, 1H, J =7.2 Hz), 6.91 (s, 1H), 6.93 (d, 
2H, J = 8.4 Hz), 7.33 (d, 2H, J = 8.4 Hz); 13C NMR (200 MHz, CDCl3) δ 13.8, 22.3, 
55.2, 65.0, 70.2, 113.7(2), 127.6, 128.6, 130.0, 133.0, 135.4, 159.1, 168.0. GC-MS rt 
19.70 min, m/z: 250(11), 232(32), 203(25), 189(42), 159(100), 144(68), 128(22), 
121(25), 115(60), 89(17), 77(12). 
 
(3R)-Z-2a: Yellow oil; IR (film) ν/cm-1 2963, 1644, 1466, 1241, 1178, 1097. 1H NMR 
(300 MHz, CDCl3) δ 1.05 (d, 6H, J = 6.6 Hz), 1.34 (m, 6H), 2.08 (s, 3H), 3.15 (m, 1H), 
4.26 (q, 2H, J =7.2 Hz), 5.65 (q, 1H, J =6.6 Hz)  5.91 (d, 1H, J = 9.9 Hz); 13C NMR 
(300 MHz, CDCl3) δ 14.1, 19.8, 21.2, 22.4, 22.5, 28.2, 60.4, 69.9, 130.5, 147.9, 
169.9,170.5. GC-MS rt 12.89 min, m/z: 213(2), 185(24), 168(35), 143(100), 123(57), 
95(83), 79(54), 67(35), 55(28). [α]25D = +36.5 (c 1.0 CHCl3) 
 
 (3R)-Z-2b: Yellow oil; IR (film) ν/cm-1 2926, 2852, 1690, 1448, 1368, 1303, 1263, 
1222, 1155, 1064. 1H NMR (200 MHz, CDCl3) δ 0.89-1.25 (m, 5H), 1.26 (t, 3H, J = 7.0 
Hz), 1.33 (d, 3H, J = 6.6 Hz), 1.55-1.77 (m, 5H),  2.02 (s, 3H), 2.80 (m, 1H), 4.19 (q, 
2H, J =7.0 Hz), 5.60 (q, 1H, J =6.6 Hz), 5.88 (d, 1H, J = 10.0 Hz); 13C NMR (200 MHz, 
CDCl3) δ 14.1, 19.9, 21.2(2), 25.5(2), 26.0, 32.4, 32.6, 37.8, 60.2, 69.9, 130.8, 146.7, 
166.4, 170.1. GC-MS rt 17.40 min, m/z: 268(2), 225(18), 208(55), 179(63), 162(100), 
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151(10), 143(95), 133(57), 119(35), 105(33), 91(41), 81(84), 67(38), 55(31).  [α]25D = 
+27.2 (c 1.0 CHCl3) 
 
(3R)-Z-2d: Yellow oil; IR (film) ν/cm-1 2981, 2936, 1735, 1718, 1618, 1607, 1511, 
1458, 1370, 1254, 1178, 1055, 1029. 1H NMR (200 MHz, CDCl3) δ 1.17 (t, 3H, J = 7.4 
Hz), 1.48 (d, 3H, J = 6.6 Hz), 2.05 (s, 3H), 3.79 (s, 3H), 4.17 (q, 2H, J =7.4 Hz), 5.68 
(q, 1H, J =6.6 Hz), 6.77 (s, 1H), 6.82 (d, 2H, J = 9.2 Hz), 7.23 (d, 2H, J = 9.2 Hz); 13C 
NMR (200 MHz, CDCl3) δ 14.2, 20.2, 21.5, 55.5, 61.1, 71.7, 113.9(2), 127.6, 129.8(2), 
130.4, 133.6, 160.0, 168.2, 170.2  GC-MS rt 20.60 min, m/z: 292(3), 249(6), 232(21), 
203(49), 187(19), 159(100), 144(62), 128(22), 115(59), 89(14), 77(12). [α]25D = +44.3 
(c 1.0 CHCl3) 
 
1c: 1H NMR (CDCl3) δ 1.15 (3H, t, J= 7.4 Hz, OCH2CH3), 1.54 (3H, d, J= 6.6 Hz, 
CH3CHO),  2.07 (3H, s, CH3CO), 4.17( 2H, q, J= 7.4 Hz, OCH2CH3), 5.74 (1H, q, J= 
6.6 Hz, CH3CHO), 6.88 (1H, s, CH=C), 7.20-7.40 (5H, m, Ph); 13C NMR (CDCl3) δC 
13.7 (CH3), 19.6 (CH3), 21.0 (CH3), 60.8 (CH2), 71.0 (CH), 128.0 (CH), 128.2 (2CH), 
133.3 (CH), 134.2 (C) 134.9(C), 167.6(C), 169.8(C); IR (film) ν/cm-1  2983, 2936, 
2360, 1740, 1447, 1371, 1239, 1151, 1055, 753; [α]D = +54.7 (c 1 in CDCl3); LC-ESI-
MS rt 9.251 min, m/z 262 (M), 285 (M+Na). 
 
General procedure for the preparation of the Carbonates. To a solution of the Z-allylic 
alcohol (1 mmol) in dry THF (10 mL), under an inert atmosphere at -78°C, LiHMDS 
(1.5 equiv, 1.5 mL 1 M solution in THF) was added dropwise. The solution was stirred 
for 30 min and then methyl chloroformate (2 equiv, 2 mmol) was added in one portion. 
After 40 min, the mixture was quenched with water (2mL) and THF removed under 
reduced pressure. The residue was diluted with ethyl acetate (10 mL) and washed twice 
with water (5 mL). The two phases were separated, the organic layer was dried over 
Na2SO4, and solvent was removed under reduced pressure. Carbonates were isolated by 
flash chromatography on silica gel (cyclohexane/ethyl acetate 95/5 as eluant). 
 
  35
3a: 1H NMR (CDCl3) δ 1.01 (6H, d, J= 6.6 Hz, CH3CHCH3 ), 1.30 (3H, t, J= 7.5 Hz, 
OCH2CH3), 1.43 (3H, d, J= 6.6 Hz, CH3CHO),  3.18 (1H, m, CH3CHCH3),  3.77 (3H, s, 
CH3OCO), 4.25 ( 2H, q, J= 7.5 Hz, OCH2CH3), 5.51 (1H, q, J= 6.6 Hz, CH3CHO), 5.96 
(1H, d, J= 9.9 Hz, CH=C); 13C NMR (CDCl3) δC 14.0 (CH3), 20.0 (CH3), 22.2 (2CH3), 
28.0 (CH), 54.5 (CH3), 60.3 (CH2), 73.5 (CH), 129.7 (C), 148.7 (CH), 154.7 (C), 
165.9(C); IR (film) ν/cm-1 2958, 2873, 1753, 1723, 1440, 1271, 1043; [α]D = -21.2 (c 1 
in CDCl3); LC-ESI-MS rt 9.917 min., m/z 267 (M+Na), 511 (2M+Na). 
 
3b: 1H NMR (CDCl3) δ 0.99-1.40 (4H, m, cyclohexyl), 1.30 (3H, t, J= 7.2 Hz, 
OCH2CH3), 1.41 (3H, d, J= 6.6 Hz, CH3CHO), 1.59-1.80 (6H, m, cyclohexyl), 2.87 
(1H, m, CHCH=C),  3.76 (3H, s, CH3OCO), 4.22 ( 2H, q, J= 7.2 Hz, OCH2CH3), 5.51 
(1H, q, J= 6.6 Hz, CH3CHO), 6.00 (1H, d, J= 9.6 Hz, CH=C); 13C NMR (CDCl3) δC 
14.1 (CH3), 20.2 (CH3), 25.5 (2CH2), 25.8 (2CH2), 32.4 (CH2), 37.9 (CH), 54.5 (CH3), 
60.4 (CH2), 73.8 (CH), 130.2 (C), 147.7 (CH), 166.1(C), 198.0 (C); IR (film) ν/cm-1 
2982, 2927, 2852, 1751, 1721, 1444, 1383, 1341, 1268, 1211, 1046; [α]D = -25.8 (c 1 in 
CDCl3);  LC-ESI-MS rt 11.730 min., m/z 285 (M+1), 307 (M+Na) . 
 
3c: 1H NMR (CDCl3) δ 1.13 (3H, t, J= 6.9 Hz, OCH2CH3), 1.57 (3H, d, J= 6.6 Hz, 
CH3CHO),  3.79 (3H, s, CH3OCO), 4.17 ( 2H, q, J= 6.9 Hz, OCH2CH3), 5.58 (1H, q, J= 
6.6 Hz, CH3CHO), 6.92 (1H, s, CH=C), 7,29 (5H, m, Ph); 13C NMR (CDCl3) δC 13.6 
(CH3), 19.9 (CH3), 54.5 (CH3), 60.9 (CH2), 74.8 (CH), 128.0 (CH), 128.3 (CH), 128.7 
(CH), 133.6 (C), 134.0 (C), 154.8 (CH), 167.3(C) (C); IR (film) ν/cm-1 3382, 2961, 
1757, 1715, 1603, 1445, 1259, 1093, 1024, 797; [α]D = -30.0 (c 1 in CDCl3);  LC-ESI-
MS rt 9.58 min., m/z 279 (M+1), 301 (M+Na), 579 (2M+Na) . 
 
8: Yellow oil; 1H NMR (CDCl3, 200 MHz) δ 1.45 (d, J=6.6 Hz, 3H, CH3CHO), 1.51 (s, 
9H, OC(CH3)3), 1.99 (d, J=7.2 Hz, 3H, CH3CHC), 3.76 (s, 3H, CH3OCO), 5.48 (q, 
J=6.6 Hz, 1H, CH3CHO), 6.23 (q, J=7.2 Hz, 1H, CH3CHC); 13C NMR (CDCl3, 75 
MHz) δC 15.3 (CH3), 20.0 (CH3), 28.3 (3CH3), 54.6 (CH3), 74.1 (CH), 81.3 (C), 134.4 
(C), 135.8 (CH), 155.0 (C), 165.5 (C). (S)-8a [α]D = -24.6 (c 1 in CHCl3); (R)-8a [α]D = 
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+25.0 (c 1 in CHCl3); LC-ESI-MS rt 9.77 min, m/z 244 (M), 267 (M+Na); Anal. cald. 
for C12H20O5(244.13): C 59.00, H 8.25; found C 59.09, H 8.28. 
 
9: Pale yellow oil; 1H NMR (CDCl3, 200 MHz) δ 1.01 (d, J=6.6 Hz, 6H, CH3CHCH3), 
1.42 (d, J=6.6 Hz, 3H, CH3CHO), 1.50 (s, 9H, OC(CH3)3), 3.02-3.17 (m, 1H, 
CH3CHCH3), 3.77 (s, 3H, CH3OCO), 5.46 (q, J=6.6 Hz, 1H, CH3CHO), 5.84 (d, J=9.6 
Hz, 1H, CHCHC);13C NMR (CDCl3, 75 MHz) δC 19.8 (CH3), 22.5 (2CH3), 26.2 (CH), 
28.1 (3CH3), 54.5 (CH3), 74.0 (CH), 81.2 (C), 131.3 (C), 146.7 (CH), 155.0 (C), 165.6 
(C). (S)-9b [α]D = -30.0 (c 1 in CHCl3); (R)-9b [α]D = +28.9 (c 1 in CHCl3); LC-ESI-
MS rt 11.82 min, m/z 272 (M), 295 (M+Na); Anal. cald. for C14H24O5(272.16): C 61.74, 
H 8.88; found C 61.76, H 8.86. 
 
10: Pale yellow oil; 1H NMR (CDCl3, 200 MHz) δ 0.86-1.30 (m, 6H, cyclohexyl), 1.39 
(d, J=6.2 Hz, 3H, CH3CHO), 1.47 (s, 9H, OC(CH3)3), 1.66-1.79 (m, 4H, cyclohexyl), 
2.78 (m, CH cyclohexyl ), 3.74 (s, 3H, CH3OCO), 5.43 (q, J=6.2 Hz, 1H, CH3CHO), 
5.83 (d, J=9.4 Hz, 1H, CHCHC); 13C NMR (CDCl3, 75 MHz) δC 19.9 (CH3), 25.5 
(2CH2), 25.8 (CH2), 28.1 (3CH3), 32.4 (2CH2), 37.7 (CH), 54.5 (CH3), 74.0 (CH), 81.0 
(C), 131.5 (C), 145.4 (CH), 154.8 (C), 165.5 (C); (S)-10 [α]D = -25.2 (c 1 in CHCl3); 
(R)-10 [α]D = +26.7 (c 1 in CHCl3); LC-ESI-MS rt 10.81 min, m/z 312 (M), 
335(M+Na); Anal. cald. for C17H28O5(312.19): C 65.36, H 9.03; found C 65.51, H 9.05. 
 
11: Yellow oil; 1H NMR (CDCl3, 200 MHz) δ 1.49 (s, 9H, OC(CH3)3), 1.53 (d, J=6.6 
Hz, 3H, CH3CHO), 3.78 (s, 3H, CH3OCO), 5.51 (q, J=6.6 Hz, 1H, CH3CHO), 6.72 (s, 
1H, CCHC), 7.14-7.31 (m, 3H, thiophenyl); 13C NMR (CDCl3, 75 MHz) δC 20.1 (CH3), 
28.0 (3CH3), 54.8 (CH3), 75.3 (CH), 82.1 (C), 125.3 (CH), 126.5 (CH), 126.7 (CH), 
128.2 (C), 133.2 (CH), 136.1 (C), 155.0 (C), 166.6 (C); LC-ESI-MS rt 10.59 min, m/z 
312 (M), 335(M+Na). Anal. cald. for C15H20O5S(312.1): C 57.67, H 6.45, S 10.26; 
found C 57.85, H 6.44, S 10.29. 
 
General procedure for the preparation of the dehydro-β-amino esters 5a-c (Pathway A). 
To a solution of the corresponding carbonates (0.2 mmol) in dry THF or CH3CN (2 
mL), under nitrogen atmosphere, benzylamine (2 equiv) was added. The solution was 
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refluxed for 24-96 h . The solvent was removed under reduced pressure. Compounds 
3a-c were isolated by flash chromatography on silica gel (cyclohexane/ethyl acetate 
95/5 as eluant). 
 
General procedure for the preparation of the dehydro-β-amino esters 5a-c (Pathway B). 
To a solution of the corresponding carbonates (0.2 mmol) in dry THF (2 mL), under 
nitrogen atmosphere, Pd2(dba)3CHCl3 (2%, 0.004 mmol) was added; the solution was 
stirred at room temperature for 30 min. Then benzylamine (2 equiv) was added. The 
solution was refluxed for 24 h. The mixture was filtered through a celite pad and 
concentrated under reduced pressure. Compounds 3a-c were isolated by flash 
chromatography on silica gel (cyclohexane/ethyl acetate 95/5 as eluant). 
 
General procedure for the preparation of the dehydro-β-amino esters 5/6a-c (with 
chiral Ligand). To a solution of dry THF (or CH2Cl2) under nitrogen atmosphere, 
Pd2(dba)3CHCl3 (5 or 2%) and (R,R)-DACH-Phenyl Trost Ligand (8 or 6%) are added 
and stirred at room temperature until the solution turned from dark purple to orange. 
Then the corresponding carbonates (0.2 mmol) was added; the solution was stirred at 
room temperature for 30 min. Then benzylamine (2 equiv) was added. The solution was 
refluxed for 24 h. The mixture was pured in pentane/ether, 1:1 (10 ml), filtered through 
a celite pad and concentrated under reduced pressure. Compounds 3/4a-c were isolated 
by flash chromatography on silica gel (cyclohexane/ethyl acetate 95/5 as eluant). 
5a: 1H NMR (CDCl3) major isomer δ 0.77 (3H, d, J= 6.6 Hz, CH3CHCH3), 1.16 (3H, d, 
J= 6.6 Hz, CH3CHCH3 ), 1.32 (3H, t, J= 6.9 Hz, OCH2CH3), 1.70 (3H, d, J= 7.2 Hz, 
CH3CH=C), 2.0 (1H, m, CH3CHCH3), 3.12 (1H, d,  J= 9.6 Hz, CHN), 3.54 (1H, d, J= 
13.5 Hz, CH2Ph ), 3.58 (1H, d, J= 13.5 Hz, CH2Ph ), 4.24 ( 2H, q, J= 6.9 Hz, 
OCH2CH3), 7.07 (1H, q, J= 6.9Hz, CH3CH=C), 7.24-7.44 (5H, m, Ph); minor isomer δ 
0.86 (3H, d, J= 6.6 Hz, CH3CHCH3), 1.02 (3H, d, J= 6.6 Hz, CH3CHCH3 ), 1.30 (3H, t, 
J= 6.9 Hz, OCH2CH3), 2.0 (1H, m, CH3CHCH3), 2.01 (3H, d, J= 7.2 Hz, CH3CHO), 
2.87 (1H, d,  J= 8.4 Hz, CHN), 3.57 (1H, d, J= 13.2 Hz, CH2Ph ), 3.82 (1H, d, J= 13.2 
Hz, CH2Ph ), 4.27 ( 2H, q, J= 6.9 Hz, OCH2CH3), 5.94 (1H, q, J= 6.9Hz, CH3CH=C), 
7.25-7.39 (5H, m, Ph); 13C NMR (CDCl3) δC major isomer 14.2 (CH3), 20.2 (CH3), 21.0 
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(CH3), 31.8 (CH), 51.1 (CH2), 54.6 (CH3), 60.1 (CH2), 61.4 (CH), 126.6 (CH), 127.5 
(CH), 128.1 (CH), 133.0 (C), 139.8 (C), 141.0 (CH), 167.3 (C); IR (film) ν/cm-1 3360, 
2958, 1946, 1711, 1653, 1445, 1267, 1093; [α]D = +14.6 (c 1 in CDCl3); HPLC 
analysis, 100% n-hexane, 0.8 ml/min, OJ column, rt 11.837 min; LC-ESI-MS rt 4.787 
min., m/z 276 (M+1) . 
5b: 1H NMR (CDCl3) major isomer δ 1.28 (3H, t, J= 7.2 Hz, OCH2CH3 ), 1.02-1.51 
(6H, m, cyclohexyl), 1.62 (3H, d, J= 7.2 Hz CH3CH=C), 1.55-1.77 (4H, m, cyclohexyl), 
2.4 (1H, bs, CHCN), 3.16 (1H, d,  J= 9.8 Hz, CHN), 3.47 (1H, d, J= 13.5 Hz, CH2Ph ), 
3.80 (1H, d, J= 13.5 Hz, CH2Ph ), 4.17 ( 2H, q, J= 7.2 Hz, OCH2CH3), 7.01 (1H, q, J= 
7.2 Hz, CH3CH=C), 7.15-7.35 (5H, m, Ph); minor isomer δ 1.94 (3H, d, J= 7.09 Hz, 
CH3CHO), 2.08 (1H, bs, CHCN), 2.85 (1H, d,  J= 8.8 Hz, CHN), 3.50 (1H, d, J= 13.28 
Hz, CH2Ph ), 5.85 (1H, q, J= 7.1 Hz, CH3CH=C); 13C NMR (CDCl3) δC major isomer 
14.1 (CH3), 14.3 (CH3), 26.2 (CH2), 26.3 (CH2), 26.7 (CH2),31.6 (CH2), 41.7 (CH), 51.0 
(CH2), 60.1 (CH2), 126.5 (CH), 128.1 (CH), 128.1 (CH), 132.8 (C), 139.8 (C), 141.0 
(CH), 167.3 (C); IR (film) ν/cm-1  3417, 2930, 2857, 1703, 1638, 1445, 1263, 1097; 
[α]D = +10.3 (c 1 in CDCl3);  HPLC analysis, 100% n-hexane, 0.8 ml/min, OJ column, 
rt 7.042 min; LC-ESI-MS rt 16.261 min., m/z 316 (M+1). 
 
5c: 1H NMR (CDCl3) major isomer δ 1.21 (3H, t, J= 7.1 Hz, OCH2CH3), 1.91 (3H, d, 
J= 7.3 Hz, CH3CH=C),  3.82 (1H, d, J= 13.3 Hz, CH2Ph), 3.96 (1H, d, J= 13.3 Hz, 
CH2Ph), 4.15 (2H, q, J= 7.1 Hz, OCH2CH3), 4.91 (1H, s, CHN), 7.2 (1H, q, J= 7.3 Hz, 
CH3CH=C), 7.2-7.5 (10H, m, Ph); ); minor isomer δ 1.23 (3H, t, J= 7.5 Hz, OCH2CH3), 
2.08 (3H, d, J= 7.0 Hz, CH3CH=C),  3.77-3.88 (2H, m, CH2Ph), 4.65 (1H, s, CHN), 
6.35 (1H, q, J= 7.23 Hz, CH3CH=C); 13C NMR (CDCl3) δC major isomer 14.0 (CH3), 
51.0 (CH2), 56.9 (CH3), 60.3 (CH2), 63.9 (CH), 126.5 (CH), 126.8 (CH), 127.0 (CH),  
128.0 (CH), 128.2 (CH), 128.4 (CH), 133.6 (C), 139.9 (C), 140.3 (CH), 166.7 (C); 
minor isomer 14.2 (CH3), 51.5 (CH2), 54.9 (CH3), 60.1 (CH2), 63.9 (CH), 126.4 (CH), 
126.9 (CH), 127.0 (CH),  128.1 (CH), 128.3 (CH), 128.4 (CH), 133.5 (C), 137.5 (C), 
142.2 (CH), 166.9 (C); IR (film) ν/cm-1 3359, 3027, 2930, 2857, 1738, 1707, 1595, 
1491, 1456, 1371, 1256, 746, 700; [α]D = -6.2 (c 1 in CDCl3);  HPLC analysis, 98:2 n-
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hexane/2-propanol, 0.8 ml/min, OJ column, rt 13.463 min (major), 21.310 min (minor); 
LC-ESI-MS rt 9.45 min., m/z 310 (M+1). 
 
General procedure for the preparation of the dehydro-β-amino esters 6a-c. To a solution 
of the corresponding carbonates (0.2 mmol) in dry CH3CN (2 mL), under nitrogen 
atmosphere, Pd2(dba)3CHCl3 (2%, 0.004 mmol) was added; the solution was stirred at 
room temperature for 30 min. Then benzylamine (2 equiv) was added. The solution was 
refluxed for 24 h. The mixture was filtered through a celite pad and concentrated under 
reduced pressure. Compounds 4a-c were isolated by flash chromatography on silica gel 
(cyclohexane/ethyl acetate 95/5 as eluant). 
6a: 1H NMR (CDCl3) δ 1.06 (3H, d, J= 6.6 Hz, CH3CHCH3), 1.08 (3H, d, J= 6.6 Hz, 
CH3CHCH3 ), 1.31 (3H, d, J= 6.9 Hz, CH3CHN),  1.35 (3H t, J= 6.9 Hz, OCH2CH3), 
1.90 (1H, s, NH), 3.01 (1H, m, CH3CHCH3), 3.43 (1H, q,  J= 6.9 Hz, CHN), 3.64 (1H, 
d, J= 12.9 Hz, CH2Ph ), 3.81 (1H, d, J= 12.9 Hz, CH2Ph ), 4.27 ( 2H, q, J= 6.9 Hz, 
OCH2CH3), 5.73 (1H, q, J= 9.9Hz, CHCH=C), 7.20-7.40 (5H, m, Ph); 13C NMR 
(CDCl3) δC 14.3 (CH3), 21.3 (CH3), 22.7 (CH3), 23.0 (CH3), 28.6 (CH), 51.0 (CH2), 
56.8 (CH), 60.1 (CH2), 126.8 (CH), 128.2 (CH), 128.3 (CH), 132.2 (C), 140.4 (C), 
146.2 (CH), 168.3 (C); IR (film) ν/cm-1 3343, 2973, 2923, 2861, 1707, 1460, 1379, 
1225, 1175, 1163, 1093, 1016; [α]D = -7.0 (c 1 in CDCl3); HPLC analysis, 100% n-
hexane, 0.8 ml/min, OJ column, rt 11.840 min;  LC-ESI-MS rt 1.507 min., m/z 276 
(M+1) . 
6b: 1H NMR (CDCl3) δ 1.29 (3H, d, J= 6.6 Hz, CH3CHN),  1.35 (3H, t, J= 6.9 Hz, 
OCH2CH3), 1.05-1.41 (6H, m, cyclohexyl), 1.69-1.80 (4H, m, cyclohexyl), 2.0 (1H, bs, 
NH), 2.70 (1H, m, CHCH=C), 3.43 (1H, q,  J= 6.6 Hz, CH3CHN), 3.63 (1H, d, J= 12.6 
Hz, CH2Ph ), 3.80 (1H, d, J= 12.6 Hz, CH2Ph ), 4.28 ( 2H, q, J= 6.9 Hz, OCH2CH3), 
5.75 (1H, d, J= 9.9Hz, CHCH=C), 7.27-7.36 (5H, m, Ph); 13C NMR (CDCl3) δC 14.2 
(CH3), 21.4 (CH3), 25.6 (CH2), 32.7 (2CH2), 33.1 (2CH2), 38.3 (CH), 51.0 (CH2), 60.2 
(CH2), 126.8 (CH), 128.3 (CH), 128.8 (CH), 132.4 (C), 140.4 (C), 145.2 (CH), 168.2 
(C); IR (film) ν/cm-1 3346, 3027, 2924, 2851, 1709, 1600, 1450, 1366, 1118; [α]D = -
12.5 (c 1 in CDCl3); HPLC analysis, 100% n-hexane, 0.8 ml/min, OJ column, rt 12.532 
min;  LC-ESI-MS rt 12.330 min., m/z 316 (M+1). 
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6c: 1H NMR (CDCl3) δ 1.40 (3H, t, J= 6.9 Hz, OCH2CH3), 1.50 (3H, d, J= 6.6 Hz, 
CH3CHN), 2.30 (1H, bs, NH), 3.45 (1H, d, J= 13.2 Hz, CH2Ph ), 3.69 (1H, d, J= 13.2 
Hz, CH2Ph ), 4.0 (1H, q,  J= 6.6 Hz, CH3CHN), 4.32 ( 2H, q, J= 6.9 Hz, OCH2CH3), 
7.16-7.38 (10H, m, Ph) 7.83 (1H, s, CCH=C); 13C NMR (CDCl3) δC 14.2 (CH3), 20.8 
(CH3), 50.4 (CH), 51.3 (CH2), 60.5 (CH2), 126.6 (CH), 128.0 (CH), 128.1 (CH), 128.2 
(CH), 128.3 (CH), 128.9 (CH), 135.1 (C), 135.3 (C), 140.2 (C), 140.4 (CH), 168.2 (C); 
IR (film) ν/cm-1 3348, 3027, 2981, 2927, 1689, 1499, 1456, 1244, 1117, 1020, 700; [α]D 
= -8.0 (c 1 in CDCl3); HPLC analysis, 98:2 n-hexane/2-propanol, 0.8 ml/min, OJ 
column, rt 14.641 min (major);  LC-ESI-MS rt 11.520 min., m/z 310 (M+1). 
 
General procedure for the preparation of the β-lactams 7a-b. To a solution of the 
corresponding dehydro-β-amino esters 4a-b (0.2 mmol) in dry THF (4 mL), under an 
inert atmosphere at -20°C, LiHMDS (1.5 equiv, 1 M solution in THF) was added drop-
wise. The solution was stirred for 50 min at the same temperature. After 40min, the 
mixture was quenched with water and THF removed under reduced pressure. The 
residue was diluted with ethyl acetate (10 mL) and washed twice with water (5 mL). 
The two phases were separated, the organic layer was dried over Na2SO4, and solvent 
was removed under reduced pressure. Compounds 5a-b were isolated by flash 
chromatography on silica gel (cyclohexane/ethyl acetate 90/10 as eluant). 
7a: 1H NMR (CDCl3) δ 1.03 (6H, d, J= 6.6 Hz, CH3CHCH3), 1.16 (3H, d, J= 6.6 Hz, 
CH3CHN), 3.21 (1H, m, CH3CHCH3),  3.86 ( 1H, q,  J= 6.0 Hz, CHN), 4.18 (1H, d, J= 
15.0 Hz, CH2Ph ), 4.66 (1H, d, J= 15.0 Hz, CH2Ph ), 5.33 (1H, d, J= 11.1 Hz, 
CHCH=C), 7.25-7.35 (5H, m, Ph); 13C NMR (CDCl3) δC 17.3 (CH3), 22.9 (2CH3), 28.0 
(CH), 44.0 (CH2), 54.7 (CH), 127.5 (CH), 128.2 (CH), 135.3 (CH), 136.2 (C), 140.0 
(CH), 163.7 (C); IR (film) ν/cm-1 3424, 2961, 2927, 1734, 1645, 1452, 1391, 1264, 
1105, 1028, 792, 700; [α]D = -61.2 (c 1 in CDCl3); HPLC analysis, 98:2 n-hexane/2-
propanol, 0.8 ml/min, AD column, rt 15.070 min; LC-ESI-MS rt 9.715 min., m/z 230 
(M+1), 252 (M+Na). 
7b: 1H NMR (CDCl3) δ 1.15 (3H, d, J= 6.0 Hz, CH3CHN), 1.07-1.42 (6H, m, 
cyclohexyl), 1.60-1.71 (4H, m, cyclohexyl),  3.86 ( 1H, q,  J= 6.0 Hz, CHN), 4.18 (1H, 
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d, J= 15.0 Hz, CH2Ph ), 4.66 (1H, d, J= 15.0 Hz, CH2Ph ), 5.36 (1H, d, J= 9.6 Hz, 
CHCH=C), 7.25-7.33 (5H, m, Ph); 13C NMR (CDCl3) δC 17.3 (CH3), 25.4 (2CH2), 25.8 
(CH2), 33.0 (2CH2), 37.3 (CH), 44.0 (CH2), 127.5 (CH), 128.2 (CH), 128.7 (CH), 134.2 
(CH), 136.3 (C), 140.3 (CH), 163.7 (C); IR (film) ν/cm-1 3390, 2923, 2846, 1738, 1452, 
1379, 1264, 1098, 1028; [α]D = -39.0 (c 1 in CDCl3); HPLC analysis, 98:2 n-hexane/2-
propanol, 0.8 ml/min, AD column, rt 16.494 min; LC-ESI-MS rt 11.773 min., m/z 270 
(M+1), 292 (M+Na). 
 
General procedure for the preparation of the dehydro-β-amino esters. To a solution of 
the carbonate 8-11 (0.2 mmol) in dry CH3CN (2 mL), under nitrogen atmosphere, 
Pd2(dba)3CHCl3 (2.5%, 0.005 mmol) was added in one portion. After stirring the 
solution at room temperature for 30 min, the amine (1.2 equiv) was added. The solution 
was refluxed for 12 h and then the mixture was filtered through a celite pad and 
concentrated under reduced pressure. The dehydro-β-amino ester was isolated by flash 
chromatography on silica gel. 
 
12a: Orange  oil (40%), (1:1 E/Z mixture); Rf (30% ethylacetate/70% cyclohexane) 
0.10; 1H NMR (200 MHz, CDCl3) (E) δ 1.09 (d, J = 6.6 Hz, 3H, CH3CHN), 1.46 (s, 9H, 
OC(CH3)3), 1.84 (d, J = 7.4Hz, 3H, CH3CHC), 2.44 (s, 3H, CH3N), 2.50–2.80 (m, 8H, 
piperazine), 3.42 (q, J = 7.4 Hz, 1H, CH3CHN), 6.63 (q, J = 6.6 Hz, 1H, CH3CHC); (Z) 
δ 1.26 (d, J = 6.6 Hz, 3H, CH3CHN), 1.42 (s, 9H, OC(CH3)3), 1.78 (d, J = 7.4Hz, 3H, 
CH3CHC), 2.44 (s, 3H, CH3N), 2.50–2.80 (m, 8H, piperazine), 3.42 (q, J = 7.4 Hz, 1H, 
CH3CHN), 5.70 (q, J = 6.6 Hz, 1H, CH3CHC).13C NMR (75 MHz, CDCl3) δ 15.6, 17.7, 
28.3 (3C), 47.6, 55.8, 57.0 (2C), 57.4 (2C), 90.0, 132.3, 135.9, 164.3; IR (neat, cm-1) 
696, 721, 802, 1014, 1119, 1152, 1261, 1367, 1392, 1454, 1622, 1712, 2795, 2852, 
2930, 2964, 3364; Anal. calcd. for C15H28N2O2 (268.4): C 67.13, H 10.52, N 10.44; 
found C 67.07, H 10.52, N 10.46. 
 
12b: Yellow oil (35%), (80:20 E/Z mixture); Rf (30% ethylacetate/70% cyclohexane) 
0.10; 1H NMR (200 MHz, CDCl3) (E) δ 1.34 (d, J = 6.6 Hz, 3H, CH3CHN), 1.52 (s, 9H, 
OC(CH3)3), 1.74 (d, J = 7.4 Hz, 3H, CH3CHC), 2.58 (bs, 1H, NH), 3.53 (d, J = 12.4 Hz, 
1H, HNCH2), 3.69 (d, J = 12.4 Hz, 1H, HNCH2), 3.73 (q, J = 6.6 Hz, 1H, CH3CHN), 
  42 
3.81 (s, 3H, OCH3), 6.80–6.86 (m, 1H, CH3CHC), 6.85 (d, J = 8.4 Hz, 2H, phenyl), 7.24 
(d, J = 8.4Hz, 2H, phenyl); 13C NMR (75 MHz, CDCl3) δ 13.8, 20.6, 28.3 (3C), 50.0, 
50.7, 55.3, 80.7, 113.8 (2C), 129.5 (2C), 132.0, 135.9, 137.9, 151.1, 166.7; IR (neat, cm-
1) 699, 766, 832, 1031, 1097, 1160, 1258, 1339, 1449, 1511, 1577, 1604, 1651, 1698, 
2850, 2926, 2961, 3366; Anal. calcd. for C18H27NO3 (305.4): C 70.79, H 8.91, N 4.59; 
found C 70.52, H 8.94, N 10.47. 
 
12f: Yellow oil (60%), (70:30 E/Z mixture); Rf (50% ethylacetate/50% cyclohexane on 
alumina plates) 0.23; 1H NMR (CDCl3, 200 MHz) (E) δ 1.31 (d, J = 7 Hz, 3H, 
CH3CHN), 1.50 (s, 9H, OC(CH3)3), 1.72 (d, J = 7.4 Hz, 3H, CH3CHC), 3.43 (d, J = 
12.4 Hz, 1H, HNCH2), 3.60 (d, J = 12.4 Hz, 1H, HNCH2), 3.72 (q, J = 6.6 Hz, 1H, 
CH3CHN), 6.63 (d, J = 8 Hz, 2H, phenyl), 6.81 (q, J = 7.4 Hz, 1H, CH3CHC), 7.08 (d, J 
= 8 Hz, 2H, phenyl); 13C NMR (CDCl3, 75 MHz) δ 13.8, 20.7, 28.4 (3C), 49.9, 51.0, 
80.5, 115.2 (2C), 129.4 (2C), 130.6, 136.3, 137.7, 145.2, 166.7; IR (neat, cm-1)1141, 
1278, 1367, 1392, 1453, 1517, 1632, 1695, 2929, 2975, 3216, 3368, 3445. LC-ESI-MS 
rt 8.39 min, m/z 290 (M), 313 (M+Na). Chiral HPLC analysis 99:1 to 96:4 n-hexane/2-
propanol in 30 min, 1.0 mL/min, AD column, rt 23.52 min for [E-(R)-5f] and 26.12 min 
[E-(S)-5f]; E-(S)-5f [α]D = -14.0 (c 1 in CHCl3); E-(R)-5f [α]D = +14.0 (c 1 in CHCl3) 
Anal. cald. for C17H26N2O2 (290.2): C 70.31, H 9.02, N 9.65; found C 70.08, H 9.00, N 
9.65.  
 
13a: Orange oil (47%), (95:5 Z/E mixture); Rf (40% ethylacetate/60% cyclohexane) 
0.12; 1H NMR (200 MHz, CDCl3) (Z): δ 0.96 (d, J = 6.6 Hz, 3H, CH3CHCH3), 0.99 (d, 
J = 6.6 Hz, 3H, CH3CHCH3), 1.09 (d, J = 7 Hz, 3H, CH3CHN), 1.49 (s, 9H, OC(CH3)3), 
2.24 (s, 3H, CH3N), 2.25–2.40 (m, 8H, piperazine), 2.65–2.83 (m, 1H, CH3CHCH3), 
3.40 (q, J = 7Hz, 1H, CH3CHN), 5.33 (d, J = 9.6 Hz, 1H, CHCHC); 13C NMR (75 
MHz, CDCl3) δ 12.8, 22.9 (2C), 28.4 (3C), 28.6, 46.1, 55.7 (4C), 60.9, 80,3, 135.6, 
140.4, 167.2 ; IR (neat, cm-1) 1014, 1148, 1239, 1322, 1366, 1455, 1716, 2793, 2869, 
2935, 2969. LC-MS-ESI rt 1.73, 297 (M+1) Anal. cald. for C17H32N2O2 (296.4): C 
68.88, H 10.88, N 9.45; found C 68.93, H 10.89, N 9.43.   
 
  43
13b: Yellow oil (45%), (95:5 Z/E mixture); Rf (30% ethylacetate/70% cyclohexane) 
0.33; 1H NMR (200 MHz, CDCl3) (Z): δ 1.03 (d, J = 6.6 Hz, 3H, CH3CHCH3), 1.07 (d, 
J = 6.6 Hz, 3H, CH3CHCH3), 1.25 (d, J = 6.6 Hz, 3H, CH3CHN), 1.53 (s, 9H, 
OC(CH3)3), 1.82 (bs, 1H, NH), 2.84–3.06 (m, 1H, CH3CHCH3), 3.32 (q, J = 6.6 Hz, 1H, 
CH3CHN), 3.53 (d, J = 12.6 Hz, 1H, HNCH2), 3.73 (d, J = 12.6 Hz, 1H, HNCH2), 3.80 
(s, 3H, OCH3), 5.55 (d, J = 10.0 Hz, 1H, CHCHC) 6.86 (d, J = 8.8 Hz, 2H, phenyl), 
7.25 (d, J = 8.8 Hz, 2H, phenyl); 13C NMR (75 MHz, CDCl3) δ 21.4, 22.8, 23.2, 28.4 
(3C), 28.7, 50.5, 55.3, 57.0, 80.9, 113.8 (2C), 129.5 (2C), 132.9, 133.7, 144.4, 158.6, 
167.9; IR (neat, cm-1) 829, 848, 1037, 1152, 1246, 1300, 1320, 1367, 1392, 1465, 1512, 
1611, 1707, 2834, 2868, 2932, 2966. LC-MS-ESI rt 4.13, 334 (M+1) Anal. cald. for 
C20H31NO3 (333.4): C 72.04, H 9.37, N 4.20; found C 71.95, H 9.40, N 4.18.   
 
13c: Yellow oil (40%), (95:5 Z/E mixture); Rf (30% ethylacetate/70% cyclohexane) 
0.35; 1H NMR (200 MHz, CDCl3) (Z): δ 0.98 (d, J = 6.2 Hz, 3H, CH3CHCH3), 1.04 (d, 
J = 6.2 Hz, 3H, CH3CHCH3), 1.24 (d, J = 6.6 Hz, 3H, CH3CHN), 1.51(s, 9H, 
OC(CH3)3), 1.77 (bs, 1H, NH), 2.86–3.02 (m, 1H, CH3CHCH3), 3.27 (q, J = 6.6Hz, 1H, 
CH3CHN), 3.65 (d, J = 13.4 Hz, 1H, HNCH2), 3.84 (d, J = 13.4 Hz, 1H, HNCH2), 3.92 
(s, 3H, OCH3), 5.51 (d, J = 9.8 Hz, 1H, CHCHC), 7.40 (d, J = 8.4 Hz, 2H, phenyl), 7.99 
(d, J = 8.4 Hz, 2H, phenyl); 13C NMR (75 MHz, CDCl3) δ  21.2, 22.7, 23.2, 28.4, 28.6, 
50.7, 52.1, 57.4, 81.1, 128.1, 128.2 (2C), 128.8, 129.7 (2C), 144.8, 146.0, 163.5, 164.2;  
IR (neat, cm-1) 699, 759, 1019, 1151, 1278, 1367, 1435, 1615, 1656, 1683, 1722, 2868, 
2930, 2965. LC-MS-ESI rt 5.33, 362 (M+1) Anal. cald. for C21H31NO4 (361.4): C 69.78, 
H 8.64, N 3.87; found C 69.52, H 8.63, N 3.87. 
 
13d: Yellow oil (60%); (95:5 Z/E mixture; 1:1 diastereomeric mix); Rf (30% 
ethylacetate/70% cyclohexane) 0.40; Z-Isomer A: 1H NMR (200 MHz, CDCl3) δ 0.92-
1.00 (m, 6H, CH3CHCH3), 1.25 (d, J = 7Hz, 3H, CH3CHN), 1.48 (s, 9H, OC(CH3)3), 
1.76–1.92 (m, 4H, NCH2CH2CH2), 2.63–2.83 (m, 2H, NCH2), 3.00–3.10 (m, 1H, 
CH3CHCH3), 3.54–3.68 (m, 2H, CH3CHN, NCHCO), 5.12 (s, 2H, CH2Ph), 5.48 (d, J = 
9.8 Hz, 1H, CHCHC), 7.28–7.41 (m, 5H, phenyl); Z-Isomer B: 1H NMR (200 MHz, 
CDCl3) δ 0.94 (m, 6H, CH3CHCH3), 1.18 (d, J = 7 Hz, 3H, CH3CHN), 1.50 (s, 9H, 
OC(CH3)3), 1.76–1.92 (m, 4H, NCH2CH2CH2), 2.63–2.83 (m, 2H, NCH2), 3.00–3.10 
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(m, 1H, CH3CHCH3), 3.54–3.68 (m, 2H, CH3CHN, NCHCO), 5.12 (s, 2H, CH2Ph), 
5.55 (d, J = 9.8 Hz, 1H, CHCHC), 7.28–7.41 (m, 5H, phenyl); 13C NMR (75 MHz, 
CDCl3) δ 17.8, 22.8, 23.4, 27.0, 28.3, 28.6, 30.1, 49.2, 59.1, 62.3, 66.0, 80.7, 128.1 
(2C), 128.2(2C), 128.6(2C), 136.2, 143.3, 168.4, 175.1; IR (neat, cm-1) 697, 750, 1149, 
1241, 1270, 1367, 1392, 1455, 1732, 2869, 2971; LC-MS-ESI rt 5.57, 402 (M+1). LC-
MS-ESI rt 5.61, 402 (M+1) Anal. cald. for C24H35NO4 (401.5): C 71.79, H 8.79, N 3.49; 
found C 72.03, H 8.78, N 3.48.  
 
13e: Brown oil (60%) (95:5 Z/E mixture); Rf (30% ethylacetate/70% cyclohexane) 0.12; 
1H NMR (200 MHz, CDCl3) (Z) δ 0.97 (d, J = 6.6 Hz, 3H, CH3CHCH3), 0.98 (d, J = 6.6 
Hz, 3H, CH3CHCH3), 1.23 (d, J = 6.6 Hz, 3H, CH3CHN), 1.41 (s, 9H, OC(CH3)3), 1.98 
(bs, 1H, NH), 2.79–3.00 (m, 5H, NCH2CH2, CH3CHCH3), 3.37 (q, J = 6.6 Hz, 1H, 
CH3CHN), 5.52 (d, J = 9.4 Hz, 1H, CHCHC), 7.01 (s, 1H, NCH aromatic), 7.01–7.21 
(m, 2H, phenyl), 7.34 (d, J = 7.4 Hz, 1H, phenyl), 7.61 (d, J = 7.8 Hz, 1H, phenyl), 8.29 
(bs, 1H, NH aromatic); 13C NMR (75 MHz, CDCl3) δ 21.4, 22.8, 23.1, 26.1, 28.2 (3C), 
28.5, 47.3, 57.5, 81.0, 111.2, 114.2, 119.0, 119.2, 121.9, 128.5, 128.8, 132.1, 136.5, 
144.8, 167.7; IR (neat, cm-1) 739, 1120, 1152, 1244, 1367, 1455, 1703, 2868, 2927, 
2971, 3057, 3408; LC-MS-ESI rt 5.57, 357 (M+1) Anal. cald. for C22H32N2O2 (356.5): 
C 74.12, H 9.05, N 7.86; found C 73,84, H 9,02, N 7,86. 
 
13f: Yellow oil (65%), (95:5 Z/E mixture); Rf (40% ethylacetate/60% cyclohexane) 
0.14; 1H NMR (CDCl3, 200 MHz) (Z): δ 1.02 (d, J = 5.4 Hz, 3H, CH3CHCH3), 1.05 (d, 
J = 5.4 Hz, 3H, CH3CHCH3), 1.23 (d, J = 7.8 Hz, 3H, CH3CHN), 1.51 (s, 9H, 
OC(CH3)3), 2.86–3.02 (m, 1H, CH3CHCH3), 3.31 (q, J = 6.6 Hz, 1H, CH3CHN), 3.46 
(d, J = 12.6 Hz, 1H, HNCH2), 3.66 (d, J = 12.6 Hz, 1H, HNCH2), 5.55 (d, J = 9.6 Hz, 
1H, CHCHC), 6.63 (d, J = 7.8 Hz, 2H, phenyl), 7.10 (d, J = 7.8 Hz, 2H, phenyl); 13C 
NMR (CDCl3, 75 MHz) δ 21.5, 22.8, 23.3, 28.4 (3C), 28.6, 50.6, 56.9, 80.9, 115.2 (2C), 
129.4 (2C), 130.7, 133.7, 144.5, 145.3, 167.9; IR (neat, cm-1) 1152, 1241, 1277, 1367, 
1392, 1454, 1518, 1622, 1700, 2868, 2929, 2969, 3218, 3372. LC-MS-ESI: rt 2.9 min 
319 (M+1); [Z-(R)- 13f]: [α]D = -4.8 (c 1 in CHCl3); [Z-(S)- 13f]: [α]D = +6.6 (c 1 in 
CHCl3), Chiral HPLC analysis 98:2 to 90:10 n-hexane/2-propanol in 25 min, 
0.8mL/min, IA column, rt 15.10 min for [Z-(R)- 13f] and 15.61 min for [Z-(S)- 13f]. 
  45
Anal. cald. for C19H30N2O2 (318.4): C 71.66, H 9.50, N 8.80; found C 71.69, H 9,46, N 
8,82. 
 
14f: Yellow oil (70%), (90:10 Z/E mixture); Rf (30% ethylacetate/70% cyclohexane) 
0.13; 1H NMR (CDCl3, 200 MHz) (Z): δ 1.00–1.10, (m, 6H, cyclohexyl), 1.25 (d, J = 
Hz, 3H, CH3CHN), 1.52 (s, 9H, OC(CH3)3), 1.60–1.80 (m, 4H, cyclohexyl), 2.52–2.68 
(m, 1H, CH cyclohexyl), 3.31 (q, J = 6.6 Hz, 1H, CH3CHN),3.45 (d, J = 13 Hz, 1H, 
HNCH2), 3.65 (d, J = 13 Hz, 1H, HNCH2), 5.57, (d, J = 9.6 Hz, 1H, CHCHC), 6.63 (d, 
J = 7.8 Hz, 2H, phenyl), 7.09 (d, J = 7.8 Hz, 2H, phenyl); 13C NMR (CDCl3, 75 MHz) δ 
21.5, 25.8, 28.4 (3C), 32.9 (2C), 33.3 (2C), 38.3, 50.6, 56.9, 80.8, 115.2 (2C), 129.4 
(2C), 130.7, 134.1, 142.9, 145.3, 167.9; IR (neat, cm-1) 826, 489, 1111, 1152, 1221, 
1252, 1267, 1367, 1392, 1448, 1518, 1622, 1698, 2850, 2925, 2974, 3218, 3372. [Z-(R)- 
14f]: [α]D = -6.1 (c 1 in CHCl3); [Z-(S)- 14f]: [α]D = +7.8 (c 1 in CHCl3), LC-MS-ESI rt 
5.56, 359 (M+1) Chiral HPLC analysis 95:5 to 90:10 n-hexane/2-propanol in 25 min, 
1.0mL/min, AD column, rt 11.10 min for [Z-(R)- 14f] and 14.08 min for [Z-(S)- 14f]. 
Anal. cald. for C22H34N2O2 (358.5): C 73.70, H 9.56, N 7.81; found C 73.77 H 9.53, N 
7.82. 
 
15f: Orange oil (87%), (80:20 E/Z mixture); Rf (40% ethylacetate/60% cyclohexane) 
0.12; 1H NMR (CDCl3, 200 MHz) (E): δ 1.32 (d, J = 7 Hz, 3H, CH3CHN), 1.57 (s, 9H, 
OC(CH3)3), 3.42 (d, J = 12 Hz, 1H, HNCH2), 3.60 (d, J = 12 Hz, 1H, HNCH2), 4.10 (q, 
J = 7 Hz, 1H, CH3CHN), 6.57 (d, J = 8.4 Hz, 2H, phenyl), 6.66 (d, J = 7.6 Hz, 1H, 
thiophenyl), 6.99 (d, J = 8.4 Hz, 2H, phenyl), 7.08–7.19 (m, 1H, thiophenyl), 7.28–7.34 
(m, 1H, thiophenyl), 7.61 (s, 1H, CCHC); 13C NMR (CDCl3, 75 MHz) δ 20.6, 28.3 
(3C), 50.6, 50.9, 81.0, 115.1 (2C), 125.7, 126.4, 128.7, 129.3 (2C), 130.3, 133.4, 135.9, 
136.4, 145.2, 166.9 ; IR (neat, cm-1) 729, 793, 841, 1163, 1249, 1306, 1392, 1455, 1519, 
1568, 1593, 1699, 2851, 2925, 2974, 3371. [E-(R)- 15f]: [α]D = +5.0 (c 1 in CHCl3); [E-
(S)- 15f]: [α]D = -4.2 (c 1 in CHCl3), LC-MS-ESI rt 2.77, 359 (M+1) Chiral HPLC 
analysis 95:5 to 90:10 n-hexane/2-propanol in 20 min, 0.8mL/min, OJ column, rt 35.80 
min for [E-(S)- 15f] and 38.58 min for [E-(R)- 15f]. Anal. cald. for C20H26N2O2S 
(358.5): C 67.01, H 7.31, N 7.81; found C 66.83 H 7.28, N 7.81. 
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Representative procedure for Pd-nanoparticles catalyzed reaction. A mixture of amine 
(1 mmol), allyl carbonate (3 mmol), PdCl2 (0.045 mmol), tetrabutylammonium iodide 
(1 mmol), and K2CO3 (2 mmol) in toluene (3 mL) was stirred at 85°C for 10 h. The 
reaction was monitored by TLC and quenched with water upon disappearance of the 
starting carbonate. The reaction mixture was extracted with Et2O (3 × 10 mL). The 
extract was washed with water and brine then dried (Na2SO4). Evaporation of solvent 
afforded the crude products, which were purified by column chromatography on silica 
[hexane/ethyl acetate (70:30)-(50:50)] to provide products. The remaining black Pd 
nanoparticles, after extraction with ether, were further washed with ether and dried for 
reuse. 
 
General procedure for the preparation of the dehydro-β-amino esters 17a-d. To a 
stirred solution of the carbonate 8-11 (0.2 mmol) in dry CH3CN (2 mL), under nitrogen 
atmosphere, methyl 4-aminomethylbenzoate hydrochloride (1.5 equiv, 0.3 mmol, 61 
mg) and triethylamine (1.5 equiv, 0.3 mmol, 42 μL) were added. The solution was 
stirred at reflux for 4 days and then the solvent was removed under reduced pressure. 
The residue was diluted with ethyl acetate (10 mL) and washed twice with water (5 
mL). The two phases were separated, the organic layer was dried over Na2SO4, and 
solvent was removed under reduced pressure. Compounds 17a-d were isolated by flash 
chromatography on silica gel (cyclohexane/ethyl acetate 95/5 as eluent). 
 
17a: Yield 45%, 30 mg, isolated as a 3:1 mixture  of Z/E isomers; 1H NMR (CDCl3, 
200 MHz) major isomer δ 1.29 (d, J=7.0 Hz, 3H, CH3CHN), 1.46 (s, 9H, OC(CH3)3), 
1.64 (d, J=7.4 Hz, 3H, CH3CHC), 2.45 (bs, 1H, NH), 3.54-3.79 (m, 3H, CH2Ph, 
NCHCH3), 3.86 (s, 3H, CH3OCO), 6.77 (q, J=7.4 Hz, 1H, CCHCH3), 7.36 (d, J=8.4 Hz, 
2H, Ph), 7.94 (d, J=8.6 Hz, 2H, Ph); minor isomer δ 1.23 (d, J=6.6 Hz, 3H, CH3CHN), 
1.48 (s, 9H, OC(CH3)3), 1.88 (d, J=7.4 Hz, 3H, CH3CHC), 3.31 (q, J=6.6 Hz, 1H, 
NCHCH3), 5.85 (q, J=7.4 Hz, 1H, CCHCH3);  13C NMR (CDCl3, 75 MHz) δC major 
isomer 13.7 (CH3), 20.6 (CH2), 28.3 (3CH3), 50.1 (CH3), 51.1 (CH), 52.0 (CH3), 80.6 
(C), 128.0 (2CH), 128.7 (C), 129.7 (2CH), 136.0 (C), 137.7 (CH), 146.2 (C), 166.5 (C), 
167.1 (C); LC-ESI-MS rt 11.04 min, m/z 333 (M), 356 (M+Na). Anal. cald. for 
C19H27NO4(333.19): C 68.44, H 8.16, N 4.20; found C 68.33, H 8.17, N 4.20.   
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17b: Yield 70%, 51 mg, isolated as a 3:1 mixture  of Z/E isomers; 1H NMR (CDCl3, 
200 MHz) major isomer δ 0.74 (d, J=6.6 Hz, 3H, CH3CHCH3), 1.12 (d, J=6.6 Hz, 3H, 
CH3CHCH3), 1.50 (s, 9H, OC(CH3)3), 1.60 (d, J=7.0 Hz, 3H, CH3CHC), 1.79-2.08 (m, 
1H, CH3CHCH3), 3.02 (d, J=9.8 Hz, 1H, CHCHN), 3.56 (d, J=13.8 Hz, 1H, 
NHCH2Ph), 3.86 (d, J=13.8 Hz, 1H, NHCH2Ph), 3.91 (s, 3H, CH3OCO), 6.92 (q, J=7.0 
Hz, 1H, CCHCH3), 7.43 (d, J=8.0 Hz, 2H, Ph), 7.98 (d, J=8.0 Hz, 2H, Ph); minor 
isomer δ 0.83 (d, J=6.6 Hz, 3H, CH3CHCH3), 1.00 (d, J=6.6 Hz, 3H, CH3CHCH3), 1.93 
(d, J=7.0 Hz, 3H, CH3CHC), 2.68 (d, J=8.4 Hz, 1H, CHCHN), 5.72 (q, J=7.0 Hz, 1H, 
CCHCH3); 13C NMR (CDCl3, 75 MHz) δC major isomer 13.7 (CH3), 20.0 (2CH3), 27.9 
(3CH3), 31.7 (CH), 50.1 (CH2), 51.6 (CH3), 61.3 (CH), 80.0 (C), 127.7 (2CH), 128.3 
(C), 129.2 (2CH), 133.9 (C), 138.5 (CH), 146.5 (C), 166.5 (C), 166.7 (C); LC-ESI-MS 
rt 13.87 min, m/z 361 (M), 362 (M+1); Anal. cald. for C21H31NO4(361.23): C 69.78, H 
8.64, N 3.87; found C 69.75, H 8.62, N 3.88.   
 
17c: Yield 65%, 52 mg, isolated as a 3:1 mixture  of Z/E isomers; 1H NMR (CDCl3, 
200 MHz) major isomer δ 1.13-1.36 (m, 4H, cyclohexyl), 1.50 (s, 9H, OC(CH3)3), 1.47-
1.81 (m, 6H, cyclohexyl), 1.59 (d, J=7.2 Hz, 3H, CH3CHC), 2.40 (m, 1H, CH 
cyclohexyl), 3.13 (d, J=9.4 Hz, 1H, CHCHN), 3.57 (d, J=13.8 Hz, 1H, NHCH2Ph), 3,81 
(d, J=13.8 Hz, 1H, NHCH2Ph), 3.91 (s, 3H, CH3OCO), 6.92 (m, J=7.2 Hz, 1H, 
CCHCH3), 7.43 (d, J=8.2 Hz, 2H, Ph), 7.98 (d, J=8.2 Hz, 2H, Ph); minor isomer δ 1.92 
(d, J=7.0 Hz, 3H, CH3CHC), 2.72 (d, J=8.8 Hz, 1H, CHCHN), 5.68 (q, J=7.0 Hz, 1H, 
CCHCH3); 13C NMR (CDCl3, 75 MHz) δC major isomer 13.9 (CH3), 26.2 (CH2), 26.3 
(CH2), 26.6 (CH2), 28.2 (3CH3), 30.6 (CH2), 31.6 (CH2), 41.4 (CH), 50.6 (CH2), 51.8 
(CH3), 60.0 (CH), 80.3 (C), 127.9 (2CH) , 128.4 (2CH), 129.4 (CH), 133.6 (C), 138.8 
(C), 146.7 (C), 166.8 (C), 167.1 (C); LC-ESI-MS rt 5.31 min, m/z 401 (M), 424 
(M+Na); Anal. cald. for C24H35NO4(401.26): C 71.79, H 8.79, N 3.49; found C 71.83, H 
8.78, N 3.48.   
 
17d: Yield 35%, 28 mg, isolated as a 3:1 mixture  of Z/E isomers; 1H NMR (CDCl3, 
200 MHz) major isomer δ 1.34 (s, 9H, OC(CH3)3), 1.75 (d, J=7.2 Hz, 3H, CH3CHC), 
2.56 (bs, 1H, NH), 3.77 (d, J=13.8 Hz, 1H, NHCH2Ph), 3.90 (s, 3H, CH3OCO), 3.94 (d, 
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J=13.8 Hz, 1H, NHCH2Ph), 4.75 (s, 1H, CHNH), 6.95-7.05 (m, 2H, CCHCH3, CH 
thiophenyl), 7.19-7.27 (m, 2H, thiophenyl), 7.48 (d, J=8.4 Hz, 2H, Ph), 8.00 (d, J=8.4 
Hz, 2H, Ph); minor isomer δ 1.99 (d, J=7.0 Hz, 3H, CH3CHC), 6.04 (q, J=7.0 Hz, 1H, 
CCHCH3); 13C NMR (CDCl3, 75 MHz) δC major isomer 13.9 (CH3), 28.1 (3CH3), 
50.6(CH3), 52.1 (CH2), 54.4 (CH), 80.8 (C), 120.3 (CH), 125.2 (CH), 126.8 (CH),  
128.0 (2CH), 128.9 (C), 129.7 (2CH), 134.4 (C), 139.0 (CH), 144.2 (C), 146.1 (C), 
166.4 (C), 167.1 (C). LC-ESI-MS rt 12.67 min, m/z 401 (M), 424 (M+Na); Anal. cald. 
for C22H27NO4S(401.17): C 65.81, H 6.78, N 3.49, S 7.99; found C 65.77, H 6.80, N 
3.50, S 7.98.   
 
Procedure for the preparation of the acid 18. To a stirred solution of the carbonate 9 
(0.2 mmol) in CH2Cl2 (2 mL) at 0°C, trifluoroacetic acid (15 equiv, 3 mmol, 223 μL) 
was added. After 2h, the mixture was washed twice with acidic water (5 mL), the 
organic layer was dried over Na2SO4, and solvent was removed under reduced pressure. 
Compound 18 was isolated in 95% yield (41 mg). 
 
18: 1H NMR (CDCl3, 200 MHz) δ 0.97 (d, J=5.4 Hz, 6H, CH3CHCH3), 1.40 (d, J=6.6 
Hz, 3H, CH3CHO), 3.25-3.42 (m, 1H, CH3CHCH3), 3.70 (s, 3H, CH3OCO), 5.46 (q, 
J=6.6 Hz, 1H, CH3CHO), 6.11 (d, J=10.0 Hz, 1H, CHCHC), 10.41 (bs, 1H, OCOH); 
13C NMR (CDCl3, 200 MHz) δC 20.1 (CH3), 21.9 (2CH3), 31.8 (CH), 54.4 (CH3), 73.3 
(CH), 128.9 (C), 142.5 (CH), 154.7 (C), 171.4 (C); LC-ESI-MS rt 6.65 min, m/z 216 
(M), 239 (M+Na); Anal. cald. for C10H16O5(216.1): C 55.55, H 7.46; found C 55.59, H 
7.49.   
 
Procedure for the preparation of the amide 19. To a stirred solution of the acid 18 (0.2 
mmol) in dry CH2Cl2 (2 mL), under nitrogen atmosphere, EDCI (1.2 equiv, 0,24 mmol, 
46 mg) and triethylamine (2.4 equiv, 0.48 mmol, 67 μL) were added. After 30 min 
HOBT (1.2 equiv, 0,24 mmol, 33 mg) and glycine t-butyl ester hydrochloride (1.2 
equiv, 0,24 mmol, 41 mg) were added. The solution was stirred overnight and then the 
mixture was diluited with CH2Cl2 and washed twice with acidic water (5 mL) and twice 
with basic water (5 mL). The two phases were separated, the organic layer was dried 
over Na2SO4, and solvent was removed under reduced pressure. Compounds 19 was 
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isolated in 65% yield (43 mg) after flash chromatography on silica gel 
(cyclohexane/ethyl acetate 80/20 as eluent).  
 
19: 1H NMR (CDCl3, 200 MHz) δ 1.01 (d, J=6.6 Hz, 6H, CH3CHCH3), 1.45 (d, J=7.0 
Hz, 3H, CH3CHO), 1.49 (s, 9H, OC(CH3)3), 2.70-2.88 (m, 1H, CH3CHCH3), 3.79 (s, 
3H, CH3OCO), 4.00 (d, J=4.8 Hz , 2H, NHCH2), 5.27 (q, J=6.6 Hz, 1H, CH3CHO), 
5.67 (d, J=10.2 Hz, 1H, CHCHC), 6.57 (bt, 1H, NH); 13C NMR (CDCl3, 200 MHz) δC 
19.9 (CH3), 22.7 (2CH3), 26.8 (CH), 28.0 (3CH3), 41.9 (CH2), 54.8 (CH3), 76.0 (CH), 
82.2 (C), 131.8 (C), 137.3 (CH), 155.1 (C), 167.3 (C), 168.8 (C); LC-ESI-MS rt 10.82 
min, m/z 329 (M), 352 (M+Na); Anal. cald. for C16H27NO6(329.18): C 58.34, H 8.26, N 
4.25; found C 58.31, H 8.24, N 4.25.   
 
Procedure for the preparation of the N-BOC-protected amide 20. To a stirred solution 
of the amide 19 (0.2 mmol) in dry THF (1 mL), DMAP (0.2 equiv, 0.04 mmol, 5mg), 
triethylamine (1.2 equiv, 0.24 mmol, 34 μL) and (BOC)2O (1.3 equiv, 0.26 mmol, 60 
μL) were added. The solution was stirred overnight and then the solvent was removed 
under reduced pressure. The residue was diluted with ethyl acetate (10 mL) and washed 
twice with water (5 mL). The two phases were separated, the organic layer was dried 
over Na2SO4, and solvent was removed under reduced pressure. Compounds 20 was 
isolated in 90% yield (77 mg) by flash chromatography on silica gel (cyclohexane/ethyl 
acetate 95/5 as eluent).  
 
20: 1H NMR (CDCl3, 200 MHz) δ 0.99 (d, J=6.6 Hz, 6H, CH3CHCH3), 1.42 (d, J=6.6 
Hz, 3H, CH3CHO), 1.48 (s, 18H, OC(CH3)3), 2.41-2.49 (m, 1H, CH3CHCH3), 3.75 (s, 
3H, CH3OCO), 4.28  (d, J=16.8 Hz , 1H, NCH2), 4.45 (d, J=16.8 Hz , 1H, NCH2), 5.42-
5.53 (m, 2H, CH3CHO, CHCHC); 13C NMR (CDCl3, 200 MHz) δC19.2 (CH3), 22.6 
(2CH3), 27.2 (CH), 27.8 (3CH3), 28.0 (3CH3), 45.9 (CH2), 54.5 (CH3), 74.7 (CH), 81.8 
(C), 83.8 (C), 126.7 (C), 137.6 (CH), 151.4 (C), 155.1 (C), 167.6 (C), 169.8 (C); LC-
ESI-MS rt 12.26 min, m/z 429 (M), 452 (M+Na); Anal. cald. for C21H35NO8(429.24): C 
58.72, H 8.21, N 3.26; found C 58.61, H 8.19, N 3.27.   
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Procedure for the preparation of the amino derivative 21. To a stirred solution of the 
amide 20 (0.2 mmol) in dry CH3CN (2 mL), under nitrogen atmosphere, 4-
aminomethylaniline (1.5 equiv, 0.3 mmol, 34 μL) was added. The solution was refluxed 
for 16h and then the solvent was removed under reduced pressure. Compound 21 was 
isolated in 70% yield (66 mg) by Flash chromatography on silica gel (cyclohexane/ethyl 
acetate 95/5 as eluent).  
 
21: 1H NMR (CDCl3, 200 MHz) δ 0.83 (d, J=6.6 Hz, 6H, CH3CHCH3), 1.42 (d, J=7.4 
Hz, 3H, CH3CHC), 1.47 (s, 18H, OC(CH3)3), 2.60-2.81 (m, 1H, CH3CHCH3), 3.59 (bs, 
2H, NH2), 3.83-3.98 (m, 3H, NCH2, CHNH), 4.34-4.61 (m, 2H, CH2Ph), 6.61 (d, J=8.0 
Hz, 2H, Ph), 6.83 (q, J=7.4 Hz, 1H, CCHCH3), 7.01 (d, J=8.0 Hz, 2H, Ph); 13C NMR 
(CDCl3, 200 MHz) δC 13.5 (CH3), 20.2 (2CH3), 28.1 (3CH3), 28.5 (3CH3), 31.8 (CH), 
42.2 (CH2), 47.3 (CH), 50.1 (CH2), 79.8 (C), 82.1 (C), 115.0 (2CH), 127.9 (2CH), 130.7 
(C), 131.3 (C), 139.6 (CH), 144.9 (C), 156.0 (C), 169.1 (C), 169.9 (C); LC-ESI-MS rt 
9.15 min, m/z 475 (M), 498 (M+Na); Anal. cald. for C26H41N3O5(475.3): C 65.66, H 
8.69, N 8.83; found C 65.55, H 8.71, N 8.80.   
 
Procedure for the preparation of the amino acid 22. To a stirred solution of compound 
21 (0.2 mmol), in CH2Cl2 (0.5mL), H3PO4 85% (5 equiv, 1 mmol, 69 μL) was added. 
After 3h the solvent was removed under reduced pressure and the crude compound was 
treated with Dowex 50WX2-200 ion exchange resin, eluting with NH4OH 0.5 M. 
Compound 22 was isolated after emoval of the aqueous solvent in 95% yield (61 mg). 
 
22: 1H NMR (CD3OD, 200 MHz) δ 0,93 (d, J=6.6 Hz, 6H, CH3CHCH3), 1.82 (d, J=7.2 
Hz, 3H, CH3CHC), 2.18-2.28 (m, 1H, CH3CHCH3), 3.83-4.38 (m, 5H, CHNH, NHCH2, 
CH2Ph), 6.74 (d, J=8.4 Hz, 2H, Ph), 6.90 (q, J=7.2 Hz, 1H, CCHCH3), 7.21 (d, J=8.4 
Hz, 2H, Ph); minor isomer δ 2.06 (d, J=7.2 Hz, 3H, CH3CHC), 6.06 (q, J=7.2 Hz, 1H, 
CCHCH3); 13C NMR (CD3OD, 200 MHz) δC major isomer 14.3 (CH3), 19.9 (2CH3), 
31.9 (CH), 46.9 (CH2), 50.9 (CH2), 62.4 (CH), 116.3 (2CH), 121.1 (C), 128.8 (CH), 
132.0 (2CH), 140.7 (C), 148.5 (C), 161.6 (C), 178.2 (C); LC-ESI-MS rt 1.06 min, m/z 
319 (M), 342 (M+Na); Anal. cald. for C17H25N3O3(319.19): C 63.93, H 7.89, N 13.16; 
found C 63.99, H 7.90, N 13.11. 
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II 
 
1,4- addition of nitrogen nucleophiles  
to unsaturated carbonyl compounds.  
Synthesis of substituted isoxazolidines and isoxazolines 
 
2.1 Introduction  
The conjugate addition of nitrogen containing nucleophiles to unsaturated carbonyl 
compounds represents one of  the most employed and versatile method for C-N bond 
construction in organic chemistry.32 The reaction may be performed under catalytic 
conditions and the use of chiral Lewis acids33 or, more recently, of organocatalysts34 has 
been described in literature.  
Alkylidene malonates have been intensively employed as Michael acceptors.35 In 
particular, a chiral Lewis acid-catalysed Michael addition of hydroxylamino derivatives 
to alkylidene malonates has been reported by our group.36 Herein, we describe the 
highly stereo-controlled synthesis of ethyl 5-hydroxyisoxazolidine-4-carboxylate 
through a Lewis acid-induced Michael addition of hydroxylamino derivatives to 
alkylidene acetoacetates, followed by intra-molecular hemiketal formation. The use of 
acetoacetates in this field is rather unusual and has the advantage of introducing a 
reactive keto-functionality that may be further elaborated. 
Furthermore, we report a new approach to this class of compounds, using N-benzyl-
(tert-butyldimethylsilyloxy)-carbamate37 as nucleophile. This procedure directly 
furnished N-Cbz-protected-5-hydroxyisoxazolidines that can be easily transformed into 
the corresponding dehydrated isoxazolines, which are useful precursors of aromatic 
oxazoles. 
Substituted isoxazolidines, isoxazolines and isoxazoles are important substrates for 
mechanistic studies of biologically interesting processes. For example, isoxazolidines 
are interesting heterocyclic compounds that may be regarded as unusual constrained β-
amino acids38 or as furanose mimetics,39 and have been also exploited as analogues of 
natural products40. Isoxazolines have been incorporated as conformational constraint 
element in αvβ3 and α5β1 integrin antagonists,41 as well as in several transcriptional 
activators.42 
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2.2 Preparation of alkylidene acetoacetates via Knoevenagel reaction  
Alkylidene acetoacetates have been prepared through a Knøvenagel reaction between 
ethyl acetoacetate and various aldehydes in the presence of a catalytic amount of proline 
(Scheme 2. 1).43 Proline was chosen among other bases since it was demonstrated to 
afford the best results in terms of yields and Z/E product selectivity. 
R
O
O
OEt
30%Pro, DMSO
rt, overnight
O O
OEt
+ RCHO
Y=65÷80%a: R= CH(CH3)2
b: R= CH(CH3)CH2CH3
c: R= Cyclohexyl
d: R= Ph
1a-d
Z/E: 3:1÷ 4:1
e: R= CH2CH(CH3)2  
Scheme 2. 1 
 
The stereochemical assignment for compounds 1a-d was made on the basis of 
DPFGSE-NOE (Double Pulse Field Gradient Spin Echo NOE) experiments. We found 
that the major isomer (Z) exhibits a strong NOE effect between the vinyl hydrogen and 
the ketone CH3 group, while the minor isomer (E) shows a strong NOE effect between 
the vinyl hydrogen and the ester CH2 group.  
 
2.3 Michael addition of hydroxylamino derivative to alkylidene 
acetoacetates 
The conjugate addition of bis-(N,O)-trimethylsilyl hydroxylamine (TMSONHTMS) to 
alkylidene acetoacetates was first examined in the absence of catalysts (Scheme 2. 2). 
Reaction conditions were optimized in order to induce the regioselective formation of 
1,4-addition products versus oximes, deriving from the 1,2-addition process.  
 
R
O
O
OEt
 TMSONHTMS (2eq.)
0°C, overnight
R
O
O
OEt
NHTMSO
2a-d
DCM
1a-d  
Scheme 2. 2 
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The reactions were completed in 16 hours, and the syn and anti 1,4-adducts 2a-d were 
obtained in quantitative yields in 60/40 ratio, respectively, as quoted by the 1H NMR of 
the crude reaction. 
The loss of the trimethylsilyl group on nitrogen occurred during reaction work-up. In 
order to characterize the intermediates a very fast chromatography on silica gel allowed 
2a-d to be obtained as inseparable mixtures of syn/anti isomers. The stereochemical 
assignment was made by comparing the 1H-NMR coupling constants of compounds 2a-
d with data available in literature44 (Jsyn=3.6Hz, Janti=7.2Hz).  
Notably, the reaction carried out on the pure Z or E isomer of 1a-d gave always 2a-d in 
the same syn/anti ratio. 
 
2.3.1 Effect of the catalyst on the coniugate addition 
We studied the influence exerted by the presence of different catalysts on the 
regioselectivity of the reaction45. In fact substrate 1 may be subjected either to 1,4- or 
1,2-nucleophilic attack depending on the reaction conditions, thus affording the 1,4-
addition product 2, the 5-hydroxyisoxazolidine-4-carboxylate 3 or the oxime 4 
respectively (Scheme 2. 3). 
CO2Et
O
1a
1) SMTNHOTMS CO2Et
O
2a
HN
OH
+
3a
+
CO2Et
N
4a
OH
OHN
OH
CO2Et
CH2Cl2
 
Scheme 2. 3 
 
We initiated our studies by examining the addition of TMSNHOTMS to Z-1a and the 
ability of the Lewis acid to direct the regioselectivity (Table 9). 
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Table 9 
 Time(h) Catalysta Conversion Yield (%)c 
   (%)b 2 3 4 
1 16 - 85 85 - - 
2 0.5 Yb(OTf)3 100  100  
3 2 BF3.Et2O 100 - 36 64 
4 2 Cu(OTf)2 65 - 10 55 
5 3 Cu(OTf)2 95 - 10 85 
6 4 Sc(OTf)3 100 - 10 90 
7 5 Mg(OTf)2 - - - - 
a) A 5% amount of catalyst was used in all reactions. b) The rest being unreacted starting material. c) Calculated on 
the basis of 1H NMR signals integration 
 
Therefore, 1a was treated in CH2Cl2 in absence of the catalyst with 2 equiv. of 
TMSNHOTMS. Under these conditions, the adduct 2a was obtained in 60:40 syn/anti 
ratio and in 85% yields (entry 1).  
After that, we screened a variety of Lewis acids as catalysts and to our surprise, the 
expected 1,4 addition product was not observed. We found that the reaction was 
accelerated significantly in the presence of Yb(OTf)3;  in fact, addition of 5% of catalyst 
allowed the compound  3,4-trans-3a to be obtained in 78/ 22 anomeric ratio, in one step 
and in a shorter reaction time (30 min, entry 2). By using BF3⋅EtO as catalyst, a mixture 
of 3a, and oxime 4a  in 36/64 ratio was obtained, as detected from the 1H NMR 
spectrum of the crude  mixture (entry 3). When the reaction was carried out in the 
presence of Cu(OTf)2, or Sc(OTf)3,  complete regioselectivity was observed and the N-
protected oxime 4a was obtained in high yield, being scandium catalyst the most 
selective (entries 5-6). 
The unpredictability of the amount of oxime 4a in repeated proofs, prompted us to 
investigate the factors that control the regioselectivity of the nucleophilic addition. 
Therefore a deeper inspection of the reaction conditions showed that the yields of 3a or 
4a are strongly influenced by the presence of traces of water. In fact, when the reaction 
was carried out in presence of the catalyst and molecular sieves, 3a was exclusively 
obtained. The experimental data show that the oxime formation is favored by the 
presence of water in the solution or present in the metal coordination sphere.The rate-
limiting step of the oxime formation at neutral pH is the dehydration of the 
carbinolamine addition compound.46 At high reactant concentration with most of the 
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carbonyl compound in the form of addition derivative, the rate of the oxime formation is 
dependent on the dehydration, that in our case seems to be favored by the presence of 
traces of water. 
R
COOEt
O
SMTNHOTMS
R
COOEt
NH
TMSO TMS
O
R
COOEt
NH
TMSO
OTMS
O
H
H
R
COOEt
N
OTMS
 
Figure 2. 1 
 
In Figure 2. 1 a plausible mechanism is outlined, accounting for the observed results. 
The H2O acting as general acid allows the TMSOH elimination to occur, shifting the 
equilibrium towards the oxime, that is more stable and less prone to hydrolysis in 
respect to the corresponding imine. 
 
To demonstrate the generality of this method and to apply this protocol to other 
substrates, we investigated in detail the reaction results under optimized conditions47.  
COOEt
O
1a
SMTNHOTMS
  5% Yb(OTf)3
CH2Cl2
OTMS
COOEt
NH
TMSO
5a
OHN
OH
COOEt3a  
Scheme 2. 4 
 
In the presence of 5% of ytterbium catalyst, compound 1a was stirred in dry CH2Cl2 
with the nucleophilic reagent  at 0°C. After completion of the reaction, as indicated by 
TLC, the solvent was evaporated and the 1H NMR spectrum of the crude mixture 
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showed the presence of the silyl enolether 5a, that slowly converted at room 
temperature into 5- hydroxyisoxazolidine-carboxylate 3a (Scheme 2. 4). 
The structure of compounds 5a has been proposed on the basis of is 1H-NMR and 13C-
NMR spectra. A further evidence of the nature of 5a  was obtained by treating the 1,4-
adduct 2a with LHMDSA and TMSCl (Scheme 2. 5). 
O
O
OEt
NHTMSO
LHMDSA, 
TMSCl
THF,
 -78°C-> rt
2a 
syn/anti mixture
OTMS
O
OEt
H
NTMSO
5a
one isomer
H
NOE
no
NOE
 
Scheme 2. 5 
 
An explanation for the different outcomes of the uncatalysed (adducts 2a-d in Scheme 
2. 2) and catalysed (silyl enolethers 5a-d in Scheme 2. 5) conjugate addition may be 
issued from the results of DFT theoretical computations on the plausible intermediates 
of the 1,4 addition. The conjugate addition of TMSONHTMS to the methyl ester of 
isopropylidene acetoacetate gave results in complete agreement with those obtained for 
ethyl esters.This  allowed to semplify the model-system as reported in Scheme 2. 6.  
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Scheme 2. 6 
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It is reasonable to believe that, after the C-N bond formation, the resulting species has a 
zwitterionic nature, with a positive charge on the nitrogen atom and a negative charge 
delocalised on the enolate moiety.48 The optimum structures of this intermediate, either 
as a free species (IntF) or forming a complex with the Lewis acid (IntC), have been 
computed (Scheme 2. 6).A schematic representation of the two possible resonance 
structures (ketonic and enolic) for these two intermediate species is given in Scheme 2. 
6. A comparison between the C-C and the C-O enolate bond lengths in these molecules 
shows that in the case of the free intermediate IntF the keto form is dominant, while for 
the intermediate complex IntC the enol form predominates (Figure 2. 2).  
 
Figure 2. 2 
 
This finding suggests that the intermediate IntF is likely to end up with a proton 
transfer to the carbon in α position, thus giving products 2a-d. On the other hand it is 
reasonable to believe that intermediate IntC, because of its  structural features, may 
transfer a TMS group from the nitrogen to the enol oxygen, affording products 5a-d. 
 
2.3.2 Intramolecular hemiketalisation 
Adducts 2a-d and silyl enolethers 5a-d at room temperature spontaneously converted to 
ethyl 5-hydroxyisoxazolidine-4-carboxylates 3a-d. In both cases the intramolecular 
hemiketalisation required, on the average, 24 hours to be completed. Remarkably, both 
classes of compounds 2a-d and 5a-d gave, with quantitative conversion, mixtures 
ranging from 80/20 to 75/25 ratio of the two stereoisomers of (3,4)-trans 
hydroxyisoxazolidines 3a-d, differing for the stereochemistry at the C5 anomeric center 
(Scheme 2. 7).  
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Scheme 2. 7 
 
The intra-molecular hemiketalisation can be accelerated by addition of silica gel to the 
crude mixture or using other acidity source that allows ready desilylation of the reagent 
(for instance, treatment with acidic water solution or acidic resins). The ethyl 
5-hydroxyisoxazolidine-4-carboxylates 3a-d were fully characterised by NMR 
spectrometry (DEPT, HETCOR, COSY and NOE) and thus their structures have been 
confirmed.(Scheme 2. 8) 
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Scheme 2. 8 
 
Once again, the derivatisation gave an unexpected result: starting from a 70/30 
diastereomeric mixture of 3a, only one (3,4)-trans isomer (J3-4= 7.2Hz) of 6a was 
obtained, probably via the isomerisation of the hemiacetalic position.  
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2.4 Michael addition of N-benzyl-(tert-butyldimethylsilyloxy)-carbamate 
to alkylidene acetoacetates 
Alkylidene acetoacetates 1a-e were treated with benzyl-(tert-butyldimethylsilyloxy)-
carbamate in the presence of various Lewis acids in CH2Cl2 solvent, to afford 
isoxazolidine hemiketals 7 and the corresponding dehydrated isoxazoline 8 in ratios that 
depend on the reaction conditions49 (Table 10). It should be noted that the TBS 
protecting group was removed during the usual work up procedure. 
R
COOEt
O
1a-e
R
COOEt
7a-e
N
CBz
N
H
OBn
O
L.A. 5%TBSO
+
8a-e
O OH
R
COOEt
N
CBz O
+CH2Cl2, r.t.
 
Scheme 2. 9 
 
Table 10 
Entrya 
1 
S.M. 
L.A. 
(5%) 
T 
(°C) 
t 
(h) 
Conversionb 
7+8 (%) 
trans-7/8 
1 1a Zn(OTf)2 0 40 / / 
2 1a Zn(OTf)2 40 16 23 >99:1 
3 1a Cu(OTf)2 0 40 / 60:40 
4 1a Cu(OTf)2 r.t. 20 >95 58:42 
5 1a Cu(OTf)2 40 5 >95 50:50 
6 1a Yb(OTf)3 0 40 / / 
7 1a Yb(OTf)3 r.t. 20 44 >99:1 
8 1a Yb(OTf)3 40 5 >95 63:37 
9 1a Sc(OTf)3 10 5 70 80:20 
10 1a Sc(OTf)3 r.t 5 >95 60:40 
11 1a Sc(OTf)3 40 5 >95 30:70 
12 1e Sc(OTf)3 r.t. 5 94 62:38 
13 1b Sc(OTf)3 r.t. 5 95 60:40 
14 1c Sc(OTf)3 r.t. 5 93 60:40 
15 1d Sc(OTf)3 r.t. 5 95 58:42 
a) The reaction was performed in the presence of 1 equivalent of nucleophile in CH2Cl2. A 5% amount of catalyst was 
used in all reactions. b) The rest being unreacted starting material. The conversion was established on the basis of 1H 
NMR peak integration. 
  60 
From Table 10 it can be appreciated that the reaction with Z-1a Zn(OTf)2 as catalyst, at 
0°C or at room temperature (entries 1-2) proceeded with unsatisfactory yields. 
Similarly, when the reaction was run in the presence of Cu(OTf)2 at 0 °C, the starting 
material was recovered even after long reaction times (entry 3). On the other hand, the 
reaction proceeded very slowly at room temperature, so it was gently warmed to 40 °C, 
affording the complete conversion of the starting material to a mixture of trans-7a (J3,4 
= 6.6 Hz) and 8a (entries 4-5). The cyclization to 7a, led to the formation of a single 
epimer. Compounds 7a and 8a were easily isolated by flash chromatography on silica 
gel, eluting with cyclohexane/ethyl acetate 80/20 as eluent. Similar results were 
observed using Yb(OTf)3 as catalyst (entries 6-8). Scandium triflate showed an 
excellent efficiency for the activation of the desired reaction. Indeed, at ambient 
temperature and in the presence of Sc(OTf)3, complete conversion of the starting 
material was observed in 5 h. A single epimer of the trans isoxazolidine 7a was 
obtained, accompanied by the corresponding product of dehydration 8a in 60/40 ratio 
(entry 10). Warming the reaction to 40°C, afforded an increased amount of 8a (entry 
11). On the other hand, in a unique experiment carried out at room temperature, a 46% 
conversion of Z-1a into trans-7a could be observed after 1.5 h, while only traces of 
dehydrated 8a were detected in the crude 1H NMR. After 3 hours of reaction, the 
conversion reached 90%, and trans-7a was present together with the corresponding 
dehydrated product 8a, in 60:40 ratio.  
The experimental conditions selected for 1a were then explored with substrates 1b-e. 
Thus, treatment of 1b-e with carbamate at room temperature overnight in the presence 
of scandium catalyst, afforded essentially quantitative conversion of the starting 
materials to 60/40 mixtures of 7b-e and 8b-e (entries 12-15). 
 
Sc(OTf)2 or Zn(OTf)2
0.5 equiv.
CH2Cl2/toluene
Δ
>95%
R
COOEt
7a-e
N
CBz
8a-e
O OH
R
COOEt
N
CBz O
 
Scheme 2. 10 
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Complete conversion of 7a-e to 8a-e was achieved upon addition of an additional half 
equivalent of Sc(OTf)2 or Zn(OTf)2 in toluene to the reaction mixture, while 
simultaneously heating to reflux for 3 h. (Scheme 2. 10). 
The structures of compounds 7a and 8a were established by NMR techniques (DEPT, 
HETCOR and COSY). The formation of a single epimer of isoxazolidine 7a was 
supported by the presence of a single set of signals in the 1H NMR spectrum. The 
relative stereochemistry of 7a was established by means of NOE experiments, that 
exhibited a strong enhancement (8%) of the isopropylic side chain upon irradiation of 
the C(4) hydrogen. By contrast, a weaker NOE effect (2%) was observed on the trans 
hydrogen at C(3). Furthermore, a medium NOE effect on the anomeric methyl 
substituent indicated a cis relationship between this group and the hydrogen at C(4). X-
Ray analysis of 8a secured the configuration assigned to this heterocycle (Figure 2. 3).50 
 
Figure 2. 3 
 
2.4.1 Reactivity of isoxazoline-4-carboxylates. Synthesis of oxazoles 
In order to remove the CBz protecting group, 8a was stirred at room temperature with 
an equimolar amount of NaBH4 in ethanol under argon (method A) or LiOH in 
MeOH/H2O/THF (method B), until the reaction was found to be complete by 
TLC.(Scheme 2. 11)  
8a 
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Scheme 2. 11 
 
Following these protocols, isoxazoline 9a was isolated in almost quantitative yield. 
Isoxazoline 9a was characterized by spectroscopic analysis as well. This compound was 
unstable and spontaneously converted to the corresponding aromatic oxazole 10a, even 
under inert atmosphere.51 Therefore, as soon as formed 9a was treated with the 3,5-
dinitrobenzoyl chloride to afford derivative 11a in quantitative yield. 
 
Table 11 
Entry S.M Product 9 Yield(%) Product 10 Yield(%) 
1 8a 
COOEt
HN O
 
>95 
COOEt
N O
 
>95 
2 8b 
COOEt
HN O
 
>95 
COOEt
N O
 
>95 
3 8c 
COOEt
HN O
 
>95 
COOEt
N O
 
>95 
4 8d 
COOEt
HN O
 
>95 
COOEt
N O
 
>95 
5 8e 
COOEt
HN O
 
>95 
COOEt
N O
 
>95 
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Similar deprotection  was carried out on 8b-e, affording 9b-e in quantitative yield. 
Rapid oxidation of isoxazolines 9b-e took place upon exposure to air, affording 10b-e 
in quantitative yield (Table 11). Compound 9c resulted particularly unstable, being 
detected only in the 1H NMR spectra of the crude product. 
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2.5 Experimental Section 
All chemicals were purchased from commercial suppliers and used without further 
purification. Anhydrous solvents were purchased in sure seal bottles over molecular 
sieves and used without further drying. Flash chromatography was performed on silica 
gel (230-400 mesh). NMR Spectra were recorded with 200, 300 or 600 MHz 
spectrometers. Chemical shifts were reported as δ values (ppm) relative to the solvent 
peak of CDCl3 set at δ = 7.27 (1H NMR) or δ = 77.0 (13C NMR). 
 
For the preparation of alkylidene acetoacetates and the characterization of 1a and 1c, 
see paragraph 1.6. 
(Z)-1b: Yield 66%, colorless clear oil; 1H NMR (CDCl3, 300 MHz) δ 0.75 (t, J = 6.9 
Hz, 3H, CH3CH2CH), 0.97 (d, J = 6.6 Hz, 3H, CHCH3), 1.22 (t, J = 7.2 Hz, 3H, 
CH3CH2O), 1.34 (m, 2H, CH3CH2CH), 2.21 (s, 3H, COCH3), 2.35 (m, 1H, 
CH3CH2CH), 4.20 (q, J = 7.2 Hz, 2H, CH3CH2O), 6.50 (d, J = 10.8 Hz, 1H, CH=). 13C 
NMR (CDCl3, 300 MHz): δ 11.5(CH3), 13.9(CH3), 19.3(CH), 26.5(CH2), 29.1(CH3), 
36.3(CH3), 60.9(CH2), 136.0(C), 152.8(CH), 166.4(C), 195.0(C). (E)-1b: 1H NMR 
(CDCl3, 300 MHz) δ 0.74 (t, J = 6.9 Hz, 3H, CH3CH2CH), 0.93 (d, J = 6.9 Hz, 3H, 
CHCH3), 1.20 (t, J = 7.2 Hz, 3H, CH3CH2O), 1.34 (m, 2H, CH3CH2CH), 2.25 (s, 3H, 
COCH3), 2.35 (m, 1H, CH3CH2CH), 4.16 (q, J = 7.2 Hz, 2H, CH3CH2O), 6.56 (d, J = 
10.8 Hz, 1H, CH=). 13C NMR (CDCl3, 300 MHz): δ 11.6(CH3), 13.9(CH3), 19.2(CH), 
26.3(CH2), 29.0(CH3), 35.4(CH3), 61.0(CH2), 134.5(C), 153.0(CH), 164.1(C), 201.2(C). 
Anal. Calcd. For C11H18O3: C, 66.64; H, 9.15. Found: C, 66.72; H, 9.14. 
 
(Z)-1d: Yield 72%, yellow oil; 1H NMR (CDCl3, 200 MHz) δ 1.28 (t, J = 7.2 Hz, 3H, 
CH3CH2O), 2.43 (s, 3H, COCH3), 4.34 (q, J = 7.2 Hz, 2H, CH3CH2O), 7.28-7.48 (m, 
5H, Ph), 7.58 (s, 1H, CH=). 13C NMR (CDCl3, 300 MHz): δ 13.8(CH3), 26.5(CH3), 
61.7(CH2), 128.8 (CH), 129.5(CH), 130.7(CH), 132.9(C), 134.6(C), 141.2(CH), 
167.7(C), 194.6(C). (E)-1d: 1H NMR (CDCl3, 200 MHz) δ 1.34 (t, J = 7.2 Hz, 3H, 
CH3CH2O), 2.36 (s, 3H, COCH3), 4.30 (q, J = 7.2 Hz, 2H, CH3CH2O), 7.34-7.39 (m, 
5H, Ph), 7.68 (s, 1H, CH=). 13C NMR (CDCl3, 300 MHz): δ 14.1(CH3), 31.1(CH3), 
61.5(CH2), 128.8 (CH), 129.6(CH), 130.3(CH), 132.8(C), 134.0(C), 140.4, (CH), 
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164.3(C), 203.3(C). Anal. Calcd. For C13H14O3: C, 71.54; H, 6.47. Found: C, 71.59; H, 
6.48. 
 
General procedure for the 1,4 addition of bis(N,O)-trimethylsilylhydroxylamine to 
alkylidene acetoacetate 1. To a stirred solution of 1a-d (0.5 mmol) in dry CH2Cl2 (2.5 
mL) at 0°C under nitrogen atmosphere, bis(N,O)-trimethylsilylhydroxylamine (2 equiv, 
1 mmol) was added in one portion. The reaction was followed by TLC and quenched 
after 16 h with water. The residue was then diluted with CH2Cl2 (10 mL) and washed 
twice with water (2 x 10 mL). The organic layer was dried over Na2SO4 and solvent was 
removed under reduced pressure.  Compounds 2a-d were purified by flash 
chromatography on silica gel (eluant cyclohex-ane/EtOAc, 9/1). 
 
(syn)-2a: Yield 77%, pale yellow oil;  1H NMR (CDCl3, 300 MHz) δ 0.08 (s, 9H, 
OSi(CH3)3), 0.95 (d, J=6.9 Hz, 3H, CHCH3 ), 1.03  (d, J=6.9 Hz, 3H, CHCH3 ), 1.28 (t,  
J= 7.2 Hz, 3H, OCH2CH3 ), 1.68 (m, 1H, CH3CHCH3), 2.25 (s, 3H, OCCH3), 3.26 (m,  
1H, NCH ), 3.45 (d, J=3.6 Hz, 1H, CHCO), 4.17 (m, 2H, OCH2CH3), 6.22 (d, J= 11.4, 
1H, NH); 13C NMR (CDCl3, 300 MHz) δC -1.1 (3CH3), 14.0 (CH3), 20.5 (2CH3), 29.4 
(CH), 30.1(CH3), 59.7 (CH),  60.9 (CH2), 67.5 (CH), 170.1 (C), 202.9 (C).  
(anti)-2a : 1H NMR (CDCl3, 300 MHz) δ 0.11 (s, 9H, OSi(CH3)3), 0.93 (m, 6H, CHCH3 
), 1.26 (t,  J= 7.2 Hz, 3H, OCH2CH3 ), 1.94 (m, 1H, CH3CHCH3), 2.29 (s, 3H, OCCH3), 
3.37 (m,  1H, NCH ), 3.71 (d, J=7.2 Hz, 1H, CHCO), 4.17 (m, 2H, OCH2CH3), 5.55 (d, 
J= 9.6, 1H, NH); 13C NMR (CDCl3, 300 MHz) δC -0.6 (3CH3), 14.0 (CH3), 18.5 (CH3), 
21.6 (CH3), 28.6 (CH), 30.1(CH3), 60.3 (CH),  61.3 (CH2), 69.8 (CH), 168.7 (C), 200.6 
(C). 
 
(syn)-2b: Yield 70%, pale yellow oil;  1H NMR (CDCl3, 300 MHz) δ 0.09 (s, 9H, 
OSi(CH3)3), 0.66-1.06 (m, 8H, CHCH2CH3 + CHCH2CH3 + CHCH3 ), 1.26 (t, J= 6.9 
Hz, 3H, OCH2CH3 ), 1.46 (m, 1H, CH3CHCH2), 2.23 (s, 3H, OCCH3), 3.36 (m, 1H, 
NCH ), 3.42 (d, J= 9.6 Hz, 1H, CHCO), 4.18 (m, 2H, OCH2CH3), 6.0 (bs, 1H, NH);  
δ13C NMR (CDCl3, 300 MHz) δC -1.1 (3CH3), 11.2 (CH3), 14.0 (CH3), 16.3 (CH3), 26.4 
(CH2), 28.6(CH3),  35.6(CH),  60.0 (CH2), 60.9 (CH ),  67.5 (CH), 170.0(C), 202.8 (C). 
(anti)-2b 1H NMR (CDCl3, 300 MHz) 0.06 (s, 9H, OSi(CH3)3), 0.66-1.06 (m, 8H, 
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CHCH2CH3 + CHCH2CH3 + CHCH3 ), 1.18 (m, 1H, CH3CHCH2), 1.25 (t, J= 6.9 Hz, 
3H, OCH2CH3 ), 2.27 (s, 3H, OCCH3), 3.69 (d, J=8.1 Hz, CHCO),  3.83 (m, 1H, NCH 
), 4.18 (m, 2H, OCH2CH3), 6.2 (bs, 1H, NH); 13C NMR (CDCl3, 300 MHz) δC -0.6 
(3CH3), 11.8 (CH3), 13.9 (CH3), 15.6 (CH3), 26.7 (CH2), 29.7(CH3),  36.0(CH),  59.3 
(CH2), 61.2 (CH), 68.4(CH), 168.9(C), 200.3 (C). 
 
(syn)-2c: Yield 75%, pale yellow oil; 1H NMR (CDCl3, 300 MHz) δ 0.07 (s, 9H, 
OSi(CH3)3), 0.90-1.22 (m, 5H, cyclohexyl), 1.27  (t,  J= 7.2 Hz, 3H, OCH2CH3), 1.44-
1.80 (m, 6H, cyclohexyl), 2.25 (s, 3H, OCCH3), 3.36 (m, 1H, NCH ), 3.44 (d, J=3.3 Hz, 
1H, CHCO), 4.12 (m, 2H, OCH2CH3), 6.20 (bs, 1H, NH); 13C NMR (CDCl3, 300 MHz) 
δC -1.1 (3CH3), 14.0 (CH3), 26.2 (2CH2), 28.6 (CH), 29.2 (CH2), 30.4 (CH2), 30.9 
(CH2), 38.8 (CH3), 59.2 (CH), 60.9 (CH2), 69.0 (CH), 170.2 (C), 203.1 (C).  
(anti)-2c : 1H NMR (CDCl3, 300 MHz) δ 0.13 (s, 9H, OSi(CH3)3), 0.90-1.22 (m, 5H, 
cyclohexyl), 1.25  (t,  J= 7.2 Hz, 3H, OCH2CH3), 1.44-1.80 (m, 6H, cyclohexyl), 2.28 
(s, 3H, OCCH3), 3.36 (m, 1H, NCH ), 3.72 (d, J=3.3 Hz, 1H, CHCO), 4.20 (m, 2H, 
OCH2CH3), 6.20 (bs, 1H, NH); 13C NMR (CDCl3, 300 MHz) δC -1.2 (3CH3), 14.1 
(CH3), 26.0(CH2), 26.5(CH2), 29.3 (CH), 30.3 (CH2), 30.6 (CH2), 31.0 (CH2), 39.2 
(CH3), 59.7 (CH), 61.2 (CH2), 67.5 (CH), 169.4 (C), 204.0 (C). 
 
(syn)-2d: Yield 66%, pale yellow oil;  1H NMR (CDCl3, 300 MHz) δ 0.03 (s, 9H, 
OSi(CH3)3), 0.94  (t,  J= 7.2 Hz, 3H, OCH2CH3), 2.36 (s, 3H, OCCH3), 3.90 (q, 
J=7.2Hz, 2H, OCH2CH3), 4.15 (d, J=7.8 Hz, 1H, CHCO), 4.68 (d, J=7.8 Hz, 1H, NCH 
), 5.59 (bs, 1H, NH), 7.20-7.50 (m, 5H, Ph); 13C NMR (CDCl3, 300 MHz) δC -0.8 
(3CH3), 13.6(CH3), 29.6(CH3), 61.3 (CH2), 63.0 (CH), 65.8 (CH), 128.0(CH), 
128.4(CH), 128.8(CH), 137.6(C), 167.2(C), 201.7 (C).  
(anti)-2d : 1H NMR (CDCl3, 300 MHz) δ 0.01 (s, 9H, OSi(CH3)3), 1.26  (t,  J= 7.2 Hz, 
3H, OCH2CH3), 2.06 (s, 3H, OCCH3), 4.05 (d, J=8.7 Hz, 1H, CHCO), 4.20 (q, 
J=7.2Hz, 2H, OCH2CH3), 4.65 (d, J=8.7 Hz, 1H, NCH ), 5.91 (bs, 1H, NH), 7.20-7.50 
(m, 5H, Ph); 13C NMR (CDCl3, 300 MHz) δC -1.2 (3CH3), 13.9(CH3), 29.8(CH3), 61.5 
(CH2), 62.4 (CH), 65.8 (CH), 127.8(CH), 128.2(CH), 129.5(CH), 137.6(C), 168.6 (C), 
201.3 (C). 
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General procedure for the catalyzed 1,4 addition of bis-(N,O)-
trimethylsilylhydroxylamine to alkylidene acetoacetate 1. To a stirred solution of 1a-d 
(0.5 mmol) in dry CH2Cl2 (2.5 mL) under nitrogen atmosphere, a catalytic amount of 
Lewis Acid (0.025 mmol) was added. The reaction mixture was cooled to 0°C and bis-
(N,O)-rimethylsilylhydroxylamine (2 equiv, 1 mmol) was added in one portion. The 
mixture was stirred for 1 hour at the same temperature and then filtered through a celite 
pad. The solvent was removed under reduced pressure to afford compounds 5a-d. 
 
5a: Yield >95%, colorless clear oil; 1H NMR (CDCl3, 300 MHz) δ 0.17 (s, 9H, 
OSi(CH3)3), 0.26 (s, 9H, OSi(CH3)3), 0.81 (d, J=6.9 Hz, 3H, CHCH3 ), 1.07  (d, J=6.6 
Hz, 3H, CHCH3 ), 1.28 (t,  J= 6.9 Hz, 3H, OCH2CH3 ), 1.54-1.64 (m, 1H, CH3CHCH3), 
1.92 (s, 3H, OCCH3), 3.12 (t,  J= 10.8, 1H, NCH ), 4.09-4.20 (m, 2H, OCH2CH3), 5.88 
(d, J= 11.4, 1H, NH); 13C NMR (CDCl3, 300 MHz) δC -0.9 (3CH3), 0.4 (3CH3), 14.3 
(CH3), 20.5 (CH3), 21.3 (CH3), 28.9 (CH), 59.7 (CH2), 69.7 (CH), 112.8 (C), 157.3 (C), 
168.4 (C). 
 
5b : Yield >95%, colorless clear oil; 1H NMR (CDCl3, 300 MHz) δ 0.10 (s, 9H, 
OSi(CH3)3), 0.20 (s, 9H, OSi(CH3)3), 0.79 (d, J=6.9 Hz, 3H, CHCH2CH3 ), 0.82-0.90 
(m, 2H, CHCH2CH3), 1.05  (d, J=6.6 Hz, 3H, CHCH3 ), 1.23-1.30 (m, 3H, OCH2CH3 ), 
1.35-1.49 (m, 1H, CH3CHCH2), 1.92 (s, 3H, OCCH3), 3.22 (bt,  J= 9.3, 1H, NCH ), 
4.07-4.27 (m, 2H, OCH2CH3), 5.88 (bs, 1H, NH); 13C NMR (CDCl3, 300 MHz) δC -0.8 
(3CH3), 0.5 (3CH3), 10.5 (CH3), 14.4 (CH3), 16.9 (CH3), 20.5 (CH), 26.6 (CH2), 34.8 
(CH3), 59.7 (CH2), 68.2 (CH), 112.8 (C), 156.9 (C), 168.5 (C). 
 
5c : Yield >95%, colorless clear oil; 1H NMR (CDCl3, 300 MHz) δ 0.14 (s, 9H, 
OSi(CH3)3), 0.24 (s, 9H, OSi(CH3)3), 0.86-1.40 (m, 6H, cyclohexyl), 1.32  (t,  J= 7.2 
Hz, 3H, OCH2CH3 ), 1.65-1.80 (m, 4H, cyclohexyl), 1.96 (s, 3H, OCCH3), 2.27 (bd, J= 
13.2 Hz, 1H, cyclohexyl), 3.29 (d, J= 10.5, 1H, NCH ), 4.12-4.23 (m, 2H, OCH2CH3), 
5.92 (bs, 1H, NH); 13C NMR (CDCl3, 300 MHz) δC -0.8 (3CH3), 0.5 (3CH3), 14.4 
(CH3), 20.6 (CH), 25.9 (CH2), 26.2 (CH2), 26.6 (CH2), 30.7 (CH2), 31.8 (CH2), 38.3 
(CH3), 59.7 (CH2), 68.3 (CH), 112.5 (C), 157.3 (C), 168.5 (C). 
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5d : Yield >95%, colorless clear oil; 1H NMR (CDCl3, 300 MHz) δ 0.21 (s, 9H, 
OSi(CH3)3), 0.30 (s, 9H, OSi(CH3)3, 1.08  (t,  J= 7.2 Hz, 3H, OCH2CH3), 2.05 (s, 3H, 
OCCH3), 4.05 (q,  J= 6.9 Hz, 2H, OCH2CH3), 4.89 (d, J= 11.4 Hz, 1H, HNCH) 6.27 (d, 
J= 11.4 Hz, 1H, NH), 7.29-7.35(m, 5H, Ph); 13C NMR (CDCl3, 300 MHz) δC -0.9 
(3CH3), 0.5 (3CH3), 14.0 (CH3), 20.9 (CH3), 59.7 (CH2), 60.9 (CH), 113.13 (C), 126.8 
(2CH), 128.0 (2CH), 128.6 (CH), 139.9 (C), 153.4 (C), 167.5 (C). 
 
General procedure for the cyclization of 2a-d or 5a-d to 5-hydroxyisoxazolidine-4-
carboxylates 3a-d: To a stirred solution of 2a-d or 5a-d (0.5 mmol) in CH2Cl2 (5 mL), 
wet silica gel or Amberlist H15 (100 mg) was added and the reaction mixture was 
stirred for two hours at room temperature. After filtration on a Gouch filter, the silica 
gel was washed with methanol, (10 mL) and the mother liquors were evaporated under 
reduced pressure to afford compounds 3a-d. 
 
3a-methyl ester: Yield >95%, colorless clear oil; Major anomer 1H NMR (CDCl3, 300 
MHz): δ 0.88 (d, J = 6.6 Hz,  3H, CHCH3), 0.97 (d, 3H, J = 6.6 Hz, CHCH3), 1.67 (s, 
3H, HOCCH3), 1.69 (m, 1H, CH3CHCH3), 2.96 (d, J = 5.4 Hz, 1H, CHCO), 3.56 (dd, J 
= 5.4, 7.5 Hz, 1H, HNCH), 3.76 (s, 3H, OCH3). 13C NMR (CDCl3, 300 MHz): δ 
18.7(CH3), 19.2(CH3), 23.8(CH), 32.5(CH3), 52.4(CH), 60.2(CH3), 67.9(CH), 106.5(C), 
171.0(C). Minor anomer 1H NMR (CDCl3, 300 MHz):  δ 0.92 (d, J = 6.9 Hz 3H, 
CHCH3), 1.00 (d, J = 6.6 Hz, 3H, CHCH3), 1.50 (s, 3H, HOCCH3), 1.70 (m, 1H, 
CH3CHCH3), 2.95 (d, J = 7.6 Hz 1H, CHCO), 3.58 (m, 1H, HNCH), 3.74 (s, 3H, 
OCH3). 13C NMR (CDCl3, 300 MHz):  δ 19.6(CH3), 20.3(CH3), 22.2(CH), 30.1(CH3), 
52.2(CH), 62.0(CH3), 71.3(CH), 108.4(C), 172.0(C). Anal. Calcd. For C9H17NO4: C, 
53.19; H, 8.43; N, 6.89. Found: C, 53.14; H, 8.45; N, 6.92. 
3a-ethyl ester: Yield 95%, yellow oil; Major anomer 1H NMR (C6D6, 600 MHz): δ 0.82 
(d, J = 6.6 Hz,  3H, CHCH3), 0.93 (t, 3H, J = 7.2 Hz, OCH2CH3), 0.97 (d, 3H, J = 6.6 
Hz, CHCH3), 1.51 (s, 3H, HOCCH3), 1.64 (m, 1H, CH3CHCH3), 2.83 (d, J = 5.4 Hz, 
1H, CHCO), 3.58 (dd, J = 5.4, 7.2 Hz, 1H, HNCH), 3.93 (m, 1H, OCH2CH3), 3.98 (m, 
1H, OCH2CH3). 13C NMR (CDCl3, 300 MHz): δ 14.1(CH3), 18.7(CH3), 19.4(CH3), 
23.8(CH), 32.6(CH3), 60.1(CH2), 61.3(CH), 67.9(CH), 106.5(C), 170.7(C). Minor 
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anomer 1H NMR (C6D6, 600 MHz):  δ 0.86 (d, J = 7.2 Hz 3H, CHCH3), 0.88 (d, J = 6.6 
Hz, 3H, CHCH3), 0.91 (t, J = 7.2 Hz, 3H, OCH2CH3), 1.45 (s, 3H, HOCCH3), 1.50 (m, 
1H, CH3CHCH3), 3.03 (d, J = 7.8 Hz 1H, CHCO), 3.88 (dd, J = 7.8, 7.2 Hz, 1H, 
HNCH), 3.92 (m, 2H, OCH2CH3). 13C NMR (CDCl3, 300 MHz):  δ 14.2(CH3), 
19.6(CH3), 20.4(CH), 22.2(CH3), 30.1(CH3), 61.1(CH2), 62.0(CH), 71.9(CH), 108.4(C), 
171.5(C). Anal. Calcd. For C10H19NO4: C, 55.28; H, 8.81; N, 6.45. Found: C, 55.31; H, 
8.79; N, 6.43. 
3b: Yield 90%, pale yellow oil; Major anomer 1H NMR (CDCl3, 300 MHz): δ 0.80-
1.06(m, 8H, CHCH2CH3 + CHCH2CH3 + CHCH3) 1.30 (t, 3H, J = 7.2 Hz, OCH2CH3), 
1.58 (m, 1H, CH3CH CH2CH3), 1.67 (s, 3H, HOCCH3),), 2.96 (d, J = 6.0 Hz, 1H, 
CHCO), 3.67 (t, J = 6.0 Hz, 1H, HNCH), 4.23 (m, 2H, OCH2CH3). 13C NMR (CDCl3, 
300 MHz): δ 11.2(CH3), 14.1(CH3), 15.2(CH3),  23.8(CH), 26.2(CH2), 39.0(CH3), 
59.8(CH), 61.3(CH2), 66.6(CH), 106.1(C), 170.7(C). Minor anomer 1H NMR (CDCl3, 
300 MHz): δ 0.80-1.06(m, 8H, CHCH2CH3 + CHCH2CH3 + CHCH3) 1.29 (t, 3H, J = 
7.2 Hz, OCH2CH3), 1.53 (s, 3H, HOCCH3), 1.58 (m, 1H, CH3CHCH2CH3), 2.95 (m, 
1H, CHCO), 3.68 (m, 1H, HNCH), 4.25 (m, 2H, OCH2CH3).13C NMR (CDCl3, 300 
MHz):  δ 11.8(CH3), 13.6(CH3), 18.2(CH3),  23.1(CH), 26.6(CH2), 40.1(CH3), 
60.3(CH), 61.9(CH2), 70.1(CH), 105.0(C), 167.2(C). Anal. Calcd. For C11H21NO4: C, 
57.12; H, 9.15; N, 6.06. Found: C, 57.11; H, 9.19; N, 6.08. 
3c: Yield 95%, yellow oil; Major anomer 1H NMR (CDCl3, 300 MHz) 0.92-1.40 (m, 
6H, cyclohexyl), 1.29  (t,  J= 7.2 Hz, 3H, OCH2CH3 ), 1.52-1.78 (m, 4H, cyclohexyl), 
1.67 (s, 3H, OCCH3), 2.00 (m, 1H, cyclohexyl), 3.00 (d, J= 5.7 Hz, 1H, CHCO), 3.56 
(dd, J= 5.7, 8.1 Hz, 1H, HNCH), 4.24 (m, 2H, OCH2CH3); 13C NMR (CDCl3, 300 
MHz) δC 14.1 (CH3), 23.9(CH), 25.8 (CH2), 26.0 (CH2), 26.3 (CH2), 29.4(CH2), 29.9 
(CH2), 42.3 (CH3), 60.1(CH), 61.4 (CH2), 67.2 (CH), 106.3 (C), 170.8 (C). Minor 
anomer 1H NMR (CDCl3, 300 MHz) 0.92-1.40 (m, 6H, cyclohexyl), 1.33  (t,  J= 7.2 Hz, 
3H, OCH2CH3 ), 1.52-1.78 (m, 4H, cyclohexyl), 1.64 (s, 3H, OCCH3), 1.85 (m, 1H, 
cyclohexyl), 2.96 (d, J= 7.5 Hz, 1H, CHCO), 3.56 (t, J= 7.5 Hz, 1H, HNCH), 4.30(m, 
2H, OCH2CH3); 13C NMR (CDCl3, 300 MHz) δC 14.1 (CH3), 22.0(CH), 25.1 (CH2), 
25.6(CH2), 26.9 (CH2), 30.9(CH2), 31.0 (CH2), 40.0 (CH3), 61.0(CH), 62.1 (CH2), 70.2 
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(CH), 108.2 (C), 171.4 (C). Anal. Calcd. For C13H23NO4: C, 60.68; H, 9.01; N, 5.44. 
Found: C, 60.75; H, 9.00; N, 5.41. 
3d: Yield 80%, yellow oil; Major anomer 1H NMR (CDCl3, 300 MHz) δ 1.31  (t,  J= 
7.2 Hz, 3H, OCH2CH3), 1.74 (s, 3H, OCCH3), 3.24 (d, J= 5.4 Hz, 1H, CHCO),  4.27 (q,  
J= 7.2 Hz, 2H, OCH2CH3), 5.09 (d, J= 5.4 Hz, 1H, HNCH),7.28-7.57 (m, 5H, Ph); 13C 
NMR (CDCl3, 300 MHz) δC  14.4 (CH3), 24.4 (CH3), 61.9 (CH2), 65.0 (CH), 70.2(CH), 
107.0 (C), 126.3 (2CH), 127.3 (2CH), 128.7 (CH), 134.1 (C), 178.0 (C). Minor anomer 
1H NMR (CDCl3, 300 MHz) δ 1.27  (t,  J= 7.2 Hz, 3H, OCH2CH3), 1.64 (s, 3H, 
OCCH3), 3.41 (d, J= 7.2 Hz, 1H, CHCO),  4.15 (q,  J= 7.2 Hz, 2H, OCH2CH3), 4.94 (d, 
J= 7.2 Hz, 1H, HNCH), 7.28-7.60 (m, 5H, Ph); 13C NMR (CDCl3, 300 MHz) δC  14.1 
(CH3), 25.1 (CH3), 60.9 (CH2), 64.2 (CH), 69.3(CH), 105.8 (C), 126.5 (2CH), 127.1 
(2CH), 128.9 (CH), 136.1 (C), 169.4 (C). Anal. Calcd. For C13H17NO4: C, 62.14; H, 
6.82; N, 5.57. Found: C, 62.19; H, 6.80; N, 5.53. 
 
4a: 1H NMR (CDCl3, 300 MHz):  δ  1.20 (m, 9H), 2.05 (s, 3H), 2.65 (m, 1H), 4.24 (m, 
2H), 5.87 (d, 1H, J =10.2). 13C NMR (CDCl3, 300 MHz): 10.6, 14.1, 22.4, 29.4, 61.0, 
131.3, 143.9154.4, 167.5. 
 
General procedure for the conversion of compounds 3a-c to 6a-c. To a stirred solution 
of 3a-c (0.5 mmol) in CH2Cl2 (2.5 mL) at 0°C, Et3N (1.1 equiv, 0.55 mmol) and 3,5-
Dinitrobenzoyl chloride (1.1 equiv, 0.55 mmol), were added. The solution was stirred 
for 1 hour and then the mixture was quenched with water. The residue was diluted with 
CH2Cl2 (5 mL) and the biphasic solution was extracted twice with water (2 x 5 mL). 
The organic layer was dried over Na2SO4, and solvent was removed under reduced 
pressure. Compounds 6a-c were purified by flash chromatography on silica gel 
(cyclohexane/ethyl acetate 85/15 as eluant). 
 
6a: Yield 80%, white solid; mp 148-152 °C; 1H NMR (CDCl3, 300 MHz) δ 1.07 (d, 
J=6.6 Hz, 6H, CH3CHCH3 ), 1.34 (t, J= 7.2 Hz, 3H, OCH2CH3 ), 1.65 (s, 3H, OCCH3), 
2.05-2.16 (m, 1H, CH3CHCH3)3.16 (d, J= 6.9, 1H, HCCO2 ), 4.29 (q, J= 7.2 Hz, 2H, 
OCH2CH3), 4.94 (t, J= 6.9, 1H, NCH), 8.97 (s, 2H, Ph), 9.14 (s, 1H, Ph); 13C NMR 
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(CDCl3, 300 MHz) δC 14.0 (CH3), 18.2 (CH3), 18.7 (CH3), 23.0 (CH3), 32.4 (CH), 57.7 
(CH), 62.2 (CH2), 65.9 (CH) 106.5 (C), 120.5 (CH), 129.6 (2CH), 137.6 (C), 148.0 
(2C), 151.0 (C), 169.9 (C). Anal. Calcd. For C17H21NO4: C, 49.64; H, 5.15; N, 10.21. 
Found: C, 49.55; H, 5.13; N, 10.26. 
 
6b: Yield 70%, pale yellow solid; mp 120-122 °C;  1H NMR (CDCl3, 300 MHz) δ 0.95-
1.05 (m, 6H, CH3CHCH2CH3 ), 1.31 (t, J= 7.2 Hz, 3H, OCH2CH3 ), 1.37-1.43 (m, 2H, 
CH3CHCH2CH3), 1.51-1.60 (m, 1H, CH3CHCH2CH3), 1.63 (s, 3H, OCCH3), 3.15 (d, J= 
6.9, 1H, HCCO2 ), 4.26 (q, J= 7.2 Hz, 2H, OCH2CH3), 5.03 (q, J= 6.3, 1H, NCH), 5.84 
(bs, OH), 8.93 (s, 2H, Ph), 9.19 (s, 1H, Ph); 13C NMR (CDCl3, 300 MHz) δC 12.9 
(CH3), 14.0 (CH3), 15.2 (CH3), 22.7 (CH3), 25.8 (CH2), 39.0 (CH), 58.3 (CH), 62.1 
(CH2), 64.6 (CH) 106.5 (C), 120.4 (CH), 129.6 (2CH), 137.4 (C), 147.9 (2C), 158.6 (C), 
169.4 (C). Anal. Calcd. For C18H23NO4: C, 50.82; H, 5.45; N, 9.88. Found: C, 50.85; H, 
5.42; N, 9.90. 
 
6c: Yield 68%, white solid; mp 145-148 °C;  1H NMR (CDCl3, 300 MHz) δ 1.02-1.31 
(m, 6H, cyclohexyl), 1.29  (t, J= 7.2 Hz, 3H, OCH2CH3 ), 1.59 (s, 3H, OCCH3), 1.62-
1.85 (m, 5H, cyclohexyl), 2.14 (d, J= 6.9, 1H, HCCO2 ), 4.24 (q, J= 6.9 Hz, 2H, 
OCH2CH3), 4.88 (t, , J= 6.3, 1H, NCH, ), 8.92 (s, 2H, Ph), 9.09 (s, 1H, Ph); 13C NMR 
(CDCl3, 300 MHz) δC 14.1 (CH3), 23.0 (CH3), 25.8 (CH2), 26.1 (CH2), 26.9 (CH2), 28.8 
(CH2), 29.3 (CH2), 42.2 (CH), 58.0 (CH), 62.3 (CH2), 65.2 (CH) 106.5 (C), 120.5 (CH), 
129.6 (2CH), 137.6 (C), 148.0 (3C), 169.9 (C). Anal. Calcd. For C20H25NO4: C, 53.21; 
H, 5.58; N, 9.31. Found: C, 53.09; H, 5.59; N, 9.28. 
 
X-ray Crystallography: The diffraction experiments for 5a were carried out at room 
temperature on a Bruker AXS Apex II CCD diffractometer using graphite-
monochromated Mo-Kα radiation (λ= 0.71073 Å). Intensity data were measured over 
full diffraction spheres using 0.3°-wide ω scans.. The SMART52software package was 
used for collecting frames of data, indexing reflections and determination of lattice 
parameters. The collected frames were then processed for integration with SAINT27 and 
an empirical absorption correction was applied with SADABS53The structures were 
solved by direct methods  (SIR 97)54 and subsequent Fourier syntheses, and refined by 
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full-matrix least-squares calculations on F2 (SHELXTL)55 with anisotropic thermal 
parameters for the non-hydrogen atoms. The methyl and aromatic hydrogen atoms were 
placed in calculated positions and refined with idealized geometry, whereas the other H-
atoms were located in the Fourier map and refined isotropically. CCDC-694159 for 5a 
contains the supplementary crystallographic data for this paper. These data can be 
obtained free of charge from The Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif.  
 
General procedure for the 1,4 addition of benzyl-(tert-butyldimethylsilyloxy)carbamate 
to 1a-e. To a stirred solution of 1a-e (0.5 mmol) and Lewis acid (0.05 equiv, 0.025 
mmol), in dry CH2Cl2 (5 mL) at the selected temperature under nitrogen atmosphere, 
the carbamate (1 equiv, 0.5 mmol, 140 mg) was added in one portion. The reaction was 
followed by TLC and quenched with water. The residue was then diluted with CH2Cl2 
(10 mL) and washed twice with water (2 x 10 mL). The organic layer was dried over 
Na2SO4 and solvent was removed under reduced pressure.  Compounds 7a-e and 8a-e 
were purified by flash chromatography on silica gel (eluant cyclohexane/EtOAc, 85/15). 
 
7a : Colorless oil; 1H NMR (300 MHz, CDCl3): δH 0.86 (d, 3H, J=6.6 Hz), 0.89 (d, 3H, 
J=6.9 Hz), 1.22 (t, 3H, J=7.2 Hz), 1.70 (s, 3H), 1.81 (m, 1H), 2.90 (d, 1H, J=6.6 Hz), 
4.23 (q, 2H, J=7.2 Hz), 4.60 (t, 1H, J=6.6 Hz), 5.10 (d, 1H, J=12.6 Hz), 5.18 (d, 1H, 
J=12.6 Hz), 7.27-7.34 (m, 5H).13C NMR (CDCl3, 75 MHz): δC 14.0(CH3), 18.1(CH3), 
18.7(CH3), 22.9(CH3), 32.7(CH), 59.3(CH), 61.3(CH2), 67.0(CH), 68.0(CH2), 106.3(C), 
127.9(CH), 128.0(CH), 128.4(CH), 135.8(C), 159.9(C), 168.2(C). LC-ESI-MS: rt 9.6 
min m/z 352 (M+1), 725 (2M+Na). Anal. Calcd. For C18H25NO6: C, 61.52; H, 7.17; N, 
3.99. Found: C, 61.58; H, 7.14; N, 4.01. 
 
7b : Pale yellow oil; 1H NMR (CDCl3, 300 MHz) δ 0.80 (d, J= 6.6 Hz,  6H, 
CH3CHCH3), 1.07-1.44 (m, 2H, CHCH2), 1.23 (t, J= 7.2 Hz, 3H, OCH2CH3), 1.64 (m, 
1H, CH3CHCH3), 1.75 (s, 3H, OCCH3), 2.82 (d, J= 6.2, 1H, OCCH), 4.17-4.28 (m, 2H, 
OCH2CH3), 4.87 (dd, J= 6.2, 7.8, 1H, NCH), 5.15-5.24 (m, 2H, OCH2Ph), 7.30-7.39 
(m, 5H, Ph); 13C NMR (CDCl3, 75 MHz) δC 14.0 (CH3), 21.9 (CH3), 22.8 (CH3), 23.0 
(CH3), 25.2 (CH), 26.9 (CH2), 60.6 (CH), 61.4 (CH2), 62.5 (CH), 68.0 (CH2), 106.1 (C), 
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127.8 (CH), 128.2 (CH), 128.5 (CH), 135.6 (C), 159.8 (C),168.1 (C). LC-ESI-MS: rt 
10.3 min m/z 366 (M+1). Anal. Calcd. For C19H27NO6: C, 62.45; H, 7.45; N, 3.83. 
Found: C, 62.41; H, 7.47; N, 3.84. 
 
7c : Pale yellow oil; 1H NMR (CDCl3, 300 MHz) δ 0.86-0.91 (m, 6H, CH3CHCH2CH3), 
1.02-1.15 (m, 2H, CH3CHCH2CH3), 1.28 (t, J= 7.2 Hz, 3H, OCH2CH3), 1.46-1.54 (m, 
1H, CH3CHCH2CH3), 1.74 (s, 3H, OCCH3), 2.97 (d, J= 6.3, 1H, OCCH), 3.97 (bs, 1H, 
OH), 4.18-4.24 (m, 2H, OCH2CH3), 4.74 (q, J= 7.2, 1H, NCH), 5.15-5.24 (m, 2H, 
OCH2Ph), 7.32-7.35 (m, 5H, Ph); 13C NMR (CDCl3, 75 MHz) δC 11.4 (CH3), 14.1 
(CH3), 14.8 (CH3), 23.0 (CH3), 25.7 (CH2), 39.2 (CH), 58.7 (CH), 61.4 (CH2), 66.2 
(CH), 68.0 (CH2), 106.5 (C), 127.9 (2CH), 128.4 (CH), 135.8 (C), 159.9 (C),168.3 (C). 
LC-ESI-MS: rt 10.0 min m/z 366 (M+1). Anal. Calcd. For C19H27NO6: C, 62.45; H, 
7.45; N, 3.83. Found: C, 62.48; H, 7.42; N, 3.86. 
 
7d : Pale yellow oil; 1H NMR (CDCl3, 200 MHz) δ 0.98-1.32 (m, 5H, cyclohexyl), 1.29 
(t, J= 7.0 Hz, 3H, OCH2CH3 ), 1.44-1.82 (m, 6H, cyclohexyl), 1.74 (s, 3H, OCCH3), 
2.99 (d, J= 6.6 Hz, 1H, CH3CCH), 3.81 (bs, OH), 4.16-4.27 (m, 2H, OCH2CH3), 4.62 (t, 
J= 6.8 Hz, 1H, NCH), 5.15 (d,, J= 18.2, Hz, 1H, OCH2Ph), 5.25 (d,, J= 18.2, Hz, 1H, 
OCH2Ph), 7.32-7.35 (m, 5H, Ph); 13C NMR (CDCl3, 50 MHz) δC 14.1 (CH3), 23.1 
(CH3), 25.8 (CH2), 26.2 (CH2), 28.8 (CH2), 29.3 (CH2), 29.7 (CH2), 42.5 (CH), 59.5 
(CH), 61.4 (CH2), 66.5 (CH), 68.0 (CH2), 106.3 (C), 127.9 (CH), 128.1 (CH), 128.4 
(CH), 135.9 (C), 160.0 (C), 168.3 (C). LC-ESI-MS: rt 11.2  min m/z 414 (M+Na), 805 
(2M+Na). Anal. Calcd. For C21H29NO6: C, 64.43; H, 7.47; N, 3.58. Found: C, 64.40; H, 
7.51; N, 3.56. 
 
7e : Yellow oil; 1H NMR (CDCl3, 300 MHz) δ 1.32 (t, J= 7.2 Hz, 3H, OCH2CH3 ), 1.88 
(s, 3H, OCCH3), 3.27 (d, J= 7.8 Hz, 1H, CH3CCH), 4.23-4.31 (m, 2H, OCH2CH3), 4.42 
(bs, OH), 5.22 (s, 2H, OCH2Ph), 5.89 (d, J= 7.8 Hz, 1H, NCH), 7.28-7.46 (m, 10H, Ph); 
13C NMR (CDCl3, 75 MHz) δC 14.0 (CH3), 22.6 (CH3), 61.5 (CH2), 64.7 (CH), 65.2 
(CH), 68.0 (CH2), 105.9 (C),126.1 (CH), 127.6 (CH), 127.7 (CH), 128.1 (CH), 128.4 
(CH), 128.7 (CH), 135.7 (C), 140.6 (C), 158.9 (C), 167.3 (C). LC-ESI-MS: rt 9.8 min 
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m/z 408 (M+Na), 793 (2M+Na). Anal. Calcd. For C21H23NO6: C, 65.44; H, 6.02; N, 
3.63. Found: C, 65.43; H, 5.99; N, 3.66. 
 
General procedure for the conversion of 7a-e into 8a-e. To the crude reaction 
containing 7 and 8, toluene (5 mL) and Sc(OTf)3 or Zn(OTf)2 (0.5 equiv.) were added 
and the solution was refluxed for 3h.  The reaction was followed by TLC and quenched,  
after disappearance of compound 2, with water. The residue was then diluted with 
CH2Cl2 (10 mL) and washed twice with water (2 x 10 mL). The organic layer was dried 
over Na2SO4 and solvent was removed under reduced pressure.  Compound  8a-e was 
purified by flash chromatography on silica gel (eluant cyclohexane/EtOAc, 85/15). 
 
8a : White solid; 1H NMR (CDCl3, 600 MHz) δ 0.71 (d, J= 6.6 Hz 3H, CH3CHCH3 ), 
0.88 (d, J= 6.6 Hz 3H, CH3CHCH3 ), 1.17 (t, J=7.2 Hz, 3H, OCH2CH3 ), 1.97-2.17 (m, 
1H, CH3CHCH3), 2.18 (s, 3H, OCCH3), 4.04-4.13 (m, 2H, OCH2CH3), 4.98 (bd, J= 2.4 
Hz 1H, NCH), 5.12 (s, 2H, OCH2Ph), 7.26-7.30 (m, 5H, Ph); 13C NMR (CDCl3, 75 
MHz) δC 11.5 (CH3), 14.2 (CH3), 15.3 (CH3), 19.5 (CH3), 31.3 (CH), 60.0 (CH2), 68.5 
(CH2), 70.3 (CH), 103.0 (C), 128.1 (CH), 128.3 (CH), 128.5 (CH), 135.2 (C), 158.5 
(C),163.4 (C), 163.7 (C). LC-ESI-MS: rt 11.7 min m/z 334 (M+1), 689 (2M+Na). Anal. 
Calcd. For C18H23NO5: C, 64.85; H, 6.95; N, 4.20. Found: C, 64.84; H, 6.94; N, 4.23. 
 
8b: Sticky yellow oil;  1H NMR (CDCl3, 300 MHz) δ 0.91 (d, J= 6.6 Hz 3H, 
CH3CHCH3), 0.95 (d, J= 6.6 Hz 3H, CH3CHCH3), 1.29 (t, J= 7.2 Hz, 3H, OCH2CH3), 
1.56 (m, 1H, CHCH2), 1.77- (m, 2H, CHCH2+  CH3CHCH3), 2.28 (s, 3H, OCCH3), 4.19 
(m, 2H, OCH2CH3), 4.87 (dd, J= 6.2, 7.8, 1H, NCH), 5.15-5.24 (m, 2H, OCH2Ph), 7.30-
7.37 (m, 5H, Ph); 13C NMR (CDCl3, 75 MHz) δC 11.7 (CH3), 14.2 (CH3), 21.3 (CH3), 
23.6 (CH3), 24.6 (CH), 43.8 (CH2), 60.0 (CH2), 64.1 (CH), 68.5(CH2), 105.1 (C), 128.2 
(CH), 128.3 (CH), 128.5 (CH), 135.3 (C), 158.1 (C), 163.3(C), 163.5 (C). LC-ESI-MS: 
rt 12.3 min m/z 348 (M+1). Anal. Calcd. For C19H25NO5: C, 65.69; H, 7.25; N, 4.03. 
Found: C, 65.70; H, 7.22; N, 4.01. 
 
8c : Pale yellow oil; 1H NMR (CDCl3, 300 MHz) δ 0.80 (d, J= 6.9 Hz 3H, 
CH3CHCH2CH3), 0.88 (t, J= 7.2 Hz, 3H, CHCH2CH3), 1.29 (t, J= 7.2 Hz, 3H, 
  75
OCH2CH3), 1.42-1.50 (m, 2H, CH3CHCH2CH3), 1.75-1.81 (m, 1H, CH3CHCH2CH3), 
2.30 (s, 3H, OCCH3), 4.16-4.22 (m, 2H, OCH2CH3), 5.12 (bd, J= 2.7 Hz 1H, NCH), 
5.24 (false t, J= 12.3 Hz, 2H, OCH2Ph), 7.34-7.40 (m, 5H, Ph); 13C NMR (CDCl3, 75 
MHz) δC 11.8 (CH3), 12.7 (CH3), 14.2 (CH3), 16.0 (CH3), 22.6 (CH2), 38.5 (CH), 60.0 
(CH2), 68.5 (CH2), 69.7 (CH), 103.1 (C), 128.3 (CH), 128.5 (CH), 129.3 (CH), 135.2 
(C), 158.3 (C),163.7 (C), 164.0 (C). LC-ESI-MS: rt 12.18 min m/z 348 (M+1). Anal. 
Calcd. For C19H25NO5: C, 65.69; H, 7.25; N, 4.03. Found: C, 65.71; H, 7.28; N, 4.07. 
 
8d : Colorless clear oil; 1H NMR (CDCl3, 600 MHz) δ 1.01-1.27 (m, 5H, cyclohexyl), 
1.28 (t, J= 7.2 Hz, 3H, OCH2CH3), 1.55-1.78 (m, 6H, cyclohexyl), 2.28 (s, 3H, 
OCCH3), 4.16-4.24 (m, 2H, OCH2CH3), 5.05 (bd, J= 1.2 Hz, 1H, NCH), 5.23 (s, 2 Hz, 
2H, OCH2Ph), 7.35-7.38 (m, 5H, Ph); 13C NMR (CDCl3, 75 MHz) δC 11.4 (CH3), 14.1 
(CH3), 25.4 (CH2), 25.9 (CH2), 26.1 (CH2), 26.2 (CH2), 30.1 (CH2), 41.0 (CH), 60.0 
(CH2), 68.4 (CH2), 69.9 (CH), 102.5 (C), 128.1 (CH), 128.3 (CH), 128.4 (CH), 135.2 
(C), 158.4 (C), 163.8 (C), 163.9 (C). LC-ESI-MS: rt 13.6  min m/z 396 (M+Na). Anal. 
Calcd. For C21H27NO5: C, 67.54; H, 7.29; N, 3.75. Found: C, 67.56; H, 7.32; N, 3.75. 
 
8e : Pale yellow oil; 1H NMR (CDCl3, 300 MHz) δ 1.05 (t, J= 7.0 Hz, 3H, OCH2CH3), 
2.32 (s, 3H, OCCH3), 3.93-4.05 (m, 2H, OCH2CH3), 5.10 (d, 1H, J= 12.6 Hz, OCH2Ph), 
5.18 (d, 1H, J= 12.6 Hz, OCH2Ph), 6.00 (bs, 1H, NCH), 7.19-7.30 (m, 10H, Ph); 13C 
NMR (CDCl3, 300 MHz) δC 11.6(CH3), 14.0 (CH3), 60.0 (CH2), 68.0 (CH), 68.5 (CH), 
105.0(C), 127.2 (CH), 128.2 (CH), 128.3 (CH), 128.4 (CH), 128.5 (2CH), 135.1 (C), 
139.9 (C), 155.9 (C), 162.5 (C), 163.0 (C). LC-ESI-MS: rt 11.2 min m/z 390 (M+Na), 
757 (2M+Na). Anal. Calcd. For C21H21NO5: C, 68.65; H, 5.76; N, 3.81. Found: C, 
68.62; H, 5.77; N, 3.84. 
 
General procedure for the conversion of 8a-e into 9a-e. Method A. To a stirred solution 
of 8a-e (0.5 mmol) in ethanol (5 mL) at 0°C under nitrogen atmosphere, NaBH4 (1 
equiv, 0.5 mmol, 18 mg) was added in one portion. The reaction was stirred at room 
temperature and followed by TLC. After quenching with water, the residue was diluted 
with EtOAc (10 mL) and washed twice with water (2 x 10 mL). The organic layer was 
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dried over Na2SO4 and solvent was removed under reduced pressure.  Compound 9a-e 
was purified by flash chromatography on silica gel (eluant cyclohexane/EtOAc, 75/25).  
Method B. To a stirred solution of 8a-e (0.5 mmol) in THF7methanol/water (4/1/1, 6 
mL) at room temperature, LiOH (3 equiv, 1.5 mmol, 36 mg) was added in one portion. 
The reaction was followed by TLC and quenched with water, the residue was diluted 
with EtOAc (10 mL) and washed twice with water (2 x 10 mL). The organic layer was 
dried over Na2SO4 and solvent was removed under reduced pressure.  Compound 9a-e 
was purified by flash chromatography on silica gel (eluant cyclohexane/EtOAc, 75/25).  
 
9a : Pale yellow oil; 1H NMR (CDCl3, 600 MHz) δ 0.87 (d, J= 7.0 Hz 3H, CH3CHCH3 
), 0.97 (d, J= 7.0 Hz 3H, CH3CHCH3 ), 1.30 (t, J=7.2 Hz, 3H, OCH2CH3 ), 1.99 (m, 1H, 
CH3CHCH3), 2.24 (s, 3H, OCCH3), 4.20 (m, 2H, OCH2CH3), 4.31 (bs, 1H, NCH),6.60-
6.80 (bs, 1H, NH); 13C NMR (CDCl3, 75 MHz) δC 11.8 (CH3), 14.3 (CH3), 15.4 (CH3), 
19.7 (CH3), 30.9 (CH), 59.6 (CH2), 68.6 (CH), 103.9 (C), 164.8 (C), 167.2 (C). LC-ESI-
MS: rt 9.3 min m/z 200 (M+1), 222 (M+Na). Anal. Calcd. For C10H17NO3: C, 60.28; H, 
8.60; N, 7.03. Found: C, 60.30; H, 8.62; N, 7.06. 
 
9b: Yellow oil;  1H NMR (CDCl3, 300 MHz) δ 0.93 (d, J= 6.6 Hz,  3H, CH3CHCH3), 
0.95 (d, J= 6.6 Hz, 3H, CH3CHCH3), 1.19-1.33 (m, 2H, CHCH2+ CH3CHCH3), 1.31 (t, 
J= 7.0 Hz, 3H, OCH2CH3), 1.73 (m, 1H, CHCH2), 2.22 (s, 3H, OCCH3), 4.20 (m, 2H, 
OCH2CH3), 4.37 (bs, 1H, NCH),6.40-6.70 (bs, 1H, NH); 13C NMR (CDCl3, 75 MHz) δC 
11.9 (CH3), 14.2 (CH3), 21.5 (CH3), 23.6 (CH3), 25.2 (CH), 43.6 (CH2), 60.0 (CH2), 
62.2 (CH), 106.2 (C), 164.5(C), 167.0 (C). LC-ESI-MS: rt 6.8 min m/z 214 (M+1). 
Anal. Calcd. For C11H19NO3: C, 61.95; H, 8.98; N, 6.57. Found: C, 61.99; H, 9.00; N, 
6.52. 
 
9c: Colorless oil; 1H NMR (CDCl3, 300 MHz) δ 0.81 (d, J= 6.9 Hz, 3H, 
CH3CHCH2CH3), 0.92 (t, J= 7.2 Hz, 3H, CHCH2CH3), 1.20-1.31 (m, 2H, 
CH3CHCH2CH3), 1.24 (t, J= 7.2 Hz, 3H, OCH2CH3), 1.74 (m, 1H, CH3CHCH2CH3), 
2.21 (s, 3H, OCCH3), 4.24 (q, J= 7.2 Hz, 2H, OCH2CH3), 4.42 (bs, 1H, NCH), 6.70-
6.80 (bs, NH); 13C NMR (CDCl3, 75 MHz) δC 11.9 (CH3), 12.4 (CH3), 14.3 (CH3), 16.0 
(CH3), 22.7 (CH2), 38.3 (CH), 59.3 (CH2), 68.5 (CH2), 103.7 (C), 164.7 (C), 167.5 (C). 
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LC-ESI-MS: rt 9.7 min m/z 214 (M+1). Anal. Calcd. For C11H19NO3: C, 61.95; H, 8.98; 
N, 6.57. Found: C, 61.98; H, 8.95; N, 6.58. 
 
9d : Colorless oil; 1H NMR (CDCl3, 600 MHz) δ 1.10-1.39 (m, 5H, cyclohexyl), 1.30 (t, 
J= 7.0 Hz, 3H, OCH2CH3), 1.45-1.80 (m, 6H, cyclohexyl), 2.22 (s, 3H, OCCH3), 4.21 
(q, J= 7.0 Hz, 2H, OCH2CH3), 5.05 (bs, 1H, NCH), 6.60-6.80 (bs, 1H, NH); 13C NMR 
(CDCl3, 75 MHz) δC 11.6 (CH3), 14.2 (CH3), 26.1 (2CH2), 26.3 (2CH2), 26.5 (CH2), 
41.0 (CH), 59.6 (CH2), 68.2 (CH2), 102.6 (C), 164.7 (C), 167.1 (C). LC-ESI-MS: rt 9.8  
min m/z 240 (M+1). Anal. Calcd. For C13H21NO3: C, 65.25; H, 8.84; N, 5.85. Found: C, 
65.23; H, 8.87; N, 5.82. 
 
9e : Pale yellow oil; 1H NMR (CDCl3, 300 MHz) δ 1.12 (t, J= 7.0 Hz, 3H, OCH2CH3), 
2.34 (s, 3H, OCCH3), 4.07 (m, 2H, OCH2CH3), 5.46 (bs, 1H, NCH), 7.20-7.45 (m, 10H, 
Ph); 13C NMR (CDCl3, 300 MHz) δC LC-ESI-MS: rt 7.6 min m/z 234 (M+1). 
 
10a : Yellow oil; 1H NMR (CDCl3, 600 MHz) δ 0.85 (d, J= 7.0 Hz 3H, CH3CHCH3 ), 
0.96 (d, J= 7.0 Hz 3H, CH3CHCH3 ), 1.39 (t, J=7.2 Hz, 3H, OCH2CH3 ), 2.64 (s, 3H, 
OCCH3), 3.44 (m, 1H, CH3CHCH3), 4.30 (m, 2H, OCH2CH3); 13C NMR (CDCl3, 75 
MHz) δC 14.2 (CH3), 17.6 (CH3), 18.2 (CH3), 20.9 (CH3), 26.8 (CH), 60.5 (CH2), 107.7 
(C), 162.0(C), 168.1 (C), 173.3 (C). LC-ESI-MS: rt 3.2 min m/z 198 (M+1), 417 
(2M+Na). Anal. Calcd. For C10H15NO3: C, 60.90; H, 7.67; N, 7.10. Found: C, 60.92; H, 
7.69; N, 7.06. 
 
10b: Pale yellow oil;  1H NMR (CDCl3, 300 MHz) δ 0.96 (d, J= 6.6 Hz, 6H, 
CH3CHCH3), 1.18-1.40 (m, 2H, CHCH2+ CH3CHCH3), 1.37 (t, J= 7.0 Hz, 3H, 
OCH2CH3), 2.05 (m, 1H, CHCH2), 2.65 (s, 3H, OCCH3), 4.30 (m, 2H, OCH2CH3); 13C 
NMR (CDCl3, 75 MHz) δC 13.4 (CH3), 14.2 (CH3), 22.9 (2CH3), 27.3 (CH), 34.5 
(CH2), 60.5 (CH2), 108.4 (C), 162.4(C), 162.5 (C), 175.2(C). LC-ESI-MS: rt 10.6 min 
m/z 212 (M+1), 445 (2M+Na). Anal. Calcd. For C11H17NO3: C, 62.54; H, 8.11; N, 6.63. 
Found: C, 62.58; H, 8.09; N, 6.67. 
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10c: Clear colorless oil; 1H NMR (CDCl3, 300 MHz) δ 0.93 (t, 3H, J= 7.5 Hz, 
CH3CHCH2CH3), 1.30 (d, J= 7.2 Hz, 3H,  CH3CHCH2CH3), 1.37  (t, J= 7.2 Hz, 3H, 
OCH2CH3), 1.57 (m, 1H, CH3CHCH2CH3), 1.83 (m, 1H, CH3CHCH2CH3), 2.65 (s, 3H, 
OCCH3), 3.27 (m, 1H, CH3CHCH2CH3), 4.32 (q, J= 7.2 Hz, 2H, OCH2CH3). 13C NMR 
(CDCl3, 75 MHz) δC 11.7 (CH3), 13.5 (CH3), 14.2 (CH3), 18.2 (CH), 28.1 (CH2), 33.0 
(CH3), 60.5 (CH2), 108.0 (C), 162.4 (C),167.3(C), 175.1 (C). LC-ESI-MS: rt 10.1 min 
m/z 212 (M+1). Anal. Calcd. For C11H17NO3: C, 62.54; H, 8.11; N, 6.63. Found: C, 
62.51; H, 8.11; N, 6.58. 
 
10d : Pale yellow oil; 1H NMR (CDCl3, 600 MHz) δ 1.22-2.05 (m, 10H, cyclohexyl), 
1.38 (t, J= 7.0 Hz, 3H, OCH2CH3), 2.64 (s, 3H, OCCH3), 3.12 (tt, J= 3.2, 11.4 Hz, 
CHC), 4.32 (q, J= 7.0 Hz, 2H, OCH2CH3); 13C NMR (CDCl3, 75 MHz) δC 13.3 (CH3), 
14.1 (CH3), 25.9 (CH2), 26.3 (2CH2), 31.2 (2CH2), 36.1 (CH), 60.4 (CH2), 107.6 (C), 
162.3 (C), 167.3 (C), 175.0 (C). LC-ESI-MS: rt 11.3  min m/z 238 (M+1). Anal. Calcd. 
For C13H19NO3: C, 65.80; H, 8.07; N, 5.90. Found: C, 65.83; H, 8.04; N, 5.96. 
 
10e: Yellow oil; 1H NMR (CDCl3, 300 MHz) δ  1.23  (t, J= 7.2 Hz, 3H, OCH2CH3), 
2.75 (s, 3H, OCCH3), 4.25 (q, J= 7.2 Hz, 2H, OCH2CH3), 7.46 (m, 3H, Ph), 7.63 (m, 
3H, Ph). 13C NMR (CDCl3, 75 MHz) δC 13.6 (CH3), 13.9 (CH3), 60.7 (CH2), 108.5 (C), 
127.9 (CH), 128.2 (CH), 128.6 (CH), 129.6 (CH), 162.0 (C), 162.6 (C), 175.8 (C). LC-
ESI-MS: rt 9.2 min m/z 232 (M+1). Anal. Calcd. For C13H13NO3: C, 67.52; H, 5.67; N, 
6.06. Found: C, 67.55; H, 6.11; N, 6.07. 
 
Preparation of 11a starting from 9a. 3,5-dinitrobenzoyl chloride (1.2 equiv., 0.6 mmol, 
138 mg) was added in one portion to a stirred solution of 9a (0.5 mmol, 110 mg) and 
TEA (1.2 equiv, 84 μl) in CH2Cl2 (5 mL) at 0°C. The reaction was sttired at r.t. for 2h 
and then quenched with water.  The residue was then diluted with CH2Cl2 (10 mL) and 
washed twice with water (2 x 10 mL). The organic layer was dried over Na2SO4 and 
solvent was removed under reduced pressure.  Compound  11a was purified by flash 
chromatography on silica gel (eluant cyclohexane/EtOAc, 98/2).  
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11a : Yellow solid; 1H NMR (CDCl3, 600 MHz) δ 0.96 (d, J= 7.0 Hz 3H, CH3CHCH3 ), 
1.08 (d, J= 7.0 Hz 3H, CH3CHCH3 ), 1.34 (t, J=7.2 Hz, 3H, OCH2CH3 ), 2.24 (s, 3H, 
OCCH3), 2.31 (m, 1H, CH3CHCH3), 4.24 (m, 2H, OCH2CH3), 5.64 (bs, 1H, CHN), 8.89 
(m, 1H, Ph), 9.10-9.17 (m, 2H, Ph) ; 13C NMR (CDCl3, 75 MHz) δC 11.5 (CH3), 14.2 
(CH3), 15.9 (CH3), 19.8 (CH3), 31.7 (CH), 56.9 (CH), 60.5 (CH2), 104.5 (C), 121.3 
(CH), 128.8 (2CH), 136.0 (C), 148.2 (2C), 162.6(C), 168.9 (C), 182.9 (C). LC-ESI-MS: 
rt 11.1 min m/z 394 (M+1). Anal. Calcd. For C17H19N3O8: C, 51.91; H, 4.87; N, 10.68. 
Found: C, 51.90; H, 4.89; N, 10.71. 
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III 
 
Synthesis of enantiopure 2-substituted-3,4-dehydropyrrole 
derivatives via ring closing metathesis 
 
3.1 Introduction 
The construction of cyclic structures  is, in organic chemistry, one of the most explored 
field since heterocyclic rings represent the most common scaffolds for the synthesis of 
biologically active molecules. In this contest, ring-closing metathesis (RCM) is finding 
an exponential number of applications for the synthesis of various heterocycles in the 
fields of natural products, medicinal chemistry or material science56. In general, olefin 
metathesis always attracted chemist’s attention because of its wide capability in organic 
synthesis. Double bonds are one of the most useful and versatile chemical functions 
because they are the base for various synthetic transformations. Indeed, lots of 
molecules having a commercial interest contain double bonds. Capability to obtain 
double bonds from other double bonds, allows the dramatic reduction of some synthetic 
pathways, especially when the scope is opening (Ring Opening Metathesis, ROM) or 
closing (Ring Closing Metathesis, RCM) wide-dimension rings. Ring Closing 
Metathesis has been particularly useful for the construction of nitrogen-containing 
compounds57. Not surprisingly, most applications have been reported for the synthesis 
of functionalized pyrrolidines and piperidines which constitute major classes of 
biologically active molecules58. These heterocycles are found in many alkaloid natural 
products, glycomimetics and drug candidates59. For these reasons in the past few years, 
RCM has become the most commonly employed metathesis in organic synthesis and 
has had an especially large impact on the pharmaceutical industry because the reaction 
allows for an efficient and direct formation of heterocycles from acyclic dienes60. 
Recently the availability of more reactive catalysts such as Grubbs-type II catalyst has 
opened the path to more demanding processes such as substituent bearing olefins, 
ruthenium catalyst have received considerable attention because of their tolerance to 
moisture, oxygen, and a large number of organic functional group61. 
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Following the synthetic pathway already reported in chapter 1, we first synthesized  
dehydro-β-amino esters starting from allylic carbonates and than we envisaged N-allyl-
dehydro-β-amino esters as suitable intermediates for the preparation of enantiopure 
substituted α-alkyl-dehydro-β-prolines via ring closing methatesis (RCM). These 
enantiopure structures may be applied as rigid scaffolds for the preparation of bioactive 
peptidomimetics. Synthesis of pyrrole derivatives starting from aza-Baylis-Hillman 
products has been already reported by Lamaty’s group on a variety of racemic aromatic-
substituted substrates62, but to our knowledge no examples of enantiopure derivatives 
bearing aliphatic chains have been reported. 
 
3.2 Synthesis of  dehydro-β-amino esters via Ir-catalyzed allylic 
amination 
In the past we have explored SN2’ reaction to synthesized different classes of  dehydro-
β-amino esters63. The reaction could be performed without catalyst or in presence of Pd-
complexes and changing the type of solvent it is possible to have different 
regioselectivity. On the basis of our previously work64, we prepared racemic and 
enantiopure carbonates 1a-b that were submitted to allylic amination using allylamine 
as nucleophile in absence of catalyst or under Pd-catalyzed conditions (Scheme 3. 1). 
H2N
R
CO2tBu
HN
R
CO2tBu
OCO2Me
a :R = -CH(CH3)2
b: R = cyclohexil
R
CO2tBu
HN
1a-b 2a-b 3a-b
 
Scheme 3. 1 
 
Moreover, the different kind of nucleophile involved, led us to explore other catalysts in 
order to optimize the reaction. In particular, we found that the combination of an iridium 
precursor and a phosphite or phosphoramidite ligand has been described as excellent 
catalyst for allylic substitution with a number of different nucleophiles65. Iridium 
complexes have been also successfully applied in the stereoselective formation of C-N 
bonds via allylic amination66, mostly on monosubstituted alkenyl carbonates67. Up to 
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our knowledge, iridium catalysis has been never applied to allylic carbonates having 
alkyl substituents on both terminals and a carboxylic group in the central position, as in 
compound 1. The regioselectivity and the stereoselectivity of the substitution strongly 
depends on the solvent of choice and on the phosphorous ligand, that influence the Ir-
allyl intermediate stability and rate of equilibration.  Ethanol has been reported68 to 
favor the formation of the product deriving from SN2’ mechanism and, on these bases, 
this solvent was used to verify the efficacy of  [Ir(COD)Cl]2-P(OPh)3 as catalyst for 
allylic amination. 
 
Table 12 
Entry Carbonate Solvent 
Allylamine
(equiv) 
Catalyst 
Time 
(h) 
Yielda(%) 2:3b 
1 rac-1a CH3CN 9 / 72 86 >99.1
2 (S)-1ac CH3CN 9 / 72 85 >99.1
3 (R)-1a CH3CN 9 / 72 85 >99.1
4 (S)-1b CH3CN 9 / 72 65 >99.1
5 (R)-1b CH3CN 9 / 72 68 >99.1
6 rac-1a THF 15 Pd2(dba)3CHCl3 72 35 >99.1
7 rac-1a EtOH 3 
[Ir(COD)Cl]2 
(2%) 
P(OPh)3 (8%) 
10 >99 >99.1
8 rac-1a EtOH 3 / 16 52 >99.1
9 rac-1a EtOH 3 
[Ir(COD)Cl]2 
(2%) 
16 60 >99.1
aYields were calculated after purification of the products by flash chromatography on silica gel. The 
unreacted carbonate 1 was completely recovered after work-up.   bCompound 2 was always obtained as 
4/1mixture of Z/E isomers. c Enantiomeric excess of substrates and products was determined by HPLC on 
chiral column. 
 
The reaction was first performed without any catalyst in refluxing acetonitrile (Table 
12, entries 1-5). Under these conditions good yields were achieved only after three days, 
using a large excess of the amine (9 equivalents). The regioisomer 2, deriving from SN2’ 
mechanism, was exclusively obtained, as 4/1 Z/E isomers mixture,  and no traces of the 
product 3 could be detected. As already observed for allylic substitution with different 
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amines, the enantiomeric excess of the starting carbonate was completely retained and 
enantiopure 2a-b was obtained starting from the corresponding chiral carbonates 
(entries 2-5). On the basis of our previous experience, the reaction was then performed 
in the presence of 3% amount of Pd2(dba)3CHCl3 in THF. The reaction on rac-1a 
afforded rac-2a  in modest yield, even in the presence of 15 equivalents of allylamine 
(entry 6). Iridium-complexes induced substitution was then performed on carbonate 1a 
(entry 7). Under these conditions, the regioselective conversion of the starting carbonate 
into amine 2a was observed in 10h. To verify whether the shorter reaction time and the 
enhanced yield had to be ascribed only to the change in solvent or also to the formation 
of the  iridium-phosphite complex, the reaction was repeated in refluxing EtOH without 
any catalyst (entry 8) and in the presence of [Ir(COD)Cl]2, without additional phosphine 
ligand (entry 9). In both cases, a lower yield was observed even after several hours, thus 
confirming the catalytic activity of the complex. The reaction was repeated on 
enantiopure (S)-1a. The “memory effect” of allylic substitution leading to conservation 
of the enantiomeric purity depends on the rate of isomerization of Ir-allyl intermediates 
and the selection of the proper phosphorous ligand may influence the e.e. erosion69. 
Therefore, the reaction was repeated in the presence of different catalysts and the 
enantiospecificity (e.s = eeproduct / eesubstrate) was determined (Table 13). The selected 
phosphoramidite ligands are reported in Figure 3. 1. 
 
Figure 3. 1 
 
As expected, all of the reactions were completely regioselective, affording exclusively 
amine 2a. The enantiomeric excess of the product was determined by HPLC on chiral 
column and the enantiospecificity was calculated. The result obtained without 
phosphorous ligand (entry 1) was quite similar to those obtained with 
triphenylphosphite or  phosphoramidite L2 (entries 2 and 4). The best result was 
observed for the reaction performed with ligand L1, that allowed to enhance  the 
enantiospecificity up to 91%.  
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Table 13 
Entrya Carbonate Ligand e.s. 
1 (S)-1a / 72 
2 (S)-1a P(OPh)3 74 
3 (S)-1a L1 91 
4 (S)-1a L2 74 
aCompound 2 was always obtained as 4/1mixture of E/Z isomers. b Enantiomeric excess of substrates and 
products was determined by HPLC on chiral column. 
 
3.2.1 Protection of the aminic Nitrogen 
Since one of the main problem with the RCM of amines is the possibility that the 
aminic nitrogen poisons the ruthenium catalyst by its coordination with the nitrogen 
electron pair to the metal-alkylidene complex, we have protected 2a as carbamate or 
amide. We decided to use three different type of N-protection in order to investigate the 
reactivity of these compounds and the large use that the RCM product could have. With 
the aim of synthesizing dihydro-pyrrole derivatives bearing more easily cleavable 
protecting groups, we decided to use Cbz- and BOC- as protecting group. Moreover we 
also synthesized the  N-malonamide derivative 6a, with the purpose to use it as a useful 
intermediate for the preparation of bioactive integrin ligands. Optimized reaction 
conditions for each protecting group are showed below. (Scheme 3. 2). 
 
Scheme 3. 2 
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The N-BOC protected derivative 4a was obtained in quantitative yield by treatment of 
2a with BOC2O in ethanol at r.t. for 3h. Introduction of benzyloxycarbonyl group was 
accomplished by addition of the corresponding chloride to a solution of 2a and 
potassium carbonate in water/dioxane (1/1 ratio) at r.t. overnight, to afford 5a in 80% 
yield. Finally, N-malonamide derivative 6a was obtained in 90% yield, by treatment of 
2a with methylmalonyl chloride  and triethylamine in dichlorometane at r.t. for 3h. 
 
3.3 Ring closing methatesis 
Before proceeding with ring closing methatesis reactions, we have screened different 
types of catalysts in order to determine which is the best for our transformations. A 
strong effect on catalyst efficacy is linked to substrate’s steric hinderance and to the 
electronic nature of the olefins. When steric bulk and electron withdrawing character of 
the olefin substituents are combined in the same substrate, the rate of RCM is strongly 
reduced and the metal-complex may decompose before reacting70. On these bases, we 
tested, for the transformation of 4a, 5a and 6a, four different catalysts (A-D). The 
reaction was performed in the presence of 3% of the catalyst in refluxing methyl tert-
butyl ether (MTBE), since that in a recent Kuhn’s work (71) is shown that MTBE is the 
ideal solvent for the synthesis of 2,5-dihydropyrroles via metathesis reaction. Selected 
results are reported in Table 14. 
R-N
CO2tBu∗
CO2tBu
R-N Grubbs catalyst
          A-D
MTBE, Δ
4a: R =BOC
5a: R =Cbz
6a: R =malonyl
7a: R =BOC
8a: R =Cbz
9a: R =malonyl  
Scheme 3. 3 
 
Figure 3. 2 
 
 
Grubbs-Hoveyda  
2° generation 
Grubbs catalyst 
 2° generation 
Grubbs catalyst 
 1° generation 
A B C D 
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Table 14 
Entrya 
Starting 
material 
Catalyst t (h) Yieldb (%) 
1 4a A 16 / 
2 4ac B 2 >98 
3 5a A 16 / 
4 5a B 1.5 >98 
5 5a C 1 >98 
6 5a D 1 >98 
7 6ac B 16 54 
8 6a C 12 >98 
9 6a D 12 >98 
a All experiments were  performed on E/Z mixtures of starting allylamino derivatives, in the presence of 
3% of the catalyst in refluxing methyl tert-butyl ether (MTBE). bYields were calculated after purification 
of the products by flash chromatography on silica gel.c The reaction was performed on racemic and 
enantiopure substrate. 
 
First generation Grubbs’ catalyst A did not catalyze the ring closing metathesis on both 
carbamate compounds 4a and 5a (entries 1 and 3) allowing to recover the unreacted 
starting material without any trace of the  heterocyclic compound, even after long 
reaction times. On the basis of these results, catalyst A was not tested on the less 
reactive amide 6a. In contrast, when the reaction was performed in the presence of 3% 
amount of the more reactive second generation Grubbs’ catalyst B, both carbamates 4a 
and 5a were converted into the corresponding dihydropyrroles 7a and 8a respectively, 
in quantitative yields (entries 2 and 4). The presence of Z/E mixtures of isomers did not 
represent a limitation, since both compounds showed the same reactivity. The reaction 
was monitored by TLC and complete disappearance of the starting material could be 
observed after only 2h for 4a and 1.5h for 5a. In order to complete the screening of 
catalysts, we performed the RCM on compound 5a using Hoveyda-Grubbs second 
generation catalyst C and its analogue D, bearing 2-methylphenyl substituents on the 
NHC ligand in place of the 2,4,6-trimethylphenyl groups. Under these conditions, the 
reaction occurred slightly faster, since in both cases compound 8a could be obtained in 
quantitative yield after 1h (entries 5-6). Comparison of the results obtained on the 
carbamate derivatives 4a and 5a with different catalysts, showed that no great 
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advantages could be observed in the use of expensive complexes C and D, since the 
cheaper catalyst B induced the complete conversion into the desired products quite 
rapidly.  The RCM was then performed on malonamide 6a, using the more efficient 
catalysts B,C and D. By using Grubbs’s II catalyst B,  the heterocyclic product could be 
obtained after 16h only in 54% yield. Enhanced reactivity could be observed in the 
presence of catalysts C and D, that quantitatively converted 6a into the corresponding 
dihydropyrrole 9a in 12h. Enantiopure 7a and 9a were obtained with the same yield 
through RCM of the corresponding optically active starting materials.  
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3.3.1 Conformational products’ study  
It is well known that the amide bond preceeding the proline nitrogen may adopt either 
the cis or trans conformation72. While for all the other proteinogenic amino acids the 
trans conformation is by far energetically more favorable than the cis, for proline the 
difference is much smaller. For this reason the less stable cis conformer is always 
present in peptide samples, in a percentage depending on the adjacent residues and on 
the polarity of the solvent73. Two distinct sets of resonances are commonly detected in 
the NMR spectrum of these compounds, as a consequence of the slow rate of 
interconversion74. This effect is enhanced for β−proline oligomers, whose cis and trans 
conformers are well populated at room temperature75. Similar considerations have been 
reported also for dehydroproline76. 
 
Figure 3. 3 
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As expected, the products of the RCM were all isolated as mixtures of  two conformers. 
The 1H NMR spectrum in CDCl3 of N-BOC protected 7a  and N-CBz derivative 8a 
showed the presence of the two forms as 1:1 mixtures. For compound 9a, where 
dehydro-β-proline ring is linked to malonamide, the ratio between the conformers was 
70:30. In order to define the conformation of amide bond, the two distinct sets of 
resonances were attributed by means of COSY  analysis. Then, spatial arrangement of 
the malonic chain for the two conformers was explored through ROESY experiments 
(Figure 3. 3). The presence of the cross peak between malonic chain CH2 and the δ-CH2 
protons for the major conformer allowed to attribute the trans conformation to the 
amide bond. On the contrary, the cross peak between  malonic chain CH2 and the α-CH 
proton confirmed the cis conformation of the minor isomer.  
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3.4 Experimental section 
General: All chemicals were purchased from commercial suppliers and used without 
further purification. Anhydrous solvents were purchased in sure seal bottles over 
molecular sieves and used without further drying. Flash chromatography was performed 
on silica gel (230-400 mesh). NMR Spectra were recorded with Varian Gemini 200, 
Mercury Plus 400 or Unity Inova 600 MHz spectrometers. Chemical shifts were 
reported as δ values (ppm) relative to the solvent peak of CDCl3 set at δ = 7.27 (1H 
NMR) or δ = 77.0 (13C NMR), CD3OD set at δ = 3.31 (1H NMR) or δ = 49.0 (13C 
NMR), D2O set at δ = 4.79 (1H NMR). Coupling constants are given in Hz. The 
enantiomeric excesses of products  were determined by HPLC analyses performed on 
an HP1100 instrument with UV-VIS detector and equipped with Chiralpak IC column 
(25 X 0.46 cm), eluted with n-hexane/2-propanol (tipical program: from 96/4 to 90/10 
in 30 min, flux 0.6 mL/min).  Optical rotations were measured in a Perkin Elmer 343 
polarimeter using a 1 dm cuvette and are referenced to the Na-D line value. Melting 
points were determined on a Stuart Scientific SMP3 apparatus and are uncorrected. LC-
MS analyses was performed on a HP1100 liquid chromatograph coupled with an 
electrospray ionization-mass spectrometer (LC-ESI-MS), using H2O/CH3CN as solvent 
at 25 °C (positive scan 100-500 m/z, fragmentor 70V). 
 
General procedure for allylic amination without catalyst: To a stirred solution of  1 (1 
mmol) in CH3CN (5 mL) under nitrogen atmosphere, allylamine (9 mmol, 9 equiv) was 
added in one portion and the mixture was wormed to reflux. After 3 days,  the solvent  
and the excess of allylamine were removed under reduced pressure and the residue was 
diluted with ethyl acetate (10 mL). The organic solution was extracted three times with 
0.1M  HCl (10 mL), then it was dried over Na2SO4, and solvent was removed under 
reduced pressure to recover unreacted 1. 1M NaOH was added dropwise to the acid 
acqueous layer  until  basic pH was achieved and then the solution was extracted three 
times with CH2Cl2 (10 mL). The organic layers were dried over Na2SO4 and solvent was 
removed under reduced pressure to afford allylamino-derivative 2 as a yellow oil (65-
86%, see Table 1), that was  used in the following step without further purification.  
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General procedure for allylic amination in the presence of Iridium catalyst.  To a stirred 
solution of [Ir(COD)(Cl)]2 (0.02 mmol)  and phosphorous ligand (0.08 mmol) in EtOH 
(5 mL) under nitrogen atmosphere, carbonate 1 (1 mmol) and allylamine (3 mmol, 3 
equiv.)  were added in one portion at r.t..  The solution was stirred under refluxing 
conditions and monitored by TLC. After removal of the solvent and the excess of 
allylamine under reduced pressure,  the residue was diluted with ethyl acetate (10 mL). 
The organic solution was extracted three times with 0.1M HCl (10 mL) , then was dried 
over Na2SO4 and solvent was removed under reduced pressure to recover unreacted 
starting carbonate. 1M NaOH  was added dropwise to the acid acqueous layer  until  
basic pH was achieved and then the solution was extracted three times with CH2Cl2 (10 
mL). The organic layers were dried over Na2SO4 and solvent was removed under 
reduced pressure to afford allylamino-derivative 2 in quantitative yield as a yellow oil 
that was  used in the following step without further purification. 
 
Tert-butyl 3-(allylamino)-2-ethylidene-4-methylpentanoate 2a: Yellow oil, (80:20 Z/E 
mixture); 1H NMR (200 MHz, CDCl3) δ Z isomer: 0.68 (d, J=6.6 Hz, 3H), 1.02 (d, 
J=6.6 Hz, 3H), 1.41 (s, 9H), 1.69 (d, J=7.4 Hz, 3H), 1.97 (m, 1H), 2.91 (dd, J=14.0, 6.2 
Hz, 1H), 3.05 (d, J=9.2 Hz, 1H), 3.16 (dd, J=14.0, 5.4 Hz, 1H), 5.03-5.18 (m, 2H), 5.84-
5.93 (m, 1H), 6.91 (q, J=7.2 Hz, 1H); E isomer: 0.77 (d, J=6.6 Hz, 3H), 0.89 (d, J=6.6 
Hz, 3H), 1.40 (s, 9H), 1.84 (d, J=7.0 Hz, 3H), 1.97 (m, 1H), 2.72 (d, J=8.2 Hz, 1H), 
2.91 (dd, J=14.0, 6.2 Hz, 1H), 3.16 (dd, J=14.0, 5.4 Hz, 1H), 5.03-5.18 (m, 2H), 5.68 
(q, J=7.0 Hz, 1H); 5.84-5.93 (m, 1H); 13C NMR (75 MHz, CDCl3) δ  Z isomer 13.9, 
20.0, 21.0, 28.1, 32.0, 49.7, 61.4, 80.4, 115.0, 133.3, 134.3, 138.4, 166.7. E isomer 14.8, 
20.0, 21.0, 28.0, 32.1, 49.8, 61.4, 80.0, 115.0, 133.3, 134.8, 137.8, 167.8. LC-MS-ESI rt 
14.97 min, 254 (M+1). (S)-2a [α]D = +19.5 (c 1 in CHCl3); (R)-2a [α]D = -20.6 (c 1 in 
CHCl3). 
 
Tert-butyl 2-((allylamino)(cyclohexyl)methyl)but-2-enoate 2b: Yellow oil, (80:20 Z/E 
mixture); 1H NMR (400 MHz, CDCl3) δ Z isomer: 0.78 (m, 1H), 0.92 (m, 1H), 1.11-
1.25 (m, 4H), 1.42 (s, 9H), 1.49 (m, 4H), 1.76 (d, J=6.8 Hz, 3H), 2.28 (m, 1H), 2.96 (dd, 
J=17.6, 6.6 Hz, 1H), 3.20 (d, J=9.2 Hz, 1H), 3.22 (dd, J=17.6, 5.6 Hz, 1H), 5.04 (dd, 
J=1.4, 10.0 Hz, 1H), 5.13 (dd, J=1.4, 17.2 Hz, 1H), 5.84-5.92 (m, 1H), 6.89 (q, J=7.2 
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Hz, 1H); E isomer: 0.78 (m, 1H), 0.92 (m, 1H), 1.11-1.25 (m, 4H), 1.42 (s, 9H), 1.49 
(m, 4H), 1.90 (d, J=6.8 Hz, 3H), 2.28 (m, 1H), 2.82 (d, J=8.6 Hz, 1H), 2.96 (dd, J=17.6, 
6.6 Hz, 1H), 3.20 (d, J=9.2 Hz, 1H), 3.22 (dd, J=17.6, 5.6 Hz, 1H), 5.04 (dd, J=1.4, 
10.0 Hz, 1H), 5.13 (dd, J=1.4, 17.2 Hz, 1H), 5.78(q, J=7.2 Hz, 1H); 5.84-5.92 (m, 1H); 
13C NMR (75 MHz, CDCl3) δ  Z isomer 14.0, 26.3, 26.7, 28.2, 30.7, 31.7, 41.6, 60.1, 
80.2, 115.2, 134.0, 137.9, 138.6, 166.9. E isomer 15.0, 26.4, 26.7, 28.2, 30.6, 31.7, 41.8, 
68.1, 80.6, 115.2, 133.6, 137.8, 138.6, 166.9. LC-MS-ESI rt 16.21 min, 294 (M+1). (S)-
2a [α]D = +14.3 (c 1 in CHCl3); (R)-2a [α]D = -16.6 (c 1 in CHCl3). 
 
Synthesis of  N-BOC derivative 4a: Boc2O (1mmol, 1 eq.) was added to a solution of 2a 
in EtOH (5 mL) at room temperature and the reaction mixture was left stirring for 3 h. 
Then, the solvent was removed under reduced pressure and the residue was diluted with 
EtOAc (10 mL). After washing three times with water (5mL), the organic layer was  
dried over Na2SO4 and solvent was removed under reduced pressure. Compound 4a was 
purified by flash chromatography on silica gel (cyclohexane/ethyl acetate 70:30 as 
eluant).  
 
Tert-butyl 3-( N-(tert-butoxycarbonyl)allylamino)-2-ethylidene-4-methylpentanoate 4a: 
Yellow oil, (80:20 Z/E mixture); 1H NMR (400 MHz, CDCl3) δ Z isomer: 0.79 (d, J=6.4 
Hz, 3H), 0.90 (d, J=6.4 Hz, 3H), 1.48 (s, 9H), 1.53 (s, 9H), 1.92 (d, J=7.4 Hz, 3H), 2.62 
(m, 1H), 3.82-4.01 (m, 2H), 4.81(d, J= 11.2 Hz, 1H), 4.94-5.04 (m, 2H), 5.68-5.79 (m, 
1H), 6.83 (q, J=7.2 Hz, 1H); E isomer: 0.92( d, J=6.8 Hz, 6H), 1.48 (s, 9H), 1.53 (s, 
9H), 1.92 (d, J=7.4 Hz, 3H), 2.62 (m, 1H), 3.82-4.01 (m, 2H), 4.62(d, J= 10.8 Hz, 1H), 
4.94-5.04 (m, 2H), 5.48 (q, J=7.2 Hz, 1H), 5.68-5.79 (m, 1H); 13C NMR (75 MHz, 
CDCl3) δ  Z isomer 14.2, 19.7, 27.7, 27.9, 28.1, 45.6, 58.4, 78.8, 79.9, 114.4, 133.9, 
136.1, 142.4, 155.8, 166.7. E isomer 14.2, 20.1, 27.7, 27.9, 29.4, 45.3, 59.6, 78.8, 79.4, 
114.4, 133.9, 135.5, 141.6, 155.4, 166.7. LC-MS-ESI rt  16.6 min (Z isomer), 14.9 min 
(E isomer), 354 (M+1), 729 (2M+23).  
 
Synthesis of  N-CBz derivative 5a: Benzyloxycarbonyl chloride (1.5 mmol, 1.5 equiv.) 
and K2CO3 (2 mmol, 2 equiv) were added to a solution of  2a (1 mmol) in 
dioxane/water (1:1 solution, 5 mL).  The reaction mixture was stirred at r.t. overnight. 
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The solution was diluted ethyl acetate (10 mL) and washed three times with water (10 
mL). The organic layer was  dried over Na2SO4 and solvent was removed under reduced 
pressure. Compound 5a was purified by flash chromatography on silica gel (eluant 
cyclohexane /EtOAc 97:3).  
 
Tert-butyl 3-( N-(benzyloxycarbonyl)allylamino)-2-ethylidene-4-methylpentanoate 5a: 
Yellow oil, (80:20 Z/E mixture); 1H NMR (400 MHz, CDCl3) δ Z isomer: 0.79 (d, J=6.8 
Hz, 3H), 0.92 (d, J=6.8 Hz, 3H), 1.46 (s, 9H), 1.90 (d, J=7.2 Hz, 3H), 2.68 (m, 1H), 
3.94-4.06 (m, 2H), 4.83 (d, J= 9.8 Hz, 1H), 4.90-5.18 (m, 4H), 5.63-5.72 (m, 1H), 6.85 
(q, J=7.2 Hz, 1H) 7.20-7.40 (m, 5H); E isomer: 0.91 (d, J=6.8 Hz, 6H), 1.44 (s, 9H), 
1.90 (d, J=7.2 Hz, 3H), 2.68 (m, 1H), 3.94-4.06 (m, 2H), 4.62 (d, J= 9.2 Hz, 1H), 4.90-
5.18 (m, 4H), 5.63-5.72 (m, 1H), 6.01 (q, J=7.2 Hz, 1H), 7.20-7.40 (m, 5H); 13C NMR 
(75 MHz, CDCl3) δ  Z isomer 14.5, 19.8, 20.0, 27.8, 28.0, 45.7, 59.7, 67.0, 80.3, 115.0, 
127.6, 128.2, 128.5, 133.6, 135.8, 137.0, 143.0, 156.8, 166.8. E isomer 14.1, 19.9, 20.3, 
27.8, 29.7, 46.2, 59.9, 67.3, 80.4, 115.3, 127.6, 128.2, 128.5, 133.5, 135.2, 136.6, 142.0, 
156.0, 166.8.  LC-MS-ESI rt 14.7 min (Z isomer), 13.5 min (E isomer), 388 (M+1), 410 
(M+23). 
 
Synthesis of  N-malonamido derivative 6a: To a stirred solution of 2a (1 mmol) in dry 
CH2Cl2(5 mL),  methyl malonyl chloride (1.5 mmol, 1.5 equiv.) and triethylamine (1.5 
mmol, 1.5 equiv.) were added at room temperature. After stirring for 3h , the reaction 
mixture diluted with CH2Cl2(10 mL) and washed twice with water (10 mL). The 
organic layer was  dried over Na2SO4 and solvent was removed under reduced pressure. 
Purification of the crude residue  by flash chromatography on silica gel, (eluant 
cyclohexane/EtOAc 9:1) afforded compound 6a. The desired product was obtained in 
yields up to 95% as an yellow oil. 
 
Tert-butyl 3-(N-allyl-3-methoxy-3-oxopropanamido)-2-ethylidene-4-methylpentanoate 
6a: Yellow oil, (80:20 Z/E mixture); 1H NMR (400 MHz, CDCl3) δ Z isomer: 0.81(d, 
J=6.6 Hz, 3H), 0.92 (d, J=6.6 Hz, 3H), 1.45 (s, 9H),  1.95 (d, J=7.4 Hz, 3H), 2.67 (m, 
1H), 3.38 (d, J=15.4 Hz, 1H), 3.53 (d, J=15.4 Hz, 1H), 3.74 (s, 3H), 3.94 (dd, J=18.2, 
5.2 Hz, 1H), 4.44 (dd, J=18.2, 2.4 Hz, 1H), 5.04 (d, J= 17.2 Hz, 1H), 5.13 (d, J=10.4 
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Hz, 1H), 5.33 (d, J=11.6 Hz, 1H), 5.65-5.74 (m, 1H), 6.91 (q, J=7.2 Hz, 1H); E isomer: 
0.94 (d, J=6.6 Hz, 3H), 0.96 (d, J=6.6 Hz, 3H), 1.43 (s, 9H),  1.92 (d, J=7.4 Hz, 3H), 
2.67 (m, 1H), 3.44 (d, J=15.4 Hz, 1H), 3.54 (d, J=15.4 Hz, 1H), 3.76 (s, 3H), 4.02 (dd, 
J=18.2, 5.0 Hz, 1H), 4.23 (dd, J=18.2, 2.0 Hz, 1H), 5.04 (d, J= 17.2 Hz, 1H), 5.13 (d, 
J=10.4 Hz, 1H), 5.15 (d, J=10.0 Hz, 1H), 5.65-5.74 (m, 1H), 6.18 (q, J=7.2 Hz, 1H); 13C 
NMR (CDCl3, 75 MHz) δ Z isomer; 14.6, 19.7, 27.8, 28.0, 41.2, 46.8, 52.1, 57.0, 80.4, 
115.7, 132.9, 135.0, 143.9, 166.6, 167.0, 168.4. E isomer:  14.3, 19.8, 27.8, 29.2, 41.0, 
46.9, 52.1, 57.3, 80.2, 115.0, 133.1, 135.0, 142.7, 166.6, 167.1, 168.4. LC-MS-ESI rt 
10.7 min (Z isomer), 10.1 min (E isomer), 376 (M+23), 729 (2M+23). Chiral HPLC 
analysis (for conditions see general section), rt 32.12 min for (S) and 36.33 min for (R); 
(S)-6a [α]D = -30.8 (c 1 in CHCl3); (R)-6a [α]D = +26.7 (c 1 in CHCl3). 
 
General procedure for the ring closing metathesis (RCM) with ruthenium catalyst : 
Catalyst A-D (0.03 mmol) was added to a solution of 4a, 5a or 6a (1 mmol) in MTBE 
and the  reaction mixture was stirred at reflux for 3 h. Then the reaction cooled to room 
temperature and was quenched by addition of  ethyl vinyl ether (0.1 mL).  The solvent 
was removed under reduced pressure and the crude residue was purified through by 
chromatography on silica gel (cyclohexane/EtOAc 95:5). 
 
Tert-butyl N-(tert-butoxycarbonyl)2-isopropyl-2,5-dihydro-1H-pyrrole-3-carboxylate 
7a: Yellow oil, (1:1 trans/cis conformers mixture); 1H NMR (400 MHz, CDCl3) δ 
Trans conformer: 0.82(d, J=6.6 Hz, 3H), 0.94 (d, J=6.6 Hz, 3H), 1.46 (s, 18H), 2.21 (m, 
1H), 3.98 (bd, J=18.6 Hz, 1H), 4.31 (bd, J=18.6 Hz, 1H), 4.91 (bm, 1H), 6.76 (bm, 1H); 
Cis conformer: 0.84 (d, J=7.0 Hz, 3H), 0.86 (d, J=7.0 Hz, 3H), 1.43 (s, 9H), 2.21 (m, 
1H), 4.08 (bd, J=18.0 Hz, 1H), 4.42 (bd, J=18.0 Hz, 1H), 4.78 (bm, 1H), 6.63 (bm, 1H); 
13C NMR (CDCl3, 100 MHz) δ Trans conformer: 17.0, 19.1, 25.0, 27.4, 31.7, 53.5, 
65.3, 78.6, 80.2, 135.3, 136.0, 153.7, 161.9. Cis conformer: 16.6, 19.2, 27.2, 27.9, 32.1, 
53.5, 67.2, 79.1, 82.4, 135.7, 136.1, 154.0, 161.1. LC-MS-ESI rt 12.6 min,  334 (M+23). 
 
Tert-butyl N-(benzyloxycarbonyl)2-isopropyl-2,5-dihydro-1H-pyrrole-3-carboxylate 8a: 
Yellow oil, (1.1 trans/cis conformers mixture); 1H NMR (400 MHz, CDCl3) δ Trans 
conformer: 0.83(d, J=7.2 Hz, 3H), 0.96 (d, J=7.2 Hz, 3H), 1.49 (s, 9H), 2.53 (m, 1H), 
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4.10 (bd, J=18.0 Hz, 1H), 4.39 (bd, J=18.0 Hz, 1H), 4.91 (bm, 1H), 6.64 (bm, 1H), 
7.28-7.41 (m, 5H); Cis conformer: 0.88 (d, J=6.6 Hz, 3H), 0.89 (d, J=6.6 Hz, 3H), 1.43 
(s, 9H), 2.21 (m, 1H), 4.10 (bd, J=18.0 Hz, 1H), 4.48 (bd, J=18.0 Hz, 1H), 4.84 (bm, 
1H), 6.71 (bm, 1H), 7.28-7.41 (m, 5H); 13C NMR (CDCl3, 100 MHz) δ Trans 
conformer: 17.6, 19.0, 28.0, 32.3, 54.6, 66.8, 67.9, 81.2, 127.9, 128.0, 128.1, 128.5, 
135.7, 136.8, 154.9, 162.6. Cis conformer: 17.4, 19.2, 29.6, 32.7, 54.0, 67.1, 68.5, 81.2, 
127.9, 128.0, 128.1, 128.5, 136.1, 136.6, 155.3, 162.6. LC-MS-ESI rt 12.2 min, 368 
(M+23). 
 
Tert-butyl N-(methylmalonyl)2-isopropyl-2,5-dihydro-1H-pyrrole-3-carboxylate 9a 
Yellow oil, (70:30 trans/cis conformers mixture); 1H NMR (400 MHz, CDCl3) δ  Trans 
conformer:  0.91(d, J=7.0 Hz, 3H), 0.92 (d, J=7.0 Hz, 3H), 1.50 (s, 9H), 2.41 (m, 1H), 
3.41 (s, 2H), 3.75 (s, 3H), 4.27 (ddd, J=16.6, 2.0, 4.4 Hz, 1H), 4.35 (dd, J=16.6, 2.4 Hz, 
1H), 5.12 (bt, J=3.2 Hz, 1H), 6.64 (bm, 1H); Cis conformer: 0.92 (d, J=6.6 Hz, 3H), 
0.96 (d, J=6.6 Hz, 3H), 1.51 (s, 9H), 1.96 (m, 1H), 3.45 (d, J=15.0 Hz, 1H), 3.51 (d, 
J=15.0 Hz, 1H), 3.76 (s, 3H), 4.08 (ddd, J=18.8, 1.6, 3.0 Hz, 1H), 4.35 (dd, J=18.8, 2.8 
Hz, 1H), 4.77 (bt, J=3.2 Hz, 1H), 6.76 (bm, 1H); 13C NMR (CDCl3, 100 MHz) δ Trans 
conformer:18.3, 18.4, 28.0, 31.8, 42.2, 52.5, 54.6, 68.0, 81.6, 134.1, 136.7, 162.5, 
164.3, 167.7. Cis conformer:17.5, 18.7, 28.0, 34.5, 40.8, 52.5, 53.8, 68.4, 81.5, 134.9, 
137.3, 162.5, 164.8, 167.5. LC-MS-ESI rt  8.25 min, 312 (M+1), 334 (M+23), 645 
(2M+23). (S)-9a [α]D = +34.9 (c 1 in CHCl3); (R)-9a [α]D = -28.7  (c 1 in CHCl3). 
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IV 
 
Linear and cyclic dehydro-β-amino acid containing integrin 
ligands. Synthesis and bioactivity 
 
4.1 Introduction  
Integrins are a large family of heterodimeric transmembrane glycoproteins involved in 
the attachment of a cell to the extracellular matrix (ECM) and in signal transduction 
from the ECM to the cell.77 These adhesion mechanisms are of fundamental importance 
in a diverse range of biological processes, including cell differentiation, apoptosis, 
embryonic cell migration, maintenance of tissue integrity, and blood coagulation.78 
Alterations or aberrations in integrin-mediated cell adhesion have been connected with 
the pathogenesis of several diseases such as atherosclerosis, osteoporosis, cancer and a 
variety of inflammatory disorders, making integrins an attractive target for the 
development of therapeutic agents.79 The identification of key recognition motifs within 
integrin ligands is the starting point for the development of antagonists. To date, these 
motifs have been identified for only a few subtypes. αvβ3 integrin (Figure 4. 1) has been 
deeply investigated as it is involved-tumor proliferation and metastasis through the 
formation of new blood vessels. αvβ3 integrin binds to a wide number of ECM 
components like fibronectin, fibrinogen, vitronectin, and osteopontin through 
recognition of the Arg-Gly-Asp (RGD) tripeptide sequence.80 
 
                           
Figure 4. 1 
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This sequence is also essential for the binding of α5β1 integrin to fibronectin, which has 
been unambiguously recognized as proangiogenic receptor.81 α5β1 integrin may regulate 
the function of integrins αvβ3 on endothelial cells during their migration in vitro or 
angiogenesis in vivo. Activation of α5β1 potentiates αvβ3-mediated migration on 
vitronectin, whereas α5β1 integrin antagonists inhibit αvβ3-mediated cell spreading. 
Therefore, antagonists of both integrins, block the same pathway of angiogenesis.82 In 
this chapter, the design, synthesis, and blockade of fibronectin-mediated cell adhesion 
of novel αvβ3/α5β1 integrin dual antagonists, whose activity could be synergistically 
effective in preventing angiogenesis, will be reported. The X-ray analysis83 of the 
complex between αvβ3 integrin and c(RGDfV) ligand (Figure 4. 2) shows that the ligand 
interacts mainly through electrostatic interactions. Arg and Asp form a charged clamp 
that binds regions with opposite charges in the protein: Asp interacts with a metal cation 
in the β subunit and Arg with two Asp in the α subunit.  
 
Figure 4. 2 
 
Several efficient classes of ligands, containing the RGD sequence, have been reported 
in the literature.84 These structures share as common features conformational restraints 
able to give a proper orientation to the peripheral substituents. Linear and cyclic 
peptides containing the RGD sequence, showing high affinity toward αvβ3 integrins, 
have significant therapeutic potential but serious limitations especially for oral dosing. 
The need for antagonists with higher bioavailability and lower molecular weight has 
prompted several research groups to develop small constrained non-peptidic molecules 
mimicking the RGD motif, which would be more promising for drug development.85 
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Most of the structures proposed so far consist of a polyfunctionalized rigid core, linked 
to appendages corresponding to arginine and aspartic acid side chains.86 Recently we 
identified a series of αvβ3 integrin ligands based on 5,6-dihydropyridin-2-one scaffold 
that showed promising interaction with the receptor.87 The basicity and the length of the 
arginine-mimicking group was found to play a central role. Moreover, the presence of a 
carboxylic function, mimicking the aspartic acid residue in the original binding motif, is 
a fundamental feature to create anionic interaction with the metal cation in the receptor 
active site.88  Many heterocyclic scaffolds have been employed to maintain the acidic 
and the basic ends of the molecule at the appropriate distance and with the suitable 
conformation for binding interaction. 
The introduction of a β-amino acid into RGD-containing cyclic peptides has been 
already reported with the aim to stabilize distinct conformations, having a γ-turn with 
centrally positioned glycine. On the other hand, incorporation of linear or constrained 
amino acid into an RGD sequence may give access to simple mimetics with increased 
bioactivity and stability.  
In this chapter, I will describe a novel class of integrin antagonists derived from 
dehydro-β-amino acids, as esemplified in Figure 4. 3, where the heterocycle in A is 
substituted by the dehydro-β-amino acid linked to a carboxylic acid and a basic function 
to mimic aspartic and guanidinic appendages. 
N
O
Ph
N
OO
HO NH2
A
R = H      IC50 (μM) αvβ3  0.6 ± 0.1 
               IC50 (μm) α5β1   0.17±0.07
R = Me   IC50 (μM) αvβ3  0.017 ± 0.11
               IC50 (μm) α5β1   0.057±0.017
IC50 (μM) αvβ3  0.038 ± 0.015
IC50 (μm) α5β1   0.043± 0.05
HO
H
N
O R
NH2
H
N
H
N
O
O
HO
R
NH2
N
O
Ph
N
NH2OO
HO
R
B
 
Figure 4. 3 
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A crucial requirement related to the bioactivity is the spatial disposition of each residue. 
Indeed, conformational differences may be responsible for a large variation in affinity 
and selectivity. We hypotesized that the restricted conformation introduced by the 
heterocycle in A, that induces a good spatial disposition of the appendages, could be 
substituted by the dehydro-β-amino acid, giving favorable alignment of both the basic 
and carboxylate moieties.  
Compounds with different variations at the substituent R or in the length of the side 
chains, maintaining the same position as in B, were synthesized and analyzed as integrin 
antagonists. 
We surmised that the global conformational constraint arising from the restriction by 
the dehydro-β-amino acid could result in a favorable spatial orientation of the integrin 
recognized functions.  
Moreover I will also describe the synthesis of  substituted isoxazolidines since they 
constitute versatile synthetic intermediates as conformational constraint. Indeed, various 
isoxazolidines are extensively used as 1,3-amino alcohol equivalents, as masked amino 
acids or as amino-sugar mimetics. Furthermore, substituted isoxazolidines, isoxazolines 
and isoxazoles are important substrates for mechanistic studies of biologically 
interesting processes. For example, isoxazolines have been incorporated as 
conformational constraint element in αvβ3 and α5β1 integrin antagonists, as well as in 
several transcriptional activators. In a similar way, constrained analogues containing the 
isoxazoline or isoxazole ring have been reported, and several AMPA (S-2-amino-3-(3-
hydroxy-5-methyl-4-isoxazolyl)-propionic acid) receptor agonists have been 
synthetized and tested. On the other hand, the synthesis of unnatural nucleoside analogs 
containing the isoxazolidinic and isoxazolinic ring is currently of significant interest 
since it has been reported that the presence of an isoxazoline ring increases the 
antibacterial activity of carbapenem derivatives. 
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4.2 Synthesis of linear substituted dehydro-β-amino acids as RGD 
mimetics 
Compounds 3a-d have been prepared in order to test the regioselectivity of p-
aminobenzylamine on carbonates 1a-d and to verify the complete stereoselectivity of 
the reaction.(Scheme 4. 1) The synthesis of these compounds was based on our 
previously reported results and has been described in chapter 1, where each compound 
has been accurately analyzed. Although the compounds 3a-d have a shorter length than 
that generally required for RGD mimetic ligands, they have been submitted to 
biological evaluation. 
 
R
CO2tBu
OCO2Me
NH2
H2N
R
CO2tBu
NH
H2N
+
CH3CN
Δ
R
CO2H
NH
H2N
TFA
CH2Cl2
1a-d 2a-d
3a-d  
Scheme 4. 1 
 
In a similar way, the RGD mimetics 8a-b have been obtained through the SN2’ 
substitution on the appropriate racemic or optically active  Boc-amides 6a-d.      
(Scheme 4. 1). 
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7a-b
8a-b
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95%
65%
70%
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NH2
 
Scheme 4. 2 
 
For details on synthetic pathway, see paragraph 1.5 and scheme 1.14  
 
4.2.1 Biological evaluation of linear substituted dehydro-β-amino acids 
In Table 15 the ability to perturb initial cell attachment mediated by αvβ3 integrin and 
α5β1 integrin using cell adhesion assays of some selected compounds, is reported. The 
integrin ligand fibronectin (10μg/ml) was immobilized on tissue culture plates. The 
ability of human melanoma cell line SK-MEL 24, expressing αvβ3 integrin, and human 
erythroleukemic cell line K562, expressing α5β integrin, to adhere to fibronectin in the 
presence or absence of the assayed compounds was examined. The anti-adhesion 
activity of the well-known integrin antagonist Ac-Asp-Arg-Leu-Asp-Ser-OH (H3534) 
was measured as a positive control. 
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Table 15 
IC50  (μM)a Entry Compound αvβ3 α5β1 
1 HO HN
O
NH2
3a  
>1,000 0.019 ± 0.003 
2 HO HN
O
NH2
3b  
1.49 0.14 
3 HO
H
N
O
NH2
(S)-3b  
19.2 31.3 
4 HO HN
O
NH2
(R)-3b  
0.307 21.2 
5 HO
H
N
O
NH2
3c
S
 
3.35 4.66 
6 HO
H
N
O
NH2
3d  
0.831 2.1 
7 
H
N
H
N
O
O
HO
NH2
8b  
0.121 9.77 
8 HN HN
O
O
HO
NH2
(S)-8a  
1.99 0.224 
aValues are means  ± standard error of three experiments. 
 
The shorter molecules reported in entries 1-6 showed unexpected activity and selectivity 
depending from the substituent in position 3. For methyl derivative 3a no adhesion 
could be observed on αvβ3 integrin receptor. On the other hand, the introduction of the 
more lipophilic ipr group (3b) gave interesting results since the racemic compound 
showed a good dual activity (entry 2). 
The orientation provided by the configuration in position 3 seems to be crucial for the 
affinity on αvβ3 integrin receptors, since (R)-3b displayed increased inhibitory activity 
in respect to the corresponding S enantiomer. 
This effect is enhanced for αvβ3 receptor, being the R isomer about more potent than the 
S one. Comparable activity towards αvβ3 and α5β integrin was observed for thiophenyl 
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derivative 3c (entry 5), while the presence of a cyclohexyl group as in 3d seems to 
favour a preferential affinity towards αvβ3  receptor (entry 6). This compound, indeed, 
resulted about more potent on αvβ3 compared to  α5β1 integrin. In entries 7 and 8, the 
results obtained for elongated ligands are reported. Compound 8b showed comparable 
affinity to the corresponding shorter analogue 3b. On the contrary, compound 8a 
displayed good activity and a strong preference towards α5β receptor, behaving as a 
selective not dual inhibitor. 
These results seem to suggest that the activity for smaller ligands 3a-d is not strictly 
connected to the substituent hinderance, while a certain effect is induced by its spatial 
orientation. On the other hand, a major influence of the substitution pattern can be 
observed for elongated compounds 8a-b, where the introduction of the smaller 
substituent increases affinity towards α5β  integrin.  
 
4.3 Synthesis of isoxazolidine - derivatives as rigid constrained cores of 
RGD mimetics 
In chapter 2 I described the highly stereocontrolled synthesis of terbutyl 5-
hydroxyisoxazolidine-4-carboxylate through a Lewis acid induced Michael addition of 
hydroxylamine derivatives to alkylideneacetoacetates, followed by intramolecular 
hemiketal formation. (Scheme 4. 3) 
 
R
COOtBu
O SMTNHOTMS
  5% Zn(OTf)2
CH2Cl2
9a-d
OHN
OH
R
O OtBu
a: R= CH3
b: R= CH(CH3)2
c: R= CH(CH3)CH2CH3
d: R=Cyclohexyl  
Scheme 4. 3 
 
The use of acetoacetates in this field is rather unusual and has the advantage of 
introducing a reactive keto functionality that may be further elaborated. Lewis acids 
have attracted much attention in organic synthesis because of their strong influence on 
the rate, the regio-, and the stereochemistry of numerous reactions. In this context, 
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carbamates have only recently been the subject of investigation as nucleophilic reagents 
for conjugate addition. 
Herein I report a modified procedure to obtain 5-hydroxyisoxazolidine-4-carboxylates 
as rigid constrained cores of RGD mimetics and a simple route to obtain the ligands. 
We surmised that grafting of these scaffold into RGD motif could result in a favorable 
spatial orientation of the integrin recognition tripeptide. 
 
R
O
O
OtBu
HN
OH
R
O
OtBu
O
N
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BnO
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R
O
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O
NBnO
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BnO
OO
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R
O
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OO
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O
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N
O
NBnO
OO
R
O
O
NHO
OO
NH2
H
N
NH2
65%
 (2 steps)
90%
70%
SOCl2,
Pyridine
DCM
MsCl
TEA
DCM
TFA
DCM
>95%
HBTU
TEA
CH3CN
H2
Pd/C
4-amino-
benzylamine
9a-d 10a-d 11a-d
12a-d13a-d
14a-d
 
Scheme 4. 4 
 
Terbutyl-5-hydroxyisoxazolidine-4-carboxylate 9a-d, were synthesized as already 
described in chapter 2 (Scheme 4. 3), than the nitrogen was protected with the benzyl 
malonic derivative that will correspond to the acidic part of  the final RGD mimetic 
(Scheme 4. 4). Adding mesyl chloride and TEA in excess, compounds 10a-d were 
converted to the corresponding dehydrated isoxazoline 11a-d. The relative acids 12a-d 
were obtained by the hydrolysis of the terbutylester with trifluoroacetic acid. 
Compounds 12a-d were coupled with 4-amino-benzylamine to afford amides, finally by 
simple hidrogenation of 13a-d final products 14a-d were obtained. 
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4.3.1 Biological evaluation of isoxazolidine- derivatives 
Isoxazolidine- derivatives 14 a-d, were evaluated for their ability to inhibit αvβ3- and 
α5β1-integrin mediated cell adhesion. In Table 16 the ability to perturb initial cell 
attachment mediated by αvβ3 integrin and α5β1 integrin using cell adhesion assays of 
some selected compounds, is reported. The integrin ligand fibronectin (10μg/ml) was 
immobilized on tissue culture plates. The ability of human melanoma cell line SK-MEL 
24, expressing αvβ3 integrin, and human erythroleukemic cell line K562, expressing 
α5β integrin, to adhere to fibronectin in the presence or absence of the assayed 
compounds was examined. The anti-adhesion activity of the well-known integrin 
antagonist Ac-Asp-Arg-Leu-Asp-Ser-OH (H3534) was measured as a positive control. 
 
Table 16 
Entry Compound  αvβ3 IC50, μMa α5β1 IC50, μMa 
1 
 
N
O
O
H
N
NH2
HO
O O
 
14a 
3.16*10-8 1.19*10-8 
2 
 
N
O
O
H
N
NH2
HO
O O
 
14b 
8.79*10-9 1.05*10-9 
3 
 
N
O
O
H
N
NH2
HO
O O
 
14c 
3.60*10-7 1.32*10-6 
4 
 
N
O
O
H
N
NH2
HO
O O
 
14d 
2.02*10-8 1.03*10-6 
aValues are means  ± standard error of three experiments. 
 
The results reported in Table 16 show that the isoxazolidine ring represents an effective 
scaffold to induce the proper orientation to the Asp and Arg mimicking chain, since the 
smaller member of the library,  14a, is a potent ligand for both αvβ3- and α5β1-integrin 
and can be regarded as a dual inhibitor.  This activity could be effective in preventing 
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angiogenesis by blocking different pathways of the blood vessel formation in tumors. 
Introduction of the isopropyl group in place of the smaller methyl substituent in position 
3, as in compound 14b, resulted in a small influence on the affinity to both receptors,  
being the effect on αvβ3-integrin stronger in respect to α5β1-integrin. The increased 
steric hinderance of the substituent in the isoxazoline ring strongly affected the activity 
of compound 14c, that showed a reduction of the bioactivity from nanomolar to 
micromolar. Finally, the trend was confirmed by the evaluation of the bulky cyclohexyl 
derivative 14d, that showed no affinity for αvβ3-integrin and only a modest preference 
for α5β1-integrin.  
 
4.4 Molecular Docking  
Before submit our compounds to the biological evaluation with the isolated receptor, we 
decided to study  the real interaction that our compounds could have inside the receptor 
with a  molecular docking study. Two compounds for each class of product were 
submitted to the docking study (3b and 8b, 14a and 14d). 
Docking studies were performed using Glide (version 4.5)89 by starting from the 
representative macrocycle conformations sampled during the unrestrained MD 
simulations. The protein binding site was derived from the X-ray crystal structure of the 
extracellular segment of integrin αVβ3 in complex with the cyclic pentapeptide ligand 
cilengitide [Protein Data Bank (PDB) entry 1L5G].90 In this X-ray structure, the potent 
αVβ3 antagonist cilengitide, bound to the headgroup of the integrin, features an extended 
conformation of the RGD sequence with a distance of ∼9 A° between the Cβ atoms of 
Asp and Arg. The crystal complex interaction pattern involves the formation of an 
electrostatic clamp between the guanidinium group of the ligand and the negatively 
charged side chains of Asp218 and Asp150 in the α unit and between the carboxylic 
group of cilengitide and the metal cation in the metal ion-dependent adhesion site 
(MIDAS) region of the β unit. Moreover, further stabilization occurs through hydrogen 
bonds between the NH group of the ligand Asp residue and the carbonyl oxygen atom 
of Arg216 in the β subunit as well as between the ligand carboxylate oxygen not 
coordinated to MIDAS and the backbone amides of Asn215 and Tyr122 in the β unit.  
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Figure 4. 4 
 
The experimentally observed binding mode of cilengitide (Figure 4. 4) with αVβ3 
integrin was taken as a reference model for the interpretation of the docking results in 
terms of the ligandbound conformation and ligand-protein interactions. 
 
4.4.1 Docking results 
For each ligand only the picture with the best pose and the range of  the score function 
for the 20 poses saved (Gscore), is reported. For each ‘best pose’ is reported the 
distance from the COO- group and the nitrogen atom of  NH2 group. In fact these two 
groups should mimic the Asp/Arg chains of the RGD sequence. In all the pictures, in 
green colour, is reported the bound geometry of the cilengitide ligand, take from the X-
Ray with αvβ3 integrin. Finally, the receptor is reported only with the parts that interact 
with the cilengitide (α chain is orange, β chain is blue and  Ca-MIDAS is a green 
sphere) and Gscore values of our ligands can be compared with cilengitide Gscore, 
where in the best pose is -9,07. 
 
Compound (R)-3b gave a Gscore of (-5,02; -3, 89) 
 
HO
H
N
O
NH2
(R)-3b  
 
In the Best pose (Figure 4.5) the NH2 group interacts with the C=O of the Ala215 (α 
chain) and there is the electrostatic interaction Ca-MIDAS/COO-. 
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Figure 4. 5 
 
In the next pose (Figure 4. 6) we can see a different orientation of the ligand inside the 
receptor, the aromatic ring seems interact with Tyr178 ring (T-shaped o stacking) of α 
subunit (15 to 20 poses). NH2 group can interact with Asp218 of α subunit. 
Figure 4. 6 
 
 
Compound (R)-8b gave a Gscore of (-5,46; -3, 68) 
H
N
H
N
O
O
HO
NH2
(R)-8b  
In the Best pose (Figure 4. 7) compound (R)-8b has the same interaction of the 
cilengitide with the COO-/ β subunit. NH2 group interacts with Asp218 and the 
aromatic ring has a stacking interaction with Tyr178 of the α subunit 
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Figure 4. 7 
 
In the other poses, there aren’t hydrogen bonds with Tyr122/Asn215 of the β subunit, 
but there is the electrostatic interaction Ca-MIDAS/COO- (for 14 poses).  
In conclusion both the ligands seem fit properly in the receptor site maintaining the key 
electrostatic interaction (Ca2+-MIDAS for β subunit and Asp218 for α subunit) with 
both the subunits but with a different distance of the pharmacophoric groups with 
consequent loss of important hydrogen bonds. 
 
Since that isoxazolidine-derivatives were synthesized in racemic way, molecular 
docking were calculated on both the isomer (R)- and (S)- . 
Moreover for all the compounds the aromatic group seems have an effect on the 
position inside the binding site interacting with Tyr 78 of α subunit. 
 
Compound (R)-14a gave a Gscore of (-6.21; -4.08) 
N
O
O
H
N
NH2
HO
O O
 
    14a 
In the Best pose the ligand has interactions with crystalline complex only with –COO- 
group (10 to 20 poses are like the best pose but not always two hydrogen bonds with 
Tyr122 e Asn215 are kept). The first pose in wich –NH2 group fits like cilengitide is 
pose number 5 where we can note also the interaction of  Tyr178 of α subunit (6 to 20 
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poses are like the 5 pose but not always two hydrogen bonds with Tyr122 e Asn215 are 
kept). 
 
 
 
 
 
 
 
 
 
 
Figure 4. 8 
 
Compound (S)-14a gave a Gscore of (-5.32;-3.40) 
 
 
 
 
 
 
 
 
 
Figure 4. 9 
 
In the Best pose the ligand has the same interaction of the cilengitide with the COO-/ β 
subunit. The –NH2 basic group interacts with Asp218. These interactions are maintained 
until pose 4. 8 to 20 poses are like the best pose. In the other poses or the ligand moves 
to β subunit or –NH2 group interacts with Asp150 of α subunit. 
In conclusion compound 14a finds poses for the interaction with αVβ3 integrin that 
conserve the crystallographic interactions observed in in the crystal structure of the 
cilengitide- αVβ3 complex. 
Best pose 
Dist=12.43 Å 
Pose 5, 
Dist =11.06Å 
Best pose 
dist=12.56 Å 
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Compound (R)-14a gave a  Gscore  of (-5.96;-4.20) 
N
O
O
H
N
NH2
HO
O O
 
14d 
In the Best Pose (Figure 4. 10) the ligand binds β subunit turning the cyclohexyl ring to 
Phe-EMD. In the next poses the ligand binds β subunit but with different orientation of 
cyclohexyl ring. 
 
 
 
 
 
 
 
 
 
Figure 4. 10 
 
Compound (S)-14a gave a Gscore  of (-6.37; -4.20) 
The ligand binds β subunit only in the first three poses turning the cyclohexyl ring to 
the binding site. In the pose 4 it preserves the crystallographic interactions observed in 
in the crystal structure of the cilengitide- αVβ3 complex for 12/20 poses. 
 
 
 
 
 
 
Best Pose 
dist= 11.96 Å 
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Figure 4. 11 
 
In conclusion both the stereoisomer R and the stereoisomer S of compound 14d, in the 
first poses interact with only the β subunit. 
 
 
Best pose 
Dist=11,22Å 
Pose 4, 
Dist= 13.30 Å 
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4.5 Experimental section 
General: All chemicals were purchased from commercial suppliers and used without 
further purification. Anhydrous solvents were purchased in sure seal bottles over 
molecular sieves and used without further drying. Flash chromatography was performed 
on silica gel (230-400 mesh). DOWEX® 50WX2-200(H) ion exchange resin was used 
for purification of free amino acids. NMR Spectra were recorded with Varian Gemini 
200, Mercury Plus 400 or Unity Inova 600 MHz spectrometers. Chemical shifts were 
reported as δ values (ppm) relative to the solvent peak of CDCl3 set at δ = 7.27 (1H 
NMR) or δ = 77.0 (13C NMR), CD3OD set at δ = 3.31 (1H NMR) or δ = 49.0 (13C 
NMR), D2O set at δ = 4.79 (1H NMR). Coupling constants are given in Hz. Optical 
rotations were measured in a Perkin Elmer 343 polarimeter using a 1 dm cuvette and are 
referenced to the Na-D line value. Melting points were determined on a Stuart Scientific 
SMP3 apparatus and are uncorrected. LC-MS analyses was performed on a HP1100 
liquid chromatograph coupled with an electrospray ionization-mass spectrometer (LC-
ESI-MS), using H2O/CH3CN as solvent at 25 °C (positive scan 100-500 m/z, 
fragmentor 70V). 
 
For the synthesis and the characterization of compounds 1a-d, 2a-d, 4a-b, 5a-b, 6a-b, 
7a-b and 8a-b, see the experimental section of chapter 1. For the synthesis and the 
characterization of compounds 9a-d, see the experimental section of chapter 2. 
 
General procedure for the synthesis of  dehydro-β-amino acids 3a-d: TFA (7 mmol, 7 
equiv.) was added  to a solution of 2a-d (1 mmol) in CH2Cl2(5mL) and the reaction 
mixture was stirred at room temperature until complete consumption of the starting 
material.  The solvent and the excess of reagent were removed under reduced pressure.  
The crude residue was treated with Dowex 50WX2-200 ion exchange resin, eluting with 
NH4OH 0.5 M. Compounds 3a-d were isolated in quantitative yield after removal of the 
aqueous solvent. 
 
3a : 1H NMR (CD3OD, 200 MHz) major isomer δ 1.53 (d, J=6.8 Hz, 3H, CH3CHN), 
1.88 (d, J=7.2 Hz, 3H, CH3CHC), 3.91 (d, J=12.8 Hz, 1H, NHCH2Ph), 4.01 (d, J=12.8 
Hz, 1H, NHCH2Ph), 4.31 (q, J=6.8 Hz, 1H, CH3CHN), 6.80 (d, J=8.4 Hz, 2H, Ph), 7.02 
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(q, J=7.2 Hz, 1H, CCHCH3), 7.23 (d, J=8.4 Hz, 2H, Ph);minor isomer δ 2.12 (d, J=7.0 
Hz, 3H, CH3CHC), 3.81 (q, J=6.6 Hz, 1H, CH3CHN), 6.05 (q, J=7.0 Hz, 1H, 
CCHCH3). 
 
3b:  1H NMR (CD3OD, 200 MHz) major isomer δ 0.80 (d, J=7.0 Hz, 3H, CH3CHCH3), 
0.91 (d, J=7.0 Hz, 3H, CH3CHCH3), 1.66 (d, J=7.2 Hz, 3H, CH3CHC), 2.01 -2.16 (m, 
1H, CH3CHCH3), 3.69-3.95 (m, 3H, CHCHN e NHCH2Ph), 6.61 (d, J=8.4 Hz, 2H, Ph), 
6.94 (q, J=7.2 Hz, 1H, CCHCH3), 7.04 (d, J=8.4 Hz, 2H, Ph); minor isomer δ 1.94 (d, 
J=7.0 Hz, 3H, CH3CHC), 5.77 (q, J=7.0 Hz, 1H, CCHCH3).  
 
3c: 1H NMR (CD3OD, 200 MHz) major isomer δ 1.19-1.36 (m, 6H, cyclohexyl), 1.64-
2.01 (m, 5H, cyclohexyl), 1.77 (d, J=7.2 Hz, 3H, CH3CHC), 3.89-4.11 (m, 3H, CHCHN, 
NHCH2Ph), 6.83 (d, J=7.0 Hz, 2H, Ph), 7.22 (d, J=7.0 Hz, 2H, Ph), 7.34 (q, J=7.4 Hz, 
1H, CCHCH3); minor isomer δ 2.13 (d, J=6.8 Hz, 3H, CH3CHC), 6.33 (q, J=6.8 Hz, 
1H, CCHCH3). 
 
3d: 1H NMR (DMSO, 200 MHz) major isomer δ 1.74 (d, J=7.4 Hz, 3H, CH3CHC), 
3.61 (d, J=13.0 Hz, 1H, NHCH2Ph), 3.78 (d, J=13.0 Hz, 1H, NHCH2Ph), 5.02 (s, 1H, 
CHNH), 6.54 (d, J=8.4 Hz, 2H, Ph), 6.78 (q, J=7.4 Hz, 1H, CCHCH3), 7.01 (d, J=8.4 
Hz, 2H, Ph), 7.10 (d, 1H, thiophenyl), 7.44 (bs, 1H, thiophenyl), 7.50-7.54 (m, 1H, 
thiophenyl); minor isomer δ 1.96 (d, J=6.6 Hz, 3H, CH3CHC), 4.60 (s, 1H, CHNH), 
5.89 (q, J=6.6 Hz, 1H, CCHCH3).  
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Compound 14a 
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Compound 14b 
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Compound 14c 
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Compound 14d 
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Materials for bioassays 
Trypsin/EDTA, non-essential amino acids, minimum essential medium (MEM), RPMI-
1640 with L-glutamine, antibiotic, and antimycotic solution, and glycine were 
purchased from Invitrogen (Carlsbad, CA, USA). Fetal bovine serum (FBS) and 
phosphate buffered saline (PBS) were from Cambrex (Walkersville, MD, USA). Citrate 
buffer solution, EDTA, DMSO, Triton-X-100, 4-nitrophenyl N-acetyl-b-D-
glucosaminide, phorbol 12-myristate 13-acetate (PMA), pyruvic acid, fibronectin from 
human plasma were obtained from Sigma–Aldrich SRL (Milan, Italy). SK-MEL-24 
(human malignant melanoma) and K-562 (human erythroleukemia) cell lines were 
obtained from American Tissue Culture Collection (ATCC, Rockville, MD, USA). 
 
 Cell culture 
SK-MEL-24 cells were routinely grown in MEM medium supplemented with 10% FBS, 
non-essential amino acids and sodium pyruvate. K-562 cells were maintained as a 
stationary suspension culture in RPMI-1640 + Lglutamine with 10% FBS. Cells were 
kept at 37 _C in a 5% CO2 humidified atmosphere. Fourty-hour before the experiment 
K-562 cells were treated with 25 ng/mL of PMA to induce differentiation with 
increased expression of cell surface antigens. 
 
Adhesion assays 
Plates (96-well) (Corning, New York, NY, USA) were coated by passive adsorption 
with fibronectin (10 lg/ mL) overnight at 4 _C. Cells were counted and exposed to 
different concentrations of the drug for 30 min at room temperature to allow the ligand–
receptor equilibrium. Stock solutions (10_2 M) of the assayed compounds were 
prepared in 33% DMSO and 66% PBS (v/v); further dilutions were done in PBS alone. 
The highest rate of DMSO in the assays was 1% of the stock solution. Control cells 
were exposed to the same concentration of DMSO. At the end of the incubation time, 
the cells were plated (50,000 cells per well) and incubated at room temperature for 1 h. 
Then, all the wells were washed with PBS to remove the non-adherent cells, and 50 lL 
of the substrate of the exosaminidase (4-nitrophenyl N-acetyl-b-D-glucosaminide 
dissolved at 7.5 mM in 0.09 M citrate buffer solution, pH 5, and mixed with an equal 
volume of 0.5% Triton X-100 in water) was added. This product is a chromogenic 
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substrate for b-N-acetylglucosaminidase that is transformed in 4-nitrophenol whose 
absorbance is measured at 405 nm. As previously described,20 there is a linear 
correlation between absorbance and enzymatic activity. It is, therefore, possible to 
identify the number of adherent cells in treated wells, interpolating the absorbance 
values of the unknowns in a calibration curve. The reaction was blocked by adding 100 
lL of a stopping solution (50 mM glycine, 5 mM EDTA, pH 10.4) and the plate was 
read in a Victor2 Multilabel Counter (Perkin-Elmer, Waltham, Massachusetts, USA). 
Experiments were carried out in quadruplicate. Data analysis and IC50 values were 
calculated using Graph-Pad Prism 3.0 (GraphPad Software Incorporated, San Diego, 
CA, USA). 
 
Molecular Docking. All calculations were run using the Schrodinger suite of programs 
(http://www.schrodinger.com) through the Maestro graphical interface. (i) Protein 
Setup. The recently determined crystal structure of the extracellular domain of the 
integrin RVβ3 receptor in complex with cilengitide and in the presence of the 
proadhesive ion Mn2þ (PDB entry 1L5G) was used for docking studies. Docking was 
performed only on the globular head of the integrin because the headgroup of integrin 
has been identified in the X-ray structure as the ligand-binding region. The protein 
structure was set up for docking as follows; the protein was truncated to residues 41-342 
for chain R and residues 114-347 for chain β. Due to a lack of parameters, the Mn2þ 
ions in the experimental protein structure were modeled via replacement with Ca2þ 
ions. The resulting structure was prepared using the Protein Preparation Wizard of the 
graphical user interface Maestro and the OPLSAA force field. (ii) Docking. The 
automated docking calculations were performed using Glide72 (Grid-based Ligand 
Docking with Energetics) within the framework of Impact version 4.5 in a Article 
Journal of Medicinal Chemistry, 2010, Vol. 53, No. 1 117 standard precision mode 
(SP). The grid generation step started from the extracellular fragment of the X-ray 
structure of the αVβ3 complex with cilengitide, prepared as described in Protein Setup. 
The center of the grid-enclosing box was defined by the center of the bound ligand. The 
enclosing box dimensions, which are automatically deduced from the ligand size, fit the 
entire active site. For the docking step, the size of the bounding box for placing the 
ligand center was set to 12 A ° . No further modifications were applied to the default 
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settings. The Glide-Score function was used to select 20 poses for each ligand. Glide 
was initially tested for its ability to reproduce the crystallized binding geometry of 
cilengitide. The program was successful in reproducing the experimentally found 
binding mode of this compound, as it corresponds to the best-scored pose. 
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